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THE IMMUNE sysTEM           
The immune system is crucial to human survival. Even minor infections can prove 
fatal in the absence of an immunological defense. However, in spite of having a 
functional immune system, all humans will suffer from a number of infections 
during their lifetime. This is because building a strong immune response towards 
invading microorganisms takes time. Meanwhile, the microorganisms can multiply 
and cause disease. Our body is permanently involved in battles with many intruding 
viruses, bacteria and fungi. Next to that, there are endogenous dangers that have 
to be averted, such as uncontrolled cells that are potential sources of cancer. 
In these battles, the human body makes use of an army with many different types 
of soldiers, in the form of various cell types and soluble molecules. Many cells 
of peripheral tissues, such as keratinocytes in the skin, pneumocytes in the lung 
and mucosal cells in the gut defend the body from invasions by microorganisms. 
When microorganisms pass these defenses, the immune system comes in to 
help. Generally, the immune system is divided into two legions: the innate and 
the adaptive immune system. Innate responses provide a crude non-specific but 
fast first line of defense, disarming many of the intruders. NK-cells, monocytes, 
granulocytes and mast cells are the most important effector cell types of the 
innate immune system. On the other hand, the adaptive system is capable of 
mounting responses aimed against specific pathogens. This adaptive response can 
be immensely powerful but it takes days to develop fully. The adaptive system 
forms long lasting memory cells, providing a faster and stronger response in 
the case of subsequent attacks by the same pathogen. In the adaptive immune 
response, conventional CD4pos helper T-cells (Tconv) are important orchestrators. 
When these cells are activated, they in turn activate an array of other immunologic 
effector cells of the adaptive immune system, such as B-cells and CD8pos cytotoxic 
T-cells, but also macrophages and other cells of the innate immune system (Figure 
1). Immune responses can destroy intruders, but also healthy bystander tissue 
figure 1. activation of cD4pos helper t-cells ultimately leads to activation of an array of other 
immune effector mechanisms.
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cells. Therefore, the immune system is equipped with brake-mechanisms. These 
prevent detrimental effects on tissues caused by escalating immune responses and 
prevent responses against harmless agents or self-antigens. There are a number of 
cell populations specialized in guiding and suppressing immune responses. Of these 
populations, regulatory T-cells (Treg) are the most well-known and well-studied.
REGUl ATORy T-CEll S         
IDENTIFyING REGUlATORy T-CEllS
Naturally occurring Treg reside within the CD4pos T-cell lineage. They develop 
in the thymus [1], and were initially thought to form as a stable thymus-derived 
cell lineage with limited plasticity. These thymus-derived Treg are referred to as 
naturally occurring Treg, or nTreg. However, it has recently been shown in vivo in 
mouse models that thymus-derived Treg can convert into Tconv [2-4]. Vice versa, 
CD4pos Tconv can be converted into Treg depending on the microenvironment. 
These Treg are called induced Treg, or iTreg, and they resemble nTreg in many of 
their phenotypic characteristics. A number of iTreg subsets have been described. 
For example, iTreg can be formed after activation of Tconv in the presence of 
IL‑10 (Tr1 cells) [5], TGFβ (Th3 cells) [6] or Il‑35 [7]. These iTreg regulate immune 
responses by increased production of Il‑10, TGFβ or Il‑35, respectively. 
To complicate matters, identification of CD4pos Treg is not straightforward. The first 
Treg were initially described as CD4posCD25high T-cells [8]. However, co-expression 
of CD4 and CD25 is not unique for Treg, since human Tconv can also express CD25 
upon activation. likewise, the Treg key transcription factor FoxP3, which is stably 
expressed by Treg, is also transiently expressed by recently activated human Tconv 
[9;10]. Moreover, the fact that FoxP3 is expressed intracellular and not on the cell 
surface limits the usefulness of this marker for the isolation of viable Treg. More 
recently, CD127 was described as a useful marker to identify Treg, since Treg 
show a high CD25 and a low CD127 expression, in contrast to Tconv, which have a 
CD25lowCD127high phenotype [11;12]. Again, recently activated Tconv can resemble 
Treg with their CD25highCD127low phenotype [13]. Despite the possible contamination 
with activated Tconv, most studies use the CD4posCD25highCD127lowFoxP3pos 
phenotype to define Treg. 
Other markers to further characterize nTreg have entered and/or left the stage, 
such as CD49d [14], PD-1 [15], GITR [16;17], CTlA-4 [18], membrane bound TGFβ 
[19], FR4 [20], CD39 and CD73 [21;22], none of them being uniformly expressed 
on all Treg or being unique for Treg. Recently, GARP, a protein expressed on the 
surface of activated Treg that is involved in the regulation of the bioavailability and 
activation of TGFβ, has been described as a marker to distinguish activated Treg 
from activated Tconv [23-28]. like GARP, NP-1 was also described to be involved in 
the binding of latent TGFβ on the Treg cell surface [29]. NP-1 has been described 
as a useful tool to distinguish naturally occurring Treg from induced Treg in animal 
models [30;31], but expression characteristics seem to be different in human cells 
[32].
Within the Treg population of humans as well as animals, several Treg subsets with 
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different properties have been identified. The differentiation of Treg resembles 
that of Tconv, with CD45RAposCD25pos naïve Treg [33;34], memory Treg expressing 
the lymph node homing markers CCR7 and CD62l, and memory Treg which do 
not express lymph node homing markers but are positive for multiple peripheral 
homing markers such as selectin ligands, adhesion markers and chemokine 
receptors other than CCR7 and CD62l [35;36]. Alternative subdivisions of Treg have 
been based on expression of CD27 [37-39] HlA-DR [40], or integrin αE [41].
REGUlATORy T-CEll FUNCTION
The exact mechanisms used by Treg to regulate immune responses remain 
incompletely understood. In general, Treg can modulate Tconv actions directly 
through cell-cell contact, by the production of cytokines, by cytokine scavenging, 
and/or indirectly by modulation of antigen presenting cells (APCs), of which 
dendritic cells (DCs) are the most important [42] (Figure 2). Here, the most 
important Treg mechanisms of action are listed.
subsets of Treg produce immunosuppressive cytokines such as IL‑10 [5], TGFβ [6], 
IL‑35 [7], and regulatory proteins such as galectin-1 [43]. These cytokines inhibit 
Tconv proliferation, suppress APC activity and/or lead to conversion of Tconv into 
iTreg. These cytokines are likely to play a role in the immunoregulatory function of 
Treg in the draining lymphoid tissue as well as at the peripheral site of inflammation. 
Treg can regulate immune responses through interactions with other cell types, 
such as Tconv, DCs, B-cells and NK-cells. Multiple interactions between Treg and DCs 
have been described. Binding of Treg CD152 (also known as CTlA-4) to its ligands 
CD80 and CD86 on DCs can reduce expression of these costimulatory molecules 
on the DCs. It also leads to IDO production by DCs, resulting in a local deprivation 
of the essential amino acid tryptophan. Both mechanisms attenuate activation 
and proliferation of CD4pos and CD8pos effector T-cells [44;45]. In lymph nodes, Treg 
have been found to limit the contact between Tconv and DCs in vivo and ex vivo in 
mice [46;47], further reducing Tconv activation and expansion in lymphoid organs. 
Other Treg/DC interactions take place in the periphery. In a mouse model of 
cutaneous immune responses, Treg rigorously eliminated DCs, thereby preventing 
Tconv activation and limiting the responses [48]. More subtle interactions between 
Treg and DCs at peripheral sites have also been described. Upon contact with Treg, 
DCs decrease chemokine production [49] and show reduced endocytosis capacity 
[50], both effects leading to a decreased immune response. Next to that, in vitro 
figure 2. treg can influence immune responses using several types of mechanisms of action.
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activation of DCs in the presence of Treg yields semi-mature DCs with a normal 
lymph node homing phenotype but with an impaired capacity to activate Tconv 
[51]. Treg interactions with Tconv lead to a reduction of Tconv proliferation in 
secondary lymphoid organs in mice [52;53]. In another mouse model, Treg did not 
reduce Tconv proliferation, but rather limited the egress of Tconv from the lymph 
nodes by inducing downregulation of S1P
1
, thereby reducing the number of Tconv 
available for an immune response in the periphery [54]. At the site of inflammation, 
Treg limit Tconv proliferation [52] and local Treg delay the influx of Tconv [55]. Treg 
have also been found in follicles in mouse and human lymph nodes [56-59], and 
these Treg suppressed B-cell responses and follicular T-cell proliferation, indicating 
another function for a subset of Treg within the secondary lymphoid organs. 
Additionally, Treg have been shown to suppress NK-cell maturation in mouse lymph 
nodes [60]. 
OTHER REGULATORy CELL sUBsETs
Besides the CD4pos Treg described above, there are a number of other T-cell 
populations with the capacity to down-regulate immune responses. CD8posCD28neg 
T-cells exert their regulatory capacity via cell-contact dependent inhibition of T-cell 
activation by APCs and via cell-contact independent inhibition through Il-10 [61;62]. 
CD4negCD8neg T-cells can diminish immune responses by killing antigen-specific 
T-cells, and by suppressing and killing APCs [63]. Subsets with immunomodulatory 
functions have been described within natural killer T-cells (NKT-cells). These cells 
function through the production of anti-inflammatory cytokines such as Il-4, and 
by inhibiting the production of pro-inflammatory cytokines such as IFNγ and TNFα 
by other cell types [64;65]. γδ T-cells have been shown to exert local regulatory 
activity in the gut mucosa, although their mechanism of action is unclear [66].
T-cells are not the only cell type with immunomodulatory subsets. In fact, 
subsets with immune inhibitory actions have been described for most leukocyte 
populations. CD19posCD24highCD38high regulatory B-cells constitute a small subset 
of the total B-cell pool and they regulate immune responses by producing Il-10 
[67;68]. Regulatory macrophages, formed upon contact with Treg or B-1 cells (a 
sub-class of B-cells), are characterized by specific morphological features and 
surface phenotype, and by the ability to suppress T-cell proliferation in vitro 
through the production of Il-10 [69]. DCs are known for their strong capacity to 
activate T-cells and promote immune responses, but even within this leukocyte 
population regulatory subsets have been defined, called tolerogenic DCs [70]. 
Immature DCs can induce T-cell tolerance [71], and certain types of plasmacytoid 
DC can induce the generation of antigen-specific Treg [72]. Myeloid-derived 
suppressor cells (MDSCs) form a heterogeneous population of progenitor cells with 
suppressive immune functions. Several subsets of MDSCs have been described and 
most exert their function in tissues during inflammation [73]. Activated MDSCs 
suppress T-cell, B-cell and NK-cell proliferation and cytokine production in vitro 
through various soluble mediators, and promote Treg induction in an IFNγ and 
Il-10 dependent manner. Mesenchymal stromal cells, the only non-leukocyte cell 
population mentioned in this paragraph, migrate to sites of inflammation and 
exert local immunomodulatory and regenerative properties, for example through 
induction of Treg [74]. 
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Immune regulation is a complex process that involves multiple mechanisms and 
the co-operation of many cell populations. It is very likely that all regulatory 
cell subsets described above co-operate in guiding immune responses, each 
functioning at different locations and at different stages of immune responses.
REGUl ATORy T-CEll BASED IMMUNOTHERAPy     
Solid organ and stem cell transplantation procedures are very valuable treatment 
modalities for patients suffering from a number of life-threatening medical 
conditions. However, due to the recognition of foreign antigens, these procedures 
evoke undesired immunological responses against the transplant or the host. In 
autoimmune diseases unwanted immune responses against self-antigens also lead 
to significant morbidity and mortality. Treg immunotherapy is a potential treatment 
modality to dampen such harmful immune responses. Below, immune responses in 
solid organ and stem cell transplantation as well as in autoimmunity are described, 
followed by a brief summary of the current status of Treg therapy in these settings.
sOLID ORGAN TRANsPLANTATION
While solid organ transplantation can solve many life-threatening medical 
conditions due to end-stage failure of kidneys, liver, lung, heart or other organs, 
it also introduces new problems. One of the major problems is caused by our own 
immune system. Immediately after transplant surgery, activation of the innate 
immune system by the injured tissue can cause significant damage. In addition, 
the adaptive immune system can recognize the graft as foreign and dangerous, 
which will induce effector mechanisms that cause deterioration of graft function 
and ultimately lead to loss of the transplant. In the past decades, advances in 
immunosuppressive drug therapy have greatly lowered the risk of early rejection 
[75], and the 1-year survival of renal allografts is about 90%. Despite these 
advances, the slowly progressive process of chronic immune rejection remains 
problematic and is the main cause of late allograft loss [76].
like in many adaptive immune responses, CD4pos T-cells play a central role in 
rejection of allografts. When these cells are activated, they in turn activate an 
array of other immunologic effectors, such as macrophages, B-cells and CD8pos 
cytotoxic T-cells (see Figure 1). Once activated, these effectors result in delayed 
type hypersensitivity reactions against donor antigens, alloantibody production 
and direct lysis of graft cells, respectively. All these processes cause damage to the 
graft.
Donor antigens are largely divided into two main categories: major 
histocompatibility complex (MHC) antigens and minor histocompatibility antigens. 
In humans, MHC antigens are called human leukocyte antigens (HlA). HlA is 
important for physiological T-cell activation, as it is involved in antigen presentation. 
HlA class II is constitutively expressed by APCs such as DCs. These cells scout their 
surroundings for antigens, take them up through phagocytosis and process them 
into peptides. These foreign peptides are then bound to HlA class II molecules 
and presented to CD4pos T-cells. CD4pos T-cells with a T-cell receptor specific for the 
peptide/HlA complex bind to the APC and are activated. HlA class I is present on 
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all nucleated cells and is used to 
present peptides derived from 
intracellular pathogens to CD8pos 
T-cells, and CD8pos T-cells with 
a T-cell receptor recognizing 
the peptide/HlA complex are 
activated.
In the transplantation setting, 
there are two well-described 
pathways for activation of 
recipient CD4pos T-cells: direct 
and indirect allorecognition 
(Figure 3). In the direct route, 
recipient T-cells are activated 
directly by donor APCs. The 
foreign HLA on these APCs 
results in the activation of a high 
number of alloreactive CD4pos 
T-cells and CD8pos T-cells. several 
studies indicate that the direct 
route is the most important pathway in the pathophysiology of acute rejection 
[77-80]. On the other hand, it seems not to be a significant contributor to chronic 
rejection, possibly because the donor APCs disappear over time [81-83]. In indirect 
alloantigen recognition, recipient APCs present alloproteins (particularly peptides 
derived from allo-HlA) to CD4pos T-cells, thereby activating them. The indirect 
activation route resembles the normal route of eliciting a response against other 
antigens. Thus, non-self HlA-molecules are highly immunogenic proteins in both 
the direct and the indirect pathway of allorecognition. An explanation for this high 
immunogenicity is that the thymus selects T-cells with a low affinity for self-HlA 
to prevent autoimmune reactions. These same T-cells can have a high affinity for 
foreign HlA molecules that differ slightly from self-HlA. To keep immunogenicity 
of donor organs to a minimum, donors are selected for maximum HLA-matching 
with the recipient. To complicate matters, many other foreign donor-proteins 
(such as minor histocompatibility antigens) are capable of activating recipient 
T-cells in the indirect alloreactivity pathway. These proteins are capable of causing 
chronic rejection in the absence of HlA-mismatches [84]. Even though the number 
of precursor T-cells in the indirect route is much lower than in the direct route 
(at least 10-fold lower in mice [77] and even 100-fold lower in humans [78]), the 
indirect route is of great importance because it does not fade over time, and it 
is associated with acute [83;85;86] as well as chronic rejection [81;87-90] in both 
animal models and human transplant recipients. 
solid organ transplant recipients currently receive lifelong treatment with 
immunosuppressive drugs to prevent unwanted immune responses to alloantigens. 
These drugs are certainly not ideal, as they do not offer complete protection from 
rejection, and the required long-term immunosuppression has major adverse 
effects, such as an increased incidence of infections and malignancies [91;92]. 
Infections in transplant recipients can trigger alloimmune responses by molecular 
figure 3. cD4pos t-cells can be activated by donor 
antigens through two pathways: the direct pathway 
(left) and the indirect pathway (right).
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mimicry, activation of APCs carrying alloantigen, and by local increase in the 
concentrations of cytokines and chemokines [93;94].
There are a number of strategies aiming at minimizing generalized 
immunosuppression while still preventing graft rejection, so-called donor-specific 
immunosuppression. Generally, these include therapies that lower relative 
frequencies or functional activity of alloreactive Tconv, and those that increase 
the frequency or activity of alloreactive regulatory cell subsets. The use of 
immunosuppressive drugs that permit or promote Treg generation and function in 
vitro, such as rapamycin [95] might have clinical benefit. Another option is to induce 
lymphopenia at the time of transplantation by administration of antibodies that 
deplete leukocyte populations such as anti-thymocyte globulin (depleting mainly T-cells, 
but also B-cells) or Alemtuzumab (anti-CD52, depleting T-cells, B-cells, monocytes, 
and granulocytes) to transplant recipients. Treg are activated by a lymphopenic 
environment [96]. Also, different subsets of leukocytes are repopulated at different 
rates and interestingly, regulatory immune cells can outnumber effector cells in 
the early stages of repopulation [97;98], which can help to create a tolerogenic 
environment for the transplant. Anti-thymocyte globulin has been shown to 
promote the generation of Treg [98], while Alemtuzumab can foster the generation 
of Treg [97] as well as CD8pos regulatory cells [99] and regulatory B-cells [100]. 
A logical approach to directly increase Treg numbers is cellular therapy using 
Treg. In a variety of experimental models of solid organ transplantation, including 
transplantation of skin [101;101-106], heart [101-103;107] and artery [108;109], 
adoptively transferred Treg were able to induce tolerance or to prolong graft 
survival. In these models, Treg immunotherapy has proven to be a very effective 
strategy for controlling both acute [104-108] as well as chronic rejection [107-
109]. Alloantigen-specific Treg are more efficient than polyclonal Treg and have 
lower potential of inducing general immune suppression. In most of the animal 
studies mentioned above, Treg with direct alloantigen-specificity were used. 
In two studies, it was shown that a combination of Treg with direct and indirect 
alloantigen-specificities was superior to only Treg with direct antigen-specificity 
[102;107]. 
Clinical trials on Treg immunotherapy with polyclonal Treg have been initiated. A 
large multicentre Phase I/II clinical trial in kidney transplant recipients is currently 
ongoing [110], and clinical trials have also been started in pediatric kidney 
transplantation recipients [111] and in liver transplantation recipients [112]. 
Before clinical trials using alloantigen-specific Treg can be envisioned, a number of 
technical difficulties have to be overcome.
sTEM CELL TRANsPLANTATION
Stem cell transplantation (SCT) is the optimal treatment modality for a number 
of hematological malignancies, such as multiple myeloma or leukemia, and other 
(hematological) diseases [113]. Although SCT has the potential to cure patients with 
life-threatening diseases, it is associated with a high burden of treatment-related 
morbidity and mortality. The treatment includes high dose chemotherapy and/
or radiotherapy to minimize the number of malignant cells in the host. Inevitably, 
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this results in temporary failure of hematopoiesis. Engrafted donor hematopoietic 
stem cells eventually reconstitute the hematopoietic system. The leukocytes that 
develop from the transplanted stem cells have the important task of eradicating 
recipient tumor cells that survived the conditioning regimen, which is called the 
graft-versus-leukemia response (Gvl) [114]. However, this new immune system 
can also recognize normal, healthy cells of the patient as non-self and can launch 
an attack. This is called graft-versus-host-disease (GvHD) [115], a complication 
that is fatal in approximately 15% of transplant recipients [116]. In contrast to the 
situation in solid organ transplantation where alloresponses are restricted to the 
allograft, in the case of SCT the donor immune cells can in potential attack every 
single healthy cell of the host. The most commonly affected organs are the gut, 
the liver and the skin. Similar to alloresponses in solid organ transplantation, the 
most important alloantigens starting these reactions are the HlA-molecules. The 
direct route of alloantigen-reactivity is important in graft-versus-host pathology 
(see Figure 3) [117]. In contrast to the situation in solid organ recipients, the 
direct route of alloantigen presentation does not fade over time in SCT recipients. 
Transplantation centers pursue a high degree of HlA-matching to prevent harmful 
reactions, as HlA-mismatching is associated with more severe GvHD [113;118]. To 
this end, the patient’s family is screened for a well-matched donor. If no suitable 
related donor can be found, international stem cell donor databases are searched 
for a matched unrelated donor. However, for patients with uncommon HlA-types, 
such as patients from ethnic minority groups, these searches often fail to provide 
a suitable donor. For these patients, HlA-locus mismatched or haploidentical stem 
cells are increasingly used for transplantation [119]. 
Nowadays, patients receive immunosuppressive drug treatment to reduce GvHD 
after stem cell transplantation. However, also for these patients immunosuppressive 
drug treatments are not ideal. Immunosuppressive drugs decrease Gvl activity, 
thereby increasing the risk of relapse, and increase the incidence of infections and 
other malignancies. Immunosuppressive regimens after stem cell transplantation 
therefore need to carefully navigate between the risks of GvHD and of tumor 
relapse and other adverse effects. 
Treg immunotherapy is a highly attractive candidate for cellular therapy after 
sCT, because these cells have the capacity to reduce GvHD while allowing GvL 
responses in vivo in animal models [120-122]. Even in aggressive SCT models with 
transplantation across complete MHC barriers, lethal GvHD can be prevented by 
Treg administration, although high ratios of Treg were needed (1:1 Treg:Tconv) 
[123-125]. Treg immunotherapy in SCT models is also very attractive because of 
the deeply lymphopenic setting, which activates Treg and gives them an advantage 
over effector cells, as described above for lymphocyte depletion after solid organ 
transplantation. When Treg were given a head start by administration one or two 
days prior to Tconv, Treg: Tconv ratios down to 1:10 were shown to be sufficient 
[52]. 
The first small-scale clinical trials in humans have been conducted. In a trial 
with twenty-three patients who received SCT from umbilical cord blood and 
polyclonally expanded Treg from third party donors [126]. The patients received 
additional immunosuppressive drugs. No adverse effects from the infused Treg 
were observed, and incidence of severe acute GvHD was significantly reduced as 
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compared with historical controls. In another trial, twenty-eight patients received 
polyclonal Treg (not expanded) four days before haploidentical SCT from the same 
donor [127]. The patients did not receive immunosuppressive drugs. The patients 
showed faster immune reconstitution, a lower rate of GvHD, and a lower rate of 
disease relapse as compared to historical controls. 
While in the studies mentioned above Treg immunotherapy is used for prevention of 
GvHD, in one study Treg were administered to two patients with active GvHD [128]. 
One patient with chronic GvHD was successfully treated and immunosuppressive 
drugs could be withdrawn. However, the other patient suffered from acute GvHD 
that progressed despite Treg immunotherapy. 
Together, these results are very promising, and other trials in sCT recipients are 
now ongoing [129;130]. 
AUTOIMMUNITy
There are many autoimmune diseases, with varying clinical presentations and 
limited therapeutic options. As over 3% of people are affected by autoimmune 
diseases, autoimmunity causes high morbidity and mortality world-wide [131]. 
Among the most prevalent autoimmune diseases are type I diabetes, rheumatoid 
arthritis, inflammatory bowel disease, psoriasis, systemic lupus erythematosus 
and multiple sclerosis. The severity of autoimmunity varies widely between 
patients, from mild intermittent symptoms to life-threatening disease. Immune 
dysregulation plays a major role in the pathogenesis of autoimmune diseases, 
for the initiation as well as the progression of these diseases. Although the exact 
pathophysiology of autoimmunity is different for all autoimmune diseases, Treg 
seem to play a role in many of them. For example, impaired Treg function has been 
shown in patients suffering from type 1 diabetes [132;133], rheumatoid arthritis 
[134], multiple sclerosis [135;136] and psoriasis [137;138]. Currently, patients are 
treated with a myriad of immunosuppressive drugs and/or biologicals, with varying 
success. 
Of special interest are the treatments that promote Treg function. Similar to the 
solid organ transplantation setting, antibody treatments creating lymphopenia 
are of interest in the treatment of autoimmune diseases, as lymphopenia causes 
Treg activation and gives Treg an advantage over effector cells. These effects might 
help to rebalance the immune system in autoimmunity. Indeed, anti-thymocyte 
globulin showed promising results in early-onset type 1 diabetes [139] and administration 
of antibodies against the T-cell receptor CD3 induces Treg that suppress type 1 
diabetes in animals [140] and improved clinical symptoms in early-onset diabetic 
patients [141]. The immunosuppressive drug rapamycin is of interest for the 
treatment of autoimmunity as it permits or promotes Treg cell generation and 
function in an animal model of type 1 diabates [142], and this drug is currently 
tested in human patients with type 1 diabetes. 
One way to directly push the immune balance towards self-tolerance in 
autoimmunity is to adoptively transfer Treg. Treg immunotherapy has been shown 
to block development of disease in animal models of multiple sclerosis [143;144], 
type 1 diabetes [145-147], systemic lupus erythematodes [148]. Treg transfer 
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slowed progression of ongoing disease in an animal models of rheumatoid arthritis 
[149], and even reversed ongoing disease in an animal models of inflammatory 
bowel disease [150], type 1 diabetes [146] and systemic lupus erythematodes [148]. 
In some of these studies, antigen-specific Treg were used, which were generally 
more efficient as compared to polyclonal Treg [144-147].
The first clinical trial on adoptive Treg transfer in human autoimmune patients has 
been reported in inflammatory bowel disease [151]. ex vivo generated autologous 
ovalbumin-specific Treg clones were administered to twenty patients with 
moderate to severe refractory inflammatory bowel disease (Crohn’s disease), and 
patients ingested an ovalbumin-enriched diet to ensure activation of gut-homing 
Treg. The adoptive transfer of Treg was safe, with eleven patients experiencing 
adverse events possibly related to Treg infusion (gastrointestinal disorders, most 
commonly temporary flare of inflammatory bowel disease), including two patients 
with serious adverse events (arterial thrombosis, septic thrombophlebitis, serious 
flare of inflammatory bowel disease). All patients recovered from the adverse 
events. Interestingly, 40% of the patients had favorable clinical responses after 
Treg infusion, including six patients with complete remission. However, the clinical 
effect was limited in time, with a maximum at five weeks after treatment and 
progressive decline thereafter, suggesting that multiple Treg infusions might be 
necessary to reach long-lasting effects. Another trial on Treg immunotherapy has 
recently been started in type 1 diabetes patients [152].
AIM AND OUTLINE Of THIs THEsIs         
Treg play a critical role in various immunological processes, and immunotherapy 
based on Treg is a potential treatment for several immunological diseases, 
including unwanted transplantation related immune processes and autoimmune 
diseases. The ideal therapeutic intervention after transplantation of solid organs 
or stem cells should induce allospecific tolerance, defined as the absence of an 
immune response against alloantigen without immunosuppressive drug treatment, 
while immune responses against other antigens, such as antigens on tumor cells 
and pathogenic microorganisms, remain intact. similarly, in autoimmunity ideally 
the autoimmune responses should be dampened without immunosuppressive 
drug treatment, while maintaining normal immunity against other antigens. 
Even though the first clinical trials on Treg immunotherapy are promising, many 
important issues regarding Treg biology in healthy or diseased humans, as well 
as Treg behavior in the immunotherapeutic setting have to be addressed before 
Treg therapy can be safely used in standard clinical practice. At what location can 
different Treg subsets exert their function? Which Treg subsets are most effective? 
How about the isolation of these Treg? How many Treg are needed? How can the 
numbers of Treg needed be obtained? What about the timing of Treg infusions? 
Will adoptively transferred Treg maintain a stable Treg phenotype in the patient, or 
is there a risk of conversion into Tconv? In the present thesis, we address a number 
of these fundamental aspects regarding Treg biology and Treg immunotherapy. We 
explored the role of Treg in the human immune system, and its potential use for 
immunotherapy, especially in transplantation. 
Chapter 1 gives a short introduction on the immune system with a focus on Treg, 
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and on Treg based immunotherapy in transplantation and autoimmunity.
In chapter 2, an overview of Treg immunotherapy in transplantation is provided.
In chapter 3, we analyzed human lymphoid tissues involved in immune responses 
in order to elucidate where and how Treg may exert their suppressive functions. 
We describe the presence of activated Treg in secondary lymphoid organs, and we 
present clues for homing behavior of Treg towards peripheral tissues. 
for Treg immunotherapy, it is important to understand the role of Treg in local 
tissue immunity. We chose the skin as an organ that harbors many lymphocytes 
and serves as a potential port of entry for external organisms. We started out by 
taking a closer look at the crosstalk between epithelial cells, the keratinocytes, 
and T-cells. In chapter 4, we describe a novel in vitro co-culture system with 
keratinocytes, CD4pos and CD8pos T-cells and Treg. We show that the keratinocytes 
and effector T-cells influence each other, and co-operate to form an effective local 
immune response. Treg were found to regulate these responses only at the level of 
proliferation.
In the following chapters, we focus on some practical aspects of Treg 
immunotherapy. for successful immunotherapy, high numbers of Treg are needed. 
In chapter 5, we describe a highly efficient protocol to expand human Treg in an 
alloantigen-specific manner. 
Subsequently, we report on the current options of isolating Treg according to 
clinical grade guidelines in chapter 6.
In chapter 7, the data presented in this thesis are summarized and discussed.
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2
ABsTRAC T            
Regulatory T-cell (Treg) based immunotherapy is of great interest to induce 
tolerance in clinical transplantation settings. In fact, the first clinical trials on Treg 
infusion after stem cell transplantation have recently been started. However, many 
important issues regarding human Treg immunotherapy are not resolved yet. In this 
review, we provide a short update on Treg and elaborate on various strategies for 
Treg based immunotherapy. first, infusion of ex vivo selected naturally occurring 
Treg is addressed, with emphasis on Treg isolation, expansion, antigen-specificity, 
homing, and stability. Next, the potential of ex vivo induced Treg transfusion 
strategies is discussed. finally, therapies aimed at in vivo increase of Treg numbers 
or function are addressed. In addition, we summarize the current knowledge on 
effects of immunosuppressive drugs on Treg. In the following years, we expect 
exciting new data regarding the clinical application of Treg immunotherapy in 
transplantation. 
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INTRODUC TION               
Transplantation of solid organs or hematopoietic stem cells is the therapy of choice 
for many end-stage diseases. A major complication after transplantation is the 
occurrence of an immune response directed towards allogeneic antigens. 
After solid organ transplantation, this can result in graft rejection with dysfunction 
and potential loss of the transplanted organ. Therefore, organ transplant recipients 
currently receive lifelong treatment with immunosuppressive drugs to prevent 
unwanted immune responses to alloantigen. These drugs do not offer complete 
protection from rejection, while the long-term immunosuppression has major 
adverse effects, such as an increased incidence of infections and malignancies [1]. 
Transplantation of allogeneic hematopoietic stem cells is used as a treatment for 
hematopoietic malignancies. The transplanted stem cells have the important task 
of eradicating recipient tumor cells that survived the conditioning regimen, which 
is called the graft-versus-leukemia response. However, the donor immune cells can 
also recognize and attack the healthy cells of recipient tissues through a so-called 
graft-versus-host response, which leads to the potentially lethal complication 
graft-versus-host disease [2;3]. After stem cell transplantation, patients receive 
immunosuppressive drug treatment to reduce graft-versus-host responses, but 
this also decreases graft-versus-leukemia activity, thereby increasing the risk of 
relapse. Immunosuppressive regimens after stem cell transplantation therefore 
carefully navigate to create a fine balance between the risks of graft-versus-host 
disease and of tumor relapse. 
The ideal therapeutic intervention after transplantation of solid organs or stem 
cells should induce specific tolerance, defined as the absence of an immune 
response against alloantigen on solid organ grafts or on healthy host tissues 
without immunosuppressive drug treatment, while immune responses against 
other antigens, such as antigens on tumor cells and pathogenic microorganisms, 
remain intact. 
Regulatory T-cells (Treg) play a critical role in various immunological processes, 
particularly in maintaining homeostasis and self-tolerance, by modulation of 
immune effector functions. Although thymic selection processes in essence 
create a population of naturally occuring Treg (nTreg) with high affinity for self 
antigens, it has been shown that the T-cell receptor repertoire of nTreg also 
includes receptors that can recognize non-self antigens [4]. The feasibility of Treg 
based immunotherapy to induce tolerance to alloantigens has been demonstrated 
in animal models of stem cell transplantation [5-13] and to a lesser extent also 
in organ transplantation [14-19]. Several studies suggest that Treg also play a 
role in the clinical outcome in human stem cell transplantation [20-22] and solid 
organ transplantation [23-26]. In this review, the current status of Treg based 
immunotherapy in human transplantation settings will be discussed.
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REGUl ATORy T-CEll S - BASIC FAC TS          
Many types of cells with regulatory properties have been identified [27]. This 
review will focus on regulatory cell types residing within the CD4pos T-cell lineage. 
CD4pos Treg can be divided in two categories: nTreg that emerge from the 
thymus, and induced Treg (iTreg) generated in the periphery by conversion of 
non-regulatory CD4pos T-cells (also called conventional CD4pos T-cells, Tconv) into 
regulatory cells. Many different stimuli can induce Tconv to convert into iTreg, as 
discussed in following sections, resulting in iTreg subsets with different phenotypic 
and functional properties. 
Most research has focused on nTreg. Although human nTreg populations were 
originally identified as CD4posCD25high T-cells [28], co-expression of these markers 
is not unique for nTreg, since human Tconv also express CD25 upon activation. The 
transcription factor FoxP3 is stably expressed by nTreg, and it is a key factor for 
their function. However, while it seems to be a specific nTreg marker in mice [29], 
in humans FoxP3 is also transiently expressed by recently activated Tconv [30;31], 
which seems to be regulated differently on the epigenetic level as compared to 
the stable expression in nTreg [32]. In contrast to Tconv and iTreg, human nTreg 
show strong DNA demethylation of several regions in the foXp3 locus [33-36]. 
The intracellular expression of FoxP3 limits the usefulness of this marker for the 
identification and isolation of viable nTreg. Further phenotypic analysis showed 
CD127 as a useful marker to identify nTreg, since nTreg show a CD25highCD127low 
expression, in contrast to Tconv, which express a CD25lowCD127high phenotype 
[37;38]. However, one study showed that subsets of activated Tconv also display 
a CD25highCD127low phenotype in vivo [39]. A recent finding suggests that low 
expression of both CD127 and CD49d in combination with high expression of CD25 
is unique for nTreg [40]. While this might be the case, this selection can exclude a 
subset of nTreg that expresses CD49d [40]. Another marker that has been described 
to differentiate between nTreg and activated Tconv is PD-1 [41]. The majority of 
resting nTreg displays a CD25highPD-1neg phenotype, in contrast to activated Tconv, 
which show a CD25posPD-1high phenotype. The disadvantage of using this strategy 
for isolation of nTreg is that activated nTreg are excluded, as activated Treg 
show surface PD-1 expression. Many other markers have been described to be 
differently expressed on nTreg as compared to Tconv, such as GITR [42;43], CTlA-4 
[44], membrane bound TGF-β [45], NP-1 [46], FR4 [47], CD39 and CD73 [48;49], but 
none of them are uniformly expressed on all nTreg and/or are unique for nTreg. 
Taken together, despite ample research, still no definite set of markers for nTreg 
has been described to date, and currently most studies define human nTreg by 
their CD4posCD25highCD127lowFoxP3pos phenotype. 
Within both the human and animal nTreg population, several subsets with different 
properties have been identified. The differentiation of nTreg resembles that of 
Tconv, with CD45RAposCD25pos naïve nTreg [50;51], memory nTreg expressing lymph 
node homing markers CCR7 and CD62l, and memory nTreg which do not express 
lymph node homing markers but are positive for multiple peripheral homing 
markers such as selectin ligands, adhesion markers and chemokine receptors 
[52;53]. Alternatively, human nTreg can be subdivided based on expression of CD27 
[54-56] or HlA-DR [57].
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The local cytokine milieu is of great importance for Treg function and differentiation. 
Many cytokines have been shown to influence Treg function [58]. Il-2 is essential 
for nTreg proliferation and regulatory function, although high concentrations of 
Il-2 abrogate suppression [55;59]. Therapy with exogenous Il-2 seems to facilitate 
Treg in vivo in human patients [60-62]. Il-15 and Il-7 abrogate suppression in vitro, 
and the presence of these cytokines in vivo in inflamed sites correlates with more 
severe inflammation in autoimmune patients [55;63]. 
A dual role in immune activation and suppression is described for TNFα. This 
cytokine has pro-inflammatory Th1-associated functions, and it also abrogates 
suppressive activity of human nTreg in vitro [64], but TNFα also has Treg promoting 
functions, as it synergizes with Il-2 in the stimulation of mouse nTreg [65]. The 
pro-inflammatory cytokines Il-1β and Il-21 inhibit the function of animal and 
human nTreg [66-68]. Importantly, human nTreg subsets can differentiate into Il-
17 producing cells upon activation, in a process that requires Il-2 and is enhanced 
by Il-1β, Il-23, Il-21, and/or Il-6 [69-71]. Evidence that this differentiation process 
also occurs in vivo comes from mouse models where it was shown that nTreg 
can differentiate into non-regulatory FoxP3neg cells [72-74]. The stability of nTreg 
is associated with epigenetic modifications of the foXp3 locus. Upon repeated 
stimulation, subsets of nTreg show partial methylation of regions within the 
foXp3 locus, correlating with loss of FoxP3 expression and production of pro-
inflammatory cytokines [75]. Also, the differentiation of nTreg into Il-17 producing 
cells can be suppressed by blocking histone deacetylation in vitro [69]. In humans, it 
has been shown that CD27neg and HLA-DRneg nTreg subsets have a higher potential to 
differentiate into Il-17 producing cells than their CD27pos or HLA-DRpos counterparts 
[69;70]. 
The significance of the effects of these cytokines on nTreg for the human in 
vivo situation after transplantation is not clear. It can be envisioned that clinical 
administration of exogenous cytokines or cytokine-blocking agents might facilitate 
Treg based immunotherapy. 
Treg MECHANIsMs AND sITE Of ACTION IN TRANsPLANTATION 
sETTINGs        
The exact mechanisms used by Treg to suppress alloantigen immune responses 
and to induce transplantation tolerance remain incompletely understood. In 
general, Treg can modulate Tconv actions directly through cell-cell contact, by 
the production of cytokines, by cytokine scavenging, or indirectly by modulation 
of antigen presenting cells [76]. Memory Tconv seem to be more resistant to 
suppression by Treg as compared to naïve Tconv, in vitro as well as in vivo [54;77].
CTlA-4 is widely known as a negative costimulation receptor, expressed on 
activated Tconv. Upon binding to costimulatory ligands CD80 or CD86, CTlA-4 
provides a negative signal that attenuates Tconv activation. As mentioned in the 
section above, Treg constitutively express high levels of CTlA-4 [44], which seems 
to be critical for Treg suppressor function. Cell-cell contact of antigen presenting 
cells and regulatory T-cells through CTlA4-CD80/CD86 interaction results in a 
downregulation of CD80 and CD86 on the antigen presenting cell, and thus in a 
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reduction of its capacity to activate Tconv [78]. Also, CTlA-4-CD80/CD86 ligation 
increases the expression of IDO in antigen presenting cells [79;80]. IDO is an 
intracellular enzyme involved in tryptophan metabolism, and antigen presenting 
cells that express IDO regulate immune tolerance by inhibiting Tconv proliferation 
and expanding Treg populations [81;82].
By producing anti-inflammatory cytokines, Treg contribute to their micro-
environment. Il-35, a newly described immunosuppressive cytokine, is produced 
by nTreg and seems to be crucial for their function [83]. Recent reports indicate 
that the cytostatic factor Galectin-1 is also important for nTreg function [84]. 
Interestingly, administration of soluble Galectin-1 prevents Th1 mediated cell 
damage and reverted autoimmune disease in an animal model [85]. Both nTreg 
and iTreg produce Il-10 and/or TGF-β, cytokines that inhibit Tconv proliferation and 
induce conversion of Tconv into iTreg [44;86-88].
In transplantation, Treg can exert their function either in the lymph nodes, in an 
organ graft [16;17;89-91], or at sites of graft-versus-host responses in stem cell 
transplantation, such as liver, gut, and skin [13;92]. In a mouse model of stem cell 
transplantation, Treg were shown to be crucial for the development of tolerance 
in the first phase after transplantation [93]. In this particular model, Treg function 
mainly took place in lymph nodes in the early stages, while in later stages Treg 
were found at target sites. In contrast, in an islet allograft model nTreg were shown 
to migrate to the graft site before migrating to lymph nodes [94]. In a mouse skin 
transplantation model it was shown that tolerance induction for MHC class II 
mismatches was largely regulated in lymph nodes by inhibition of Tconv activation 
and expansion, while tolerance for grafts with MHC class I mismatches was mainly 
due to decreased survival or active deletion of alloantigen specific Tconv in the 
periphery [77]. In the setting of human transplantation, insufficient data are 
available to draw conclusions on the mechanism and site of action of Treg.
REGUl ATORy T-CEll BASED THERAPy            
Approaches for Treg based therapy can be divided into three categories (Figure 1). 
The Treg pool can be increased by infusion of ex vivo selected nTreg, by infusion of 
ex vivo generated iTreg, or therapy can be aimed at increasing numbers or function 
of Treg in vivo. These different strategies will be discussed in the next sections. 
TRANsfER Of eX ViVo  sELECTED nTreg      
In mouse models of hematopoietic stem cell transplantation, nTreg have an 
important role in the regulation of graft-versus-host disease. Indeed, depletion 
of nTreg from the stem cell graft led to an accelerated graft-versus-host disease 
[5;7]. On the other hand, addition of freshly isolated [5;6;8;12] or ex vivo expanded 
[5;7;9-11] donor Treg could delay or even prevent graft-versus-host disease. Also, 
nTreg promoted bone marrow engraftment in sublethally irradiated animals 
[12;95]. Importantly, recipient animals remained capable of graft-versus-leukemia 
responses in most cases [8-10;13], although some anti-leukemia responses were 
compromised [10]. It has also been reported that infusion of nTreg induces 
accelerated donor lymphoid reconstitution, leading to increased virus-specific 
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immune responses early after transplantation, thereby preventing infection-
induced death [96].
In animal models of solid organ transplantation, the infusion of ex vivo selected 
nTreg also appeared to be beneficial. Infusion of nTreg in this setting has been 
shown to result in increased graft survival, delay of rejection, and induction 
of alloantigen-specific tolerance [15-19]. However, achievement of long-term 
tolerance to solid organ transplants seems to be difficult, as it required additional 
immunosuppressive drug administration [19], use of immune-incompetent animals 
[15;16], hematopoietic chimerism [18] or infusion of antigen-specific nTreg [15-17]. 
Removal of transferred nTreg after the induction of tolerance led to graft rejection, 
indicating the crucial role of nTreg in the maintenance of tolerance [15].
For successful translation of promising nTreg based therapies into humans, a 
number of important issues need to be addressed: the purity of the cell population 
to be infused, the antigen-specificity of the cells, the stability of infused cells in 
vivo, and the timing of nTreg infusion. Moreover, all ex vivo manipulations need 
to take place in clinical-grade conditions, which requires the development of new 
good manufacturing practice (GMP) protocols.
PURITy Of IsOLATED nTreg
For clinical application of nTreg, it is required that nTreg populations can be isolated 
in a reproducible GMP fashion. GMP nTreg isolation strategies using the CliniMACS 
system have been reported [97-100]. The basis of these isolation protocols consists 
of magnetic enrichment of CD25pos cells from aphaeresis products. CD19pos B-cells 
and/or CD8pos cytotoxic T-cells can be depleted to minimize contamination with 
immune effector cells. However, a significant percentage of CD4posCD25neg/low 
T-cells remains present in the isolated nTreg populations, and up to now, CliniMACS 
isolation strategies yield only 40-60% pure nTreg. To increase the purity of GMP 
isolated nTreg populations, several strategies could be employed. As mentioned, 
Tconv can be distinguished from nTreg by their expression of CD127 [37;38]. 
Depletion of CD127pos cells (in a non-GMP fashion) from CliniMACS isolated nTreg 
populations indeed greatly increases the purity [99]. Other possible approaches 
are depletion of CD49dpos cells or PD-1pos cells from the nTreg populations, as this 
improves purity of nTreg in small scale flowcytometry based isolation procedures 
[40;41]. CliniMACS isolation tools for CD127, CD49d or PD-1 are not available yet, 
but the development of some of these new tools is in progress (Miltenyi Biotec, 
personal communication). 
For solid organ graft recipients, a high purity of nTreg for immunotherapy is strongly 
desirable. Infusion of non-regulatory cells in these patients can potentially intensify 
graft rejection. However, for stem cell transplantation recipients, suboptimal nTreg 
purity may not pose a problem. Currently, in many stem cell transplant centers, 
recipients are treated with donor lymphocyte infusions to enhance graft-versus-
leukemia responses. The main adverse effect of this treatment is an increased 
incidence and severity of graft-versus-host disease. The aim of Treg immunotherapy 
in this patient group is to reduce these graft-versus-host responses, while sparing 
the graft-versus-leukemia responses. Co-infusion of both non-regulatory T-cells to 
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ensure graft-versus-leukemia responses and Treg to prevent excessive graft-versus-
host responses would therefore be a logical approach in this setting. The purity 
obtained by current GMP isolation methods could well fit within this strategy. 
Indeed, the first clinical trials on nTreg infusion after stem cell transplantation have 
recently started, using this approach (see www.clinicaltrials.gov).
HIGH NUMBERs Of PURE nTreg
Treg therapy in human patients will require very high numbers of nTreg, which 
might be obtained by ex vivo nTreg expansion. It has been shown that human nTreg 
can be expanded polyclonally with bead-bound anti-CD3 and anti-CD28 antibody 
stimulation in combination with Il-2 and/or Il-15 [30;101-105]. Artificial antigen 
presenting cells modified to express anti-CD3 and costimulatory molecules produce 
even greater nTreg expansion [102;106;107]. These polyclonal expansion protocols 
efficiently increase nTreg numbers, while preserving suppressive capacity. 
Due to the relatively low proliferative capacity of nTreg and the technical 
difficulties in obtaining highly pure starting populations for large-scale clinical 
grade expansion, outgrowth of non-Treg cells in expansion cultures is a significant 
risk that must be prevented. Once nTreg isolation protocols are improved and 
high nTreg purity can be obtained routinely, it might be worthwhile to go even 
a step further and isolate only a subset of nTreg prior to expansion, as isolated 
naïve CD45RApos nTreg, or CD62lposCCR7pos lymph node homing nTreg prove to be 
more stable in ex vivo expansion cultures [108]. Next to improvement of nTreg 
isolation protocols, the risk of non-regulatory T-cell outgrowth can be minimized 
by addition of selected immunosuppressive drugs to nTreg expansion cultures, 
which allow Treg proliferation while inhibiting non-Treg growth. Rapamycin seems 
a promising candidate drug for this purpose, as addition of rapamycin to nTreg 
expansion cultures prevents outgrowth of non-Tregs [109;110]. On the downside, 
depending on concentration and culture system, it can also reduce the yield of 
nTreg expansion cultures [107;110]. Histone deacetylation inhibitors might also be 
used to maintain nTreg purity during expansion. Addition of a histone deacetylation 
inhibitor to nTreg cultures in vitro blocks differentiation of nTreg into Il-17 cytokine 
producing cells [69]. 
ANTIGEN-SPECIFICITy OF nTreg
There are drawbacks regarding clinical application of polyclonal nTreg. First, 
since nTreg populations express a broad range of T-cell receptor specificities, the 
infused polyclonal nTreg may suppress immune responses other than the target 
alloantigen response, thereby increasing the risk for opportunistic infections and 
tumor-growth. second, due to the low percentage of nTreg within a polyclonal cell 
pool that is specific for the target alloantigen, large numbers of cells need to be 
infused to inhibit specific responses. Indeed, in animal models, alloantigen-specific 
nTreg were shown to be more efficient than polyclonal nTreg [10;111-114]. Non-
specific suppression occurred only when very high numbers of alloantigen-specific 
nTreg are infused [11]. 
There are two main pathways for the generation of alloantigen immune responses 
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[115]. In the direct pathway, T-cells recognize intact allogeneic MHC molecules 
on allogeneic antigen presenting cells, putatively through cross-reactivity. In the 
indirect pathway of alloreactivity, alloantigen is presented by autologous antigen 
presenting cells in the context of self-MHC molecules. Human alloantigen-specific 
nTreg can be obtained by ex vivo expansion, either by stimulation with intact 
allogeneic cells, enriching for direct pathway antigen-specific nTreg [54;105;116] or 
by stimulation with alloantigen-peptides, enriching for indirect pathway antigen-
specificity [117;118]. 
FIguRe 1. oveRvIew oF stRategIes FoR treg BaseD IMMuNotHeRaPy. 
the treg pool can be increased by infusion of ex vivo selected naturally occurring treg (ntreg, 
upper box), or ex vivo induced treg (itreg, middle box), isolated from the recipient (in solid organ 
transplantation) or the donor (in stem cell transplantation). alternatively, therapy can be aimed at 
increasing numbers or function of treg in vivo (lower box). treg based immunotherapy will likely take 
place under the cover of concurrent treatment with immunosuppressive drugs.
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As intact donor cells can be used for ex vivo generation of nTreg with direct 
alloantigen-specificity, exact knowledge of the alloantigens involved is not 
required. However, the direct route of alloantigen presentation is mainly active in 
the first period after transplantation, and infusion of nTreg with direct specificity 
might not be effective to regulate chronic alloantigen responses [18;119]. Treg with 
indirect alloantigen-specificity seem to play an important role in the maintenance 
of long term tolerance in animal models [120], and the presence of nTreg with 
indirect alloantigen-specificity in stable human organ transplant recipients has 
been demonstrated [23]. The generation of nTreg with indirect specificity is 
more complicated. Stimulation of nTreg through the indirect pathway requires 
presentation of alloantigen in the context of autologous MHC molecules. Autologous 
dendritic cells (DC) loaded with alloantigen can be used for this purpose [117;118]. 
However, this method leads to outgrowth of autoantigen-specific nTreg and only 
a minority of expanded cells indeed has alloantigen-specificity. This problem can 
be overcome by using an artificial antigen-presentation method with allopeptide-
loaded HlA-tetramers [118]. Expansion of nTreg with indirect alloantigen-specificity 
requires detailed information about immunogenic allogeneic HlA epitopes that 
can be presented by autologous HlA, and subsequently preparation of both HlA-
peptides and autologous DC or HlA-tetramers for each specific donor-recipient 
combination. Because the indirect pathway is important in chronic graft rejection 
and chronic graft-versus-host disease, nTreg with indirect alloantigen specificity 
are potentially of great therapeutic benefit.
Another way of obtaining alloantigen-specific nTreg is through transduction of 
specific T-cell receptor genes using a retroviral vector, thereby artificially conferring 
alloantigen specificity. Interestingly, nTreg with dual alloantigen-specificity 
were created in this manner, by first generating nTreg with direct alloantigen 
specificity using direct alloantigen expansion, and subsequently adding a receptor 
gene for indirect alloantigen-specificity [121]. In an animal model of solid organ 
transplantation, nTreg with dual alloantigen-specificity were very efficient at 
inducing long-term graft survival [121]. Obviously, such an approach again requires 
very detailed knowledge of alloantigen presentation and appropriate receptors, 
specific for each patient/donor pair.
HOMING AND sTABILITy Of INfUsED nTreg in ViVo
Currently, there is no information about homing of infused nTreg in the human 
setting. In animal models, infused nTreg subsets are capable of homing to lymph 
nodes as well as to target sites of alloantigen responses [13;16;17;52;122]. In 
mouse models, the potency of nTreg with a lymph node homing phenotype versus 
nTreg with a peripheral homing phenotype may well depend on the phase of 
the response: CCR7posCD62lpos nTreg seemed to be stronger in the priming phase 
[95;123-125], while CCR7negCD62lneg memory nTreg appeared more efficacious in 
controlling ongoing autoimmune responses [126] and ongoing graft-versus-host 
disease [127]. In animal models, a potent peripheral homing memory nTreg subset 
can be characterized by their expression of CD103 [126;127]. However, there is 
a discrepancy between animals and humans, as CD4posCD103pos nTreg are rare in 
humans [128] and other markers to identify potent human peripheral homing nTreg 
are required. As mentioned above, it is hypothesized that lymph node homing 
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nTreg are actively suppressing Tconv priming in the induction phase of tolerance, 
while peripheral homing nTreg likely function by regulating active inflammation 
on site during the maintenance phase of tolerance. Thus, both subsets are likely 
to be beneficial in transplantation tolerance in different stages of the alloantigen 
responses. Depending on the nature of the response to be modulated, it might 
therefore be optimal to select and infuse different subsets of nTreg. 
Another concern is the stability of the infused nTreg in vivo. As addressed above, it 
has been shown that the nTreg cell pool is not absolutely stable in vitro, as under 
pro-inflammatory conditions human nTreg subsets can convert into a less desirable 
and possibly pro-inflammatory phenotype, for example Il-17 producing cells [69-
71]. As Il-17 is associated with chronic inflammatory processes, caution should 
be taken regarding the timing of nTreg infusion. Infusion into a pro-inflammatory 
microenvironment, such as found early after transplantation, may facilitate in 
vivo conversion of infused nTreg into Il-17 producing cells. Alternatively, the more 
stable nTreg phenotypes (CD27pos [69] or HlA-DRpos [70]) might be selected for 
infusion. However, this is currently not realistic in the clinical setting as proper GMP 
selection tools are lacking and cell yield will be very low.
Recently, it was reported that human nTreg can be transfected with a suicide 
gene (HSCV-1 co-thymidine kinase) without loss of suppressive function in vitro. 
This interesting safety measure would give the ability to specifically eliminate the 
cells after infusion by treatment with ganciclovir, should the cells show an instable 
phenotype [129].
TIMING Of eX ViVo sELECTED nTreg INfUsION
The optimal therapeutic schedule of nTreg infusion(s) in the human setting is 
not yet established. In most animal models, nTreg are administered in a single 
infusion at the time of transplantation. It is not known whether a single infusion 
will be sufficient and optimal in clinical settings, and multiple infusions might be 
necessary. Administration of a single dose of nTreg at various time points after 
stem cell transplantation showed that in this setting, the efficacy is optimal in the 
initial phase [13]. This might partially be explained by the finding that infused nTreg 
can efficiently prevent allogeneic immune responses exerted by co-infused naïve 
T-cells, but are less potent in inhibiting allogeneic immunity by co-infused memory 
T-cells [77]. Infusion of nTreg to treat ongoing alloimmune responses does not 
seem wise, because the cytokines present in an inflammatory microenvironment 
might decrease nTreg suppressive activity and/or could potentially lead to nTreg 
differentiation into non-regulatory cell types, as discussed above. If these data can 
be extrapolated to the human clinical setting, nTreg based therapy will be most 
effective if started some time before transplantation or, alternatively, at a later 
time point when peri-operative inflammatory conditions have subsided and non-
specific immunosupressive treatment has created an immunological quiescent 
state. Currently initiated clinical trials are in agreement with these considerations.
Administration of alloantigen-specific nTreg before transplantation requires 
foregoing knowledge of donor HLA-type and availability of donor cells. This should 
not pose problems in stem cell transplantation and in living donor solid organ 
41
IMMUNOTHERAPY WITH REGULATORY T-CELLS IN TRANSPLANTATION
2
transplantation, but a complication arises in cases of transplantation of organs 
from deceased donors, where there is obviously no knowledge of the donor 
characteristics prior to the transplantation. 
The feasibility of cryopreservation of GMP isolated nTreg in liquid nitrogen has 
recently been shown [99]. Clinical implementation of nTreg based therapy is 
facilitated if isolated nTreg populations can be stored prior to infusion, as this will 
allow a more flexible timing of nTreg therapy and/or therapeutic schemes with 
multiple nTreg infusions over time. 
TRANsfER Of eX ViVo  GENERATED iTreg      
Treg INDUCTION AND PREsERVATION
several methods to convert Tconv into iTreg have been described, which can 
roughly be divided into two categories. In the first, the Tconv are directly modulated 
by blocking or adding signals. In the other category, the iTreg are induced indirectly 
by signals from tolerogenic types of DC. 
DIRECT MODUlATION OF T-CEllS TO GENERATE iTreg in Vitro
One of the most studied iTreg subtypes are Tr1 cells [88]. Tr1 cells are CD25low and 
show transient upregulation of FoxP3 expression upon activation, similar to Tconv. 
The development of Tr1 iTreg from Tconv in vitro is driven by activation of CD4pos 
T-cells in the presence of Il-10. After conversion, Tr1 iTreg can be expanded by 
culture in the presence of Il-2 and Il-15, in the absence of T-cell receptor signaling 
[130]. The suppressive function of Tr1 iTreg is due to production of Il-10 and TGF-β, 
cytokines that have been shown to play a role in vivo in human stem cell and solid 
organ transplantation tolerance [131;132]. Infusion of Tr1 iTreg cells seems to 
have potential for clinical application, as it induced tolerance in animal models of 
transplantation [133], inflammation [134], and autoimmunity [135].
Another iTreg subset are those induced by in vitro activation in the presence of 
TGF-β signaling [86;87]. These cells show a CD4posCD25highFoxP3pos phenotype. 
TGF-β induced iTreg have strong suppressive capacity in animal models, and were 
shown to inhibit immune responses upon infusion in vivo [136-138], although one 
study showed less promising results [139]. For human TGF-β induced iTreg, strong 
suppressive capacity has been reported [86], which could not be confirmed in 
another study [140]. 
An alternative method of producing iTreg in vitro is by forcing FoxP3 expression in 
Tconv cells, which in animal models creates suppressive iTreg, capable of inducing 
transplantation tolerance [141;142]. In human cells, it has also been shown that 
iTreg can be generated from Tconv by FoxP3 transduction [143;144].
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INDIRECT MODUlATION OF T-CEllS VIA DENDRITIC CEllS TO GENERATE 
iTreg in Vitro
Some DC subsets have been described to have tolerance promoting functions, 
which can be exerted through a number of ways. Tolerizing DC have a low 
activation potential towards Tconv. In addition, they have been described 
to mediate iTreg conversion, lead to apoptosis of Tconv, and stimulate Treg 
proliferation and function. Human DC can be subdivided into two subsets: myeloid 
DC (also referred to as DC1) and plasmacytoid DC (also referred to as DC2). Mature 
human myeloid DC are potent activators of immune responses, while plasmacytoid 
DC are less effective in activating Tconv [145]. Plasmacytoid DC are associated 
with the induction of Il-10 producing iTreg, possibly mediated by the expression 
of IDO and ICOS-l [82;146]. When DC are in an immature state, they also have 
tolerizing qualities. Interestingly, interaction of human immature DC with activated 
nTreg leads to tolerogenic DC that are fixed in an immature-like state [147]. DC 
can also artificially be fixed in steady immature-like states by treatment with anti-
inflammatory agents such as cytokines (TGF-β, Il-10), cAMP activators, vitamin 
D3 receptor agonists, IlT receptor ligands (HlA-G), and immunosuppressive drugs 
(rapamycin, lF15-0195) [148]. Alternatively, DC can be rendered tolerogenic by 
forced expression of immunosuppressive molecules such as cytokines (Il-10, 
TGF-β), negative costimulatory molecules (CTlA4, PD-l1), or certain enzymes (IDO) 
[148;149].  
POTENTIAL CLINICAL APPLICATION Of iTreg
for ex vivo generated iTreg infusion in clinical settings, the same issues as for nTreg 
infusion should be addressed, regarding purity, antigen-specificity and stability 
after infusion in vivo. Of course, all ex vivo manipulations needed to generate iTreg 
ex vivo also require the development of appropriate GMP protocols.
Different ex vivo iTreg induction strategies yield iTreg populations of varying purity, 
but will probably always contain a residual amount of Tconv. These cells could 
potentially worsen immune pathology upon infusion in vivo. for this reason, it 
would be optimal if iTreg could be isolated out of the generated cell populations 
prior to infusion. However, there are currently no usable iTreg markers for this 
purpose. Human alloantigen-specific iTreg can be obtained by stimulation with 
immature allogeneic DC during the ex vivo iTreg conversion, which produces iTreg 
with direct alloantigen-specificity [150;151]. There are currently no reports on the 
generation of iTreg with indirect alloantigen-specificity. Genetic manipulation to 
force expression of alloantigen-specific receptors as described for nTreg can also be 
envisioned for iTreg. The stability of ex vivo generated iTreg populations and their 
homing pattern after infusion in vivo should be assessed before application of iTreg 
infusion in human patients. Interestingly, TGF-β induced iTreg, in contrast to nTreg, 
seem to be resistant to conversion into Il-17 producing cells under the influence 
of Il-6 in vitro, which suggests that these iTreg might be suitable for functioning in 
an inflammatory environment [152]. However, another study showed that only a 
minority of iTreg maintain FoxP3 expression after infusion in vivo [153]. Altogether, 
information on these important issues is very scarce. 
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in ViVo  Treg fACILITATION         
Blockade of costimulation signals in vivo during the initiation of alloantigen 
responses can reduce the activation of Tconv and facilitate the formation of iTreg 
and tolerance in animal models of transplantation. Next to the CD28-CD80/CD86 
and CD40l-CD40 costimulatory pathways mentioned above, other costimulatory 
pathways such as OX40-OX40l, ICOS-ICOSl, 4-1BB-4-1BBl, CD27-CD70 and GITR-
GITRl have been described to play a role in transplantation immunology in mouse 
models and are potential targets for interventions aimed at tolerance induction in 
vivo [154]. In particular, blockade of the OX40-OX40l pathway might aid the Treg 
pool in vivo, as in vitro data show that OX40 costimulation of nTreg abrogates their 
suppressive function and OX40 costimulation on Tconv inhibits conversion into 
iTreg [155].
Although in some animal models blockade of a single pathway is sufficient to 
induce tolerance, blockades of multiple pathways are required in more stringent 
models, suggesting that this will also be necessary in human clinical situations. 
Several reports have shown that combined blockade of the CD40l-CD40 and CD28-
CD80/CD86 signals favors nTreg function in vivo in mouse models [156-158]. in vitro 
studies using human cells suggest that combined blockade of these pathways might 
have potential for the induction of tolerance [159;160]. An anti-CD40/anti-CD86-
fusion protein has been developed that simultaneously inhibits CD28-CD80/CD86 
and CD40l-CD40 costimulatory pathways, which might be of great potential for 
clinical application [161]. In other animal models, dual blockade of CD28/ICOS and 
ICOS/CD40 induced iTreg and produced tolerance in solid organ transplantation 
tolerance [162;163], and a triple blockade of CD28/CD154/OX40 was reported to 
be effective in another study [164]. 
Another experimental strategy to induce iTreg mediated allograft tolerance in 
vivo makes use of altered T-cell receptor signaling by blocking CD4 in combination 
with pretreatment with alloantigen [165;166]. The iTreg that are induced by this 
approach are antigen-specific, but once activated, they also display bystander 
suppression of responses to other antigens. Interestingly, the phenomenon 
of linked suppression could be exploited to produce tolerance without prior 
administration of alloantigen. To this end, tolerance towards a non-graft antigen 
was induced by immunization under the cover of anti-CD4 prior to transplantation. 
If the same non-graft antigen was administered again at the time of transplantation, 
linked suppression produced subsequent alloantigen specific tolerance [167]. If 
this strategy can be translated into the human clinical setting, this would allow for 
the induction of tolerance which does not require detailed knowledge of donor 
characteristics and also does not require pre-transplantation availability of donor 
antigen. 
Infusion of tolerizing DC in a vaccination strategy can be envisioned to induce 
transplantation tolerance. Several ex vivo modulated DC subsets have been shown 
to produce transplantation tolerance upon infusion in animal models, for example 
DC with forced CTlA-4 expression, or DC preconditioned with immunosuppressive 
drugs or Il-10 [168-171].
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COMBINATION Of Treg BAsED THERAPy WITH 
IMMUNOsUPPREssIVE DRUGs         
The induction of tolerance crucially depends on reduction and control of the 
alloantigen reactive Tconv pool [172;173]. While Treg based immunotherapy aims 
to achieve this goal, immunosuppressive drugs can certainly help in this process. 
Therefore, introduction of Treg based therapy into the human clinical setting will 
likely take place under the cover of concurrent treatment with immunosuppressive 
drugs with known efficacy to reduce the alloantigen reactive Tconv pool. Many 
immunosuppressive drugs that affect Tconv also have the potential to influence 
Treg, so it is crucial to select drugs that efficiently reduce the number or function 
of alloantigen-specific Tconv cells but allow Treg function and/or iTreg induction 
as much as possible. Calcineurin inhibitors such as cyclosporine and tacrolimus 
decrease T-cell receptor mediated Il-2 production and efficiently reduce the 
expansion of Tconv [174-176]. Caution is warranted if these drugs are to be used 
in combination with Treg based therapy, as although Treg suppressor function 
is maintained by calcineurin inhibitor treatment [177;178], Treg proliferation 
is severely reduced and induction of iTreg is abrogated [179]. Rapamycin is an 
immunosuppressive drug that is widely used in transplantation settings. This drug 
inhibits T-cell cycle progression by binding to mTOR [180]. Rapamycin is promising 
for combination with Treg based therapies, as it inhibits proliferation of Tconv more 
potently than that of nTreg [181;182] and it also allows nTreg suppressive function 
[177;182]. This is reflected in the finding that patients treated with rapamycin have 
higher percentages of Treg in peripheral blood as compared to cyclosporine treated 
patients [183;184]. Rapamycin also seems to promote the induction of TGF-β 
mediated iTreg [179]. Interestingly, in an animal model of transplantation, the 
administration of rapamycin combined with recombinant Il-10 leads to tolerance 
by in vivo induction of Tr1 cells [185].
Antibody therapy aimed at reducing the pool of Tconv after transplantation is being 
used in the clinical setting for decades. In recent years, it has been reported that 
some antibodies not only cause a reduction of Tconv numbers, but also mediate 
iTreg conversion. This has been shown for OKT3 (anti-CD3 monoclonal antibody) 
[186], anti-thymocyte-globulin (polyclonal antibody cocktail) [187;188], and 
alemtuzumab (anti-CD52, present on T-cells,  B-cells, monocytes, and granulocytes) 
[189;190]. The monoclonal anti-CD25 antibodies daclizumab and basiliximab, also 
used in the clinic, are aimed at inhibition of CD25pos activated Tconv, but obviously 
also affect CD25high nTreg. Indeed, nTreg populations are transiently undetectable 
in peripheral blood after daclizumab treatment [191]. The function of human nTreg 
is not affected by daclizumab and basiliximab in vitro [191;192], and a single dose 
allows the formation of Treg with indirect alloantigen-specificity in vivo in humans 
[23]. However, in an animal model of stem cell transplantation, tolerance induction 
was abrogated if daclizumab was administered at the time of transplantation 
[93]. The experimental drug malononitrilamide inhibits cell cycle progression 
and suppresses human Tconv while inducing iTreg conversion in vitro [193]. The 
novel immunosuppressive drug fingolimod interferes with cell trafficking between 
lymphoid organs and blood. Treatment of animals with fingolimod shifts the Treg 
to Tconv ratio towards the Treg side in lymphoid tissues as well as at inflammatory 
sites and enhances the suppressor activity of the Treg pool [194;195]. 
45
IMMUNOTHERAPY WITH REGULATORY T-CELLS IN TRANSPLANTATION
2
Taken together, these studies strongly indicate that for successful implementation 
of tolerance inducing strategies in the clinical setting, the choice of 
immunosuppressive drugs may be crucial. 
fUTURE PERsPEC TIVE            
Recently, the first clinical trials on infusion of ex vivo selected nTreg and ex vivo 
generated iTreg have been initiated in patients receiving stem cell transplantations. 
An overview of these studies is provided in recent review papers [196;197]. Several 
important issues should be clarified by these frontline trials. First, a cautious 
estimation of the clinical potential of Treg therapy may be obtained. Furthermore, 
data regarding the safety of Treg infusion in human patients will become available. 
Issues that require special attention are the occurrence of non-specific suppression 
and the detrimental effects of co-infused Tconv. The results of these first trials will 
have a great impact on the further development of Treg infusion therapy in the 
human transplantation setting. 
For the near future, efforts should be made to find biomarkers to monitor the 
efficacy and safety of Treg therapy after transplantation. Up to now, evaluation of 
the efficacy of therapy is largely based on clinical outcome. A genuine assessment 
of the presence of tolerance after organ transplantation would require complete 
withdrawal of immunosuppressive drug treatment, which is not an attractive 
experiment for the graft recipient. When an accurate marker of tolerance would 
be available this could guide safe tapering of immunosuppressive drug treatment 
in patients with alloantigen-tolerance, and maintenance or intensification of 
treatment in patients in which the tolerance induction treatment has failed. 
Recent studies have described biomarkers that are associated with the presence 
of operational allograft tolerance [198;199]. However, there is no test available yet 
that can reliably identify patients in whom non-specific immunosuppression can be 
tapered successfully. 
We expect that in future years, the technical difficulties regarding GMP Treg isolation 
will be largely resolved, which will lead to an increase in the number of clinical 
trials on Treg infusion after transplantation. Tracking of infused cells will provide 
information about the in vivo homing and stability of Treg, which is also crucial 
for optimal timing of Treg transfusion. An important issue regarding the infusion 
of Treg is that the techniques required for the custom-made cell preparations for 
each recipient are very laborious and expensive. Therefore, in vivo interventions 
resulting in increases of Treg number and function form attractive adjuncts or even 
alternatives. We expect that the current strategies will be fine-tuned for use in the 
human clinic and that therapies aimed to enhance the Treg mediated suppression 
of donor-specific immune responses at the expansion of Treg facilitation in vivo will 
significantly contribute to the establishment of transplantation tolerance.
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CONCLUsION              
Considerable progress has been made in the development of Treg based 
immunotherapeutic strategies for transplantation purposes in preclinical models. 
Recently, the first clinical trials using infusion of ex vivo selected nTreg and ex vivo 
generated iTreg have been started in stem cell transplantation recipients. These 
studies will provide crucial information about the safety and clinical potential of 
Treg infusion immunotherapy. However, issues regarding the identification of stable 
Treg, and in vivo behavior of these cells upon infusion remain to be elucidated. 
Also, technical limitations regarding GMP Treg isolation still challenge successful 
application of Treg based therapies. 
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ABsTRAC T           
Regulatory T-cell (Treg) based immunotherapy is of great interest to prevent 
pathology in autoimmunity and transplantation. However, to achieve clinical 
efficacy, a number of questions regarding human Treg biology still need to be 
answered. In this study, we characterized Treg function and phenotype in human 
bone marrow, spleen, lymph nodes and peripheral blood samples. Blood and 
bone marrow derived Treg showed a resting phenotype, and displayed both 
suppressive and anergic behavior in vitro. Interestingly, the majority of Treg in 
secondary lymphoid organs were activated CD69posCD45RAneg cells and exhibited 
a broad T-cell receptor Vβ repertoire, implying polyclonal activation. These Treg 
revealed normal suppressive capacity, but, in contrast to peripheral blood derived 
Treg, were not anergic and had the capacity to produce cytokines such as IL-
2, which provides these cells with the capacity of autocrine activation and self-
renewal. Treg expressed functional homing markers enabling them to migrate to 
chemokines linked to peripheral sites. In conclusion, our data suggest an active 
role for human secondary lymphoid organs in the maintenance and regulation 
of Treg function and homeostasis. This increased understanding of human Treg 
biology will guide in selection of Treg subsets and lead to further optimization of 
Treg based immunotherapy.
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INTRODUC TION             
Regulatory T-cells (Treg) play a critical role in the maintenance of immune 
homeostasis and self-tolerance. Immunotherapy based on Treg is therefore a 
potential treatment for many immune disorders. Indeed, the first human clinical 
trials appear promising [1-3]. Still, a number of fundamental questions on human 
Treg behavior and localization are left unanswered and a greater understanding 
of Treg biology is crucial before Treg infusion therapy can be safely and efficiently 
administered on a large scale. Knowledge on Treg localization and extended 
phenotypes might provide us with clues to optimize Treg selection, differentiation 
and expansion protocols. To date, limited information is available on the function 
and phenotype of Treg in human tissues. From mouse studies we learned that 
under inflammatory conditions Treg may accumulate in draining lymph nodes [4;5], 
and that lymph node homing Treg actively suppress Tconv priming in the induction 
phase of transplantation tolerance [6-9]. In mice, Treg were reported to reduce 
Tconv expansion in lymphoid organs [5;10], and limit egress of Tconv from the 
lymph nodes by inducing down regulation of S1P
1
 [11]. Besides their presence in 
T-cell areas, Treg have also been found in B-cell areas of mouse as well as human 
lymphoid organs [12-17], and these Treg were found to suppress B-cell responses 
and follicular T-cell proliferation. Additionally, mouse Treg have been shown to 
suppress NK-cell maturation in lymph nodes [18]. 
The notion that mouse Treg upregulate expression of homing markers with tropism 
for specific peripheral tissues in the body following activation by dendritic cells in 
lymph nodes in vivo suggests that Treg will leave the lymph nodes and migrate to 
the periphery to exert their function locally, similar to Tconv [19;20]. Indeed, human 
peripheral blood Treg that express homing markers for peripheral sites have been 
identified [21-23] and Treg were found in human peripheral tissues in both healthy 
steady state conditions [21;23-25] as well as during inflammation [26;27]. Adoptive 
transfer of Treg with a specific homing code indicated that these Treg subsets likely 
function by regulating on site [28;29]. Moreover, Treg subsets were characterized 
that posses the capacity to specifically control defined Thelper cell responses; for 
example Th1 and Th2 responses were efficiently controlled by Treg that express 
chemokine receptors or transcription factors that associated with these specific 
Thelper counterparts [30-33]. These data indicate that optimal Treg function is at 
least partly dictated by their phenotypic make up, and the specific combination of 
functional characteristics and homing markers may determine the efficacy of the 
response.
Here, we examined presence, phenotype and function of human Treg in healthy 
lymphoid tissues. Interestingly, our data shows that while Treg in peripheral blood 
were in a resting state, the majority of Treg in lymph nodes and spleen had an 
activated CD69posCD45RAneg phenotype. Most of these cells were Ki67pos and 
revealed a broad T-cell receptor- (TCR-)Vβ repertoire. This implies that in healthy 
secondary lymphoid tissues Treg are under constant polyclonal activation and 
expansion. Both activated as well as resting lymphoid organ derived Treg had 
different functional properties as compared to peripheral blood Treg. While Treg 
derived from peripheral blood and lymphoid organs showed similar suppressive 
capacity, lymphoid organ Treg subsets were not anergic, and produced Il-2 as 
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well as Il-10 and IFNγ. Analysis of chemokine receptor expression and migratory 
capacity of Treg isolated from secondary lymphoid organs showed that Treg can 
indeed migrate to chemokines associated with peripheral tissues. 
METHODs           
sAMPLE sOURCE          
Bone marrow and peripheral blood samples were obtained from healthy human 
stem cell donors, spleen samples from deceased human liver or kidney donors, 
liver-draining lymph node samples from deceased human liver donors, and 
inguinal lymph node samples from human kidney transplant recipients at the time 
of transplantation (not treated with immunosuppressive drugs prior to lymph node 
excision). Sample collection was performed at Radboud University Medical Centre 
(Nijmegen, The Netherlands) as well as at Erasmus University Rotterdam Medical 
Centre (Rotterdam, The Netherlands). For functional assays, peripheral blood 
mononuclear cells were isolated from buffy coats obtained from healthy human 
blood donors (Sanquin bloodbank, Nijmegen, The Netherlands). The Medical 
Ethical Committees for human research in the regions Arnhem/Nijmegen and 
Rotterdam approved the current study, and informed consent was obtained from 
all study participants or their representatives. 
CELL PREPARATION           
lymph node and spleen samples were forced through 74 μm netwell filters (Costar, 
Corning International, Ny) to obtain single cell suspensions. Mononuclear cells 
were isolated by density gradient centrifugation (lymphoprep, Nycomed Pharma, 
Roskilde, Denmark). Cell subsets for functional assays were obtained by positively 
selecting CD4pos T-cells from mononuclear cell fractions by MACS-sorting, using 15 
μl anti-CD4 magnetic microbeads / 107 mononuclear cells (Miltenyi Biotec, Bergisch 
Gladbach, Germany), where indicated followed by staining with conjugated mAbs 
against CD4, CD25 and CD69, and separation of different subsets by FACS-sorting 
(Altra, Beckman Coulter, Fullerton, CA). In some experiments, mononuclear cell 
fractions were cryopreserved prior to analysis.
fLOWCyTOMETRy        
The phenotype of cells was analyzed by five-color flowcytometry (FC500, 
Beckman Coulter). For cell surface staining, the following conjugated mAbs 
were used: CD25(M-A251)-PE, CD29/ITGβ1(K20)-FITC, CD45RA(HI100)-FITC, 
CD127(hIl-7R-M21)-AlexaFluor647, CD183/CXCR3(1C6/CXCR3)-PC5, CD194/
CCR4(1G1)-PC7, CD196/CCR6(11A9)-PE, ITGβ7(FIB504)-PE (BD Biosciences, San 
Jose, CA, USA), CD4(SFCI12T4D11)-ECD or -PC7, CD45RA(2H4lDH11lDB9)-ECD, 
CD62l(DREG56)-ECD, CD69(TP1.55.3)-PC5 or -ECD, Beta Mark kit (Beckman 
Coulter), CD127(eBioRDR5)-PC7 CD184/CXCR4(12G5)-PC5, (eBioscience, San 
Diego, CA), CD197/CCR7(150503)-PE CDw199/CCR9(112503)-PE, CCR10(314305)-
PE (R&D Systems, Minneapolis, MN), GARP/lRRC32(Plato-1)-atto674 (Enzo 
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lifesciences, Farmingdale, Ny) and CD25(4E3)-bio (Miltenyi Biotec) in combination 
with Streptavidin-PC7 (eBioscience). For intracellular staining, Fix and Fix/Perm 
buffer (eBioscience) were used according to the manufacturer’s instructions 
in combination with FoxP3(PCH101)-FITC (eBioscience), FoxP3(259D/C7)-
AlexaFluor647 and Ki67(B56)-FITC (BD Biosciences). Isotype controls were used for 
gate settings.
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FIguRe 1. DIstRIButIoN oF MoNoNucleaR cells IN DIFFeReNt HealtHy HuMaN tIssues.
Mononuclear cells were isolated from healthy human peripheral blood (PB), bone marrow (BM), 
liver-draining lymph nodes (lilN), inguinal lymph nodes (inlN) and spleen (sPl) samples and analyzed 
by flowcytometry. (a) Distribution of cD3poscD4pos helper t-cells (t4), cD3poscD8pos t-cells (t8), cD19pos 
B-cells (B), cD56pos NK-cells (NK) and cD14pos monocytes (Mo). Data are depicted as percentages 
of cell type within cD45pos mononuclear gate. each line represents one sample (N=4-8 for each 
tissue). (B) Representative examples of cD25/cD127 staining on cD4pos t-cells and foxp3 expression 
on cD25poscD127neg (gray filled histograms) and cD25negcD127pos cells (black line histograms). (c) 
summary of percentages of cD25poscD127neg treg within cD4pos t-cells (N=10-14 for each tissue). Data 
were compared using one-way aNova and no significant differences were found.
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in Vitro ACTIVATION OF T-CEllS TO DETERMINE KI67 AND 
GARP EXPRESSION         
2.5x104 CD4pos cells isolated from different tissues or CD25pos Treg and CD25neg Tconv 
sorted from freshly isolated PB CD4pos T-cells were stimulated with 5x103 anti-CD3/
anti-CD28 coated microbeads (Dynal Biotech, Oslo, Norway) in culture medium, 
consisting of RPMI-1640 supplemented with l-glutamine (2 mM; Invitrogen, 
Carlsbad, CA), pyruvate (0.02 mM; Invitrogen), penicillin (100 U/ml; Invitrogen), 
streptomycin (100 μg/ml; Invitrogen), and 10% human pooled serum. 12.5 U/ml 
Il-2 (Chiron, Amsterdam, the Netherlands) was added to Treg cultures, not to Tconv 
or mixed cultures. We confirmed that absence of exogenous Il-2 to Tconv and 
mixed cultures did not influence GARP expression (data not shown). On day 0 and 
day 2 cells were analyzed for expression of GARP and Ki67 by flowcytometry.
PROLIfERATION AssAy         
Proliferative capacity of freshly isolated Treg was examined in stimulation assays. 
Wells were set up in duplicate with 1.25x104 cells in culture medium with either 
no stimulation, 12.5 U/ml exogenous Il-2, 2.5x103 anti-CD3/anti-CD28 coated 
microbeads, or both microbeads and Il-2. Proliferation was measured at day 4 
of culture. To this end, 0.5 μCi [3H]-labeled thymidine (Amersham Biosciences, 
Piscataway, NJ) was added to each well. After 8 hours, [3H] incorporation was 
measured using a beta-plate counter (Packard, Canberra, Australia), counting for 
5 minutes. 
CO-CUlTURE SUPPRESSION ASSAy       
suppressive capacity of freshly isolated Treg was determined in co-culture assays. 
1-5x106 peripheral blood derived allogeneneic CD4pos T-cells were labeled with 
CFDA-SE (0.5 µM; Invitrogen) and used as responder cells. To increase comparability, 
responder cells from the same donor were used for all suppression assays. 2.5x104 
CfsEpos responder cells were stimulated with 2.5x103 anti-CD3/anti-CD28 coated 
microbeads in culture medium. Unlabeled Treg subsets were titrated into the 
cultures. At day 4, 7-amino-actinomycin-D (7AAD; Sigma-Aldrich, St. louis, MO) 
and 1x104 flowcount microspheres (Beckman Coulter) were added to the samples. 
Responder T-cell division was analyzed by flowcytometry, excluding 7AADpos 
cells and CfsEneg Treg. Suppression was defined as the number of proliferating 
responder T-cells in the presence of titrated cell subsets as a percentage of that in 
the absence of added cells. 
MIGRATION AssAy           
Migration capacity of freshly isolated CD4pos T-cells from spleen or peripheral 
blood was determined in a transwell culture assay. Culture wells were supplied 
with XVivo15 serum-free medium (lonza, Verviers, Belgium) with or without 
recombinant chemokines CCl20 (1 μg/ml), CCl22 (1 μg/ml), CCl25 (2.5 μg/ml) or 
CXCl10 (1 μg/ml) (R&D systems). 0.5-1x106 CD4pos T-cells, stained with conjugated 
mAbs against CD25, CD127 and CD69 were added into 3 μm filter inserts 
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FIguRe 2. actIvatIoN status oF treg aND tconv IN DIFFeReNt HealtHy HuMaN tIssues.
the activation status of human cD4pos treg and tconv as indicated by cD45Ra and cD69 expression 
was analyzed by flowcytometry on peripheral blood (PB), bone marrow (BM), liver-draining lymph 
nodes (lilN), inguinal lymph nodes (inlN) and spleen (sPl). (a) Representative examples of cD45Ra 
and cD69 staining on expression on cD25poscD127neg treg and cD25negcD127pos tconv. (B) summary of 
distributions of treg and tconv over four activation stages, based on expression of cD45Ra and cD69. 
Data are depicted as percentages of cells within each stage. each line represents one sample (N=10-
14 for each tissue). Data were compared on the log-odds scale using a mixed model, and significant 
differences are indicated by asterisks (*: p<0.05, **: p<0.01, ***: p<0.001).
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(Millipore, Billerica, MA). Tests were set up in duplicate (chemokine filled wells) or 
quadruplicate (medium controls). After 2 hours incubation, cells were harvested 
from the bottom compartment. 104 flowcount microspheres were added and 
samples were analyzed using flowcytometry. Migration was defined as the number 
of migrating cells in the presence of chemokine as a percentage of that in medium 
controls.
ANALysIs Of CyTOKINE PRODUCTION       
2.5x104 FACS-sorted cell subsets were cultured in 96-wells round bottom plates in 
the presence PMA (12.5 ng/ml; Sigma-Aldrich) and ionomycin (0.5 μg/ml; Sigma-
Aldrich). After 24 hours of culture, supernatants were taken and the concentrations 
of Il-2, Il-4, Il-10, Il-17, IFNγ and TNfα were determined by Luminex according to 
manufacturer’s instructions (Biorad, Veenendaal, The Netherlands).
IMMUNOHIsTOCHEMIsTRy     
Human liver-draining lymph node, inguinal lymph node and spleen tissue samples 
were fixed in neutral buffered 4% formalin (Mallinckrodt Baker Inc, Deventer, The 
Netherlands) for 4 hours, processed and embedded in paraffin. Sections (6μm) were 
or processed for immunohistochemical staining. The following antibodies were 
used: anti-FoxP3 (PCH101; 1:50; eBioscience) and anti-CD69 (CH11 ab49516; 1:100; 
Abcam, Cambridge, UK). Antibody stainings were visualized using AEC (Calbiochem, 
la Jolla, CA) or labeled Streptavidin Biotin (Universal lSAB Kit/AP; Dako) combined 
with 5-Bromo-4-Chloro-3-Indolyl Phosphate / Nitro Blue Tetrazolium (BCIP/NBT) 
(Vector laboratories, Burlingame, CA). Sections were photographed using an 
Axiokop2 MOT microscope (Zeiss, Sliedrecht, the Netherlands) accommodated 
with an Axiocam MRc5digital camera (Zeiss) and analyzed using AxioVision 
software (Zeiss) and ImageJ software (version 1.45s, National Institute of Health, 
Bethesda, MD). 
FIguRe 3. IMMuNoHIstocHeMIstRy oF actIvateD (cD69Pos) aND RestINg (cD69neg) 
foXp3Pos cells IN HuMaN secoNDaRy lyMPHoID oRgaNs. 
one representative liver draining lymph node specimens labelled with anti-FoxP3 (red) and anti-
cD69 (blue) (magnification 40x). left panel shows original photograph. Middle panel shows original 
photograph with overlaying mask indicating FoxP3 staining in black. Right panel shows original 
photograph with FoxP3pos cells scored for cD69 expression (red circles: FoxP3poscD69pos cells, yellow 
circles: FoxP3poscD69neg cells) and a digital magnification of an example of each cell subset.
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The distribution of Treg and Tconv cells over the four categories of activation 
between tissue types was compared on the log-odds scale using a mixed model, 
which accounts for the fact that this distribution was estimated from several 
samples for each tissue type. To compare percentages of cells positive for single 
markers between the different tissue types, a random effect logistic regression 
model was used, accounting for the fact that several samples of each tissue type 
were taken. Migration, proliferation and cytokine production assays were analyzed 
using one-way ANOVA. Suppression assays were analyzed using two-way ANOVA. 
GARP expression was analyzed using Pearson correlation test. P-values lower than 
0.05 were considered statistically significant. 
REsULTs                
Treg DIsTRIBUTION IN DIffERENT HUMAN LyMPHOID ORGANs 
           
First, we determined the relative compositions of human mononuclear cells in 
peripheral blood (PB), bone marrow (BM), liver-draining an inguinal lymph node 
(lilN, inlN), and spleen samples (SPl) by flowcytometry (Figure 1A). As expected, 
the PB samples contained a high percentage of CD4pos T-cells (range 45-75%). Also 
in BM samples, the CD4pos T-cell fraction was predominant (range 25-50%). In 
contrast, CD4pos T-cell content of lilN and inlN samples varied widely (range 5-70%)
and SPl samples contained relatively few CD4pos T-cells (range 5-15%). The average 
percentages of CD25highCD127low Treg, expressing the transcription factor FoxP3, 
appeared similar for all lymphoid tissues analyzed (means 5-7%) (Figures 1B and C). 
The CD25negCD127pos cells did not express FoxP3. 
Treg IN sECONDARy LyMPHOID ORGANs sHOW A POLyCLONALLy 
ACTIVATED PHENOTyPE      
Next, we analyzed the phenotype of the Treg in the different lymphoid organs in 
more detail. Based on surface expression of CD45RA and CD69, the process of 
CD4pos T-cell activation can largely be divided into four stages [22]. Cells in stage I are 
naïve (CD45RApos) and resting (CD69neg). Recently activated T-cells switch to stage II, 
displaying a CD45RAposCD69pos phenotype. A few days after the first activation signal 
the T-cells enter stage III, where they downregulate CD45RA, but still express CD69. 
Finally, in stage IV the cells lose CD69 expression and turn into CD45RAnegCD69neg 
resting memory cells. Reactivation of a resting memory T-cell causes a temporary 
re-expression of CD69. Using this classification, we found remarkable differences 
between Treg in different body compartments, and between Treg and Tconv in the 
same compartments (Figure 2A and B). PB and BM Treg showed a similar activation 
pattern, with almost all Treg in resting stages I and IV. Interestingly, as compared to 
PB and BM samples, a completely different pattern was found for Treg in secondary 
lymphoid organs; here the majority of cells had an activated memory phenotype 
(stage III). We found no difference in Treg activation status between lilN and inlN. 
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While SPl samples generally resembled lilN and inlN patterns with regard to a high 
percentage of activated cells in stage III, they contained a higher percentage of 
Treg in stage IV, and statistically differed from lilN and inlN. In comparison, Tconv 
subsets contained on average 50% naïve cells (combined stage I and II) in all tissues 
tested. Similar to Treg, in PB and BM there were few activated Tconv, while lilN, 
inlN and SPl contained significantly more activated memory Tconv in comparison 
to PB and BM. However, secondary lymphoid organs contained significantly higher 
proportions of stage III Treg compared to stage III Tconv. 
To analyze the localization of FoxP3posCD69pos and FoxP3posCD69pos Treg in the 
FIguRe 4. actIvateD treg IN HuMaN secoNDaRy lyMPHoID aRe IN a late actIvatIoN 
stage.
(a) Mononuclear cells were obtained from healthy human liver-draining lymph nodes (lilN), 
inguinal lymph nodes (inlN) and spleen (sPl) samples and analyzed by flowcytometry. Figure shows 
percentages of garppos cells directly ex vivo within cD4poscD25pos treg (N=5 for each tissue). Data 
were analyzed using a random effect logistic regression model and no significant differences were 
found. (B) cD4pos t-cells were isolated from peripheral blood (PB) samples, and sorted into cD25pos 
treg and cD25neg tconv. t-cells were activated in vitro with anti-cD3/cD28 microbeads (bead:cell 
ratio 1:5). Figure shows gaRP expression on treg (gray histogram) and tconv (black line histogram) 
at day 2 after activation. (c) sorted PB cD4poscD25pos treg were activated in vitro with anti-cD3/cD28 
microbeads. Figure shows 
gaRP and cD69 expression 
plotted against culture time. 
(D) sorted PB cD4poscD25pos 
treg and cD4poscD25neg tconv 
were mixed as indicated 
and activated in vitro with 
anti-cD3/cD28 microbeads. 
Figure shows percentages of 
cD4poscD25pos t-cells at start 
plotted against percentages 
of garppos cells at day 2. Data 
were analyzed using Pearson 
correlation test (R=0.998, 
P<0.0001). (e) cD4pos t-cells 
isolated from human lilN, 
inlN and sPl samples were 
activated in vitro with anti-
cD3/cD28 microbeads. 
Figure shows percentages of 
cD4poscD25pos t-cells at start 
plotted against percentages 
of garppos cells at day 2 
(N=5 for each tissue). Data 
were analyzed using Pearson 
correlation test (R=0.721, 
P<0.001). (F) Flowcytometry 
of Ki67 expression in 
cD4poscD25poscD69pos treg 
in human lilN, inlN and 
sPl samples. (N=5 for each 
tissue). Data were analyzed 
using a random effect logistic 
regression model and no 
significant differences were 
found.
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human secondary lymphoid organ we performed immunohistochemistry (Figure 
3). Corresponding with our single-cell flowcytometric analyses we confirmed the 
presence of both FoxP3posCD69pos and FoxP3posCD69pos cells. There was no obvious 
preference in location for activated or non-activated Treg, both subsets seemed 
randomly distributed over T-cell and B-cell areas of spleens and lymph nodes.
To further exclude the possibility that part of activated CD4posCD25posCD127neg 
cells were in fact activated Tconv with transiently upregulated Foxp3 expression, 
we analyzed expression of GARP, which has been described as a marker to 
distinguish activated Treg from activated Tconv [34-38]. The majority of 
CD4posCD25posCD127neg cells in lymphoid organs did not express GARP directly ex 
vivo (Figure 4A). In validation experiments, we noticed that sorted PB Treg (defined 
as CD4posCD25posCD127neg), but not Tconv (defined as CD4posCD25negCD127pos), 
expressed GARP upon in vitro activation (Figure 4B). However, GARP was only 
expressed briefly on activated Treg with peak values at day 2, and thereafter 
expression was quickly lost (Figure 4C). CD69 expression in these cells was 
upregulated faster and sustained for a longer period, indicating that activated 
Treg can be CD69posGARPpos as well as CD69posGARPneg, depending on the time 
after activation. Based on the distinction in GARP expression between Treg and 
Tconv, we hypothesized that we could use the in vitro day 2 GARP expression in 
stimulated CD4pos cells to estimate the percentage of Treg. We first validated this 
approach by re-mixing sorted PB Treg and Tconv populations in known ratios and 
determining GARP expression on day 2. The percentage of GARPpos cells at day 2 
indeed correlated significantly with the percentages of sorted Treg added at the 
start of the culture (Figure 4D). We then employed this strategy to determine 
Treg in CD4pos T-cells isolated from liLN, inLN and sPL samples. The percentages of 
GARP-positive cells at day 2 upon stimulation showed a significant correlation with 
the percentage of cells defined as CD4posCD25posCD127neg (including CD69neg as well 
as CD69pos cells) at the start of culture (Figure 4E), providing support for the notion 
that the activated CD4posCD25posCD127negFoxP3pos cells found in the lymphoid 
tissues are Treg, and not activated Tconv. 
To further analyze the activation status of the Treg, we determined Ki67 expression. 
Ki67 is a molecule that is expressed by all proliferating cells, but not by resting 
cells. Upon in vitro activation, Treg upregulate Ki67 expression from day 2 onward, 
with high expression levels at day 4 (data not shown). We analyzed the expression 
of Ki67 on CD69pos Treg in lilN, inlN and SPl (Figure 4F) and found that on average 
65% of these Treg are Ki67pos, while in the CD69neg Treg population on average 
5-12% expressed Ki67 (data not shown). These data suggest that the activated 
CD4posCD25posCD127negFoxP3pos cells found in lymph nodes and spleens are Treg in 
a late activation stage at which they have already downregulated GARP, but still 
express CD69 and Ki67. 
We were then interested to see whether the activation state of lymphoid tissue 
Treg was due to specific antigenic stimulation resulting in mono- or oligoclonal 
proliferation, or rather due to polyclonal activation. To this end we determined 
TCR-Vβ patterns of the activated CD69pos and resting CD69neg cells in selected inLN, 
lilN and SPl samples by flowcytometry (Figure 5). While TCR-Vβ patterns within 
each tissue varied between donors (data not shown), for each donor the activated 
and resting Treg in secondary lymphoid tissues showed a similar and broad TCR-
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Vβ pattern. This indicates that in non-inflammatory conditions, Treg in human 
secondary lymphoid organs are polyclonally activated. 
ACTIVATED AND REsTING Treg IN sECONDARy LyMPHOID 
ORGANs sHOW sIMILAR sUPPREssIVE CAPACITy AND BOTH 
DIsPLAy INCREAsED PROLIfERATIVE AND CyTOKINE PRODUCING 
POTENTIAL As COMPARED TO PERIPHERAL BLOOD Treg    
     
To compare the suppressive capacity of activated and non-activated Treg found 
in secondary lymphoid organs and PB Treg, FACS-sorted SPl CD69pos and CD69neg 
Treg and CD69neg PB Treg were titrated into cultures of CFSE-labeled CD4pos T-cells 
stimulated with anti-CD3/anti-CD28 coated microbeads (Figure 6A). CD69neg and 
CD69pos Treg subsets sorted from sPL samples showed comparable suppressive 
activity as compared to PB Treg. These data indicate that both resting as well as 
activated Treg isolated from spleen display full suppressive capacity.
Next, we determined the in vitro proliferative capacity of activated and resting Treg 
in secondary lymphoid organs. FACS-sorted CD69pos and CD69neg Treg from human 
spleen samples were stimulated with anti-CD3/anti-CD28 coated microbeads in 
absence or presence of exogenously added Il-2. None of the Treg subsets showed 
any in vitro proliferation in the absence of exogenous stimulation. In sharp 
contrast to peripheral blood derived CD69negTreg, both spleen derived CD69pos and 
CD69neg Treg clearly revealed the capacity to proliferate when stimulated in the 
absence of exogenously added Il-2 (Figure 6B). Proliferation of SPl Treg was not 
further increased following co-adminstration of Il-2, which might be explained by 
autologous Il-2 production by these cells. Therefore, we measured the cytokine 
producing potential of SPl CD69pos and CD69neg Treg upon stimulation with PMA 
and ionomycin. In contrast to PB Treg, SPl CD69pos and CD69neg Treg showed 
significant Il-2 production (Figure 6C). Interestingly, SPl Treg also produced higher 
levels of IFNγ, Il-10 and TNFα.
These data indicate that human spleen Treg are not anergic to CD3/CD28-
stimulation. It seems that Treg that are present in the splenic micro-environment 
use an alternative program for their activation and autocrine activation.
Treg HOMING RECEPTOR EXPRESSION PATTERNS AND 
MIGRATORy CHARACTERIsTICs DIffER BETWEEN ANATOMICAL 
LOCATIONs         
To further analyze the nature of the activation status of the Treg in the secondary 
lymphoid tissues, we looked at homing receptor expression (Figure 7). Treg in BM 
and PB revealed similar homing marker expression patterns. Of note, while Treg 
in the secondary lymphoid organs liLN, inLN and sPL resembled each other with 
respect to homing receptor expression, their pattern was clearly different from that 
of PB and BM Treg. PB and BM Treg mainly expressed homing receptors associated 
with lymph node (CD62l: means 70-80%; CCR7: means 60- 70%) and skin homing 
(CCR4: means 30-40%; CCR10: means 20%; ITGα4β1: means 50%), while expression 
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FIguRe 6. cD69Pos aND cD69neg treg IN sPleeN 
aND cD69neg treg IN PeRIPHeRal BlooD Have 
sIMIlaR suPPRessIve caPacIty, But DIFFeReNt 
PRolIFeRatIve aND cytoKINe PRoDuctIoN 
PoteNtIals.
cD4pos t-cells were isolated from spleen (sPl) and 
peripheral blood (PB) samples of healthy human 
donors, and sorted into cD69neg and cD69pos treg 
(spleen) or only cD69neg treg (peripheral blood). (a) 
suppressive capacity of treg subsets was determined in 
co-culture assays using flow cytometry. cFse-labeled 
allogeneic cD4pos tresp isolated from peripheral 
blood were activated in vitro with anti-cD3/cD28 
microbeads (bead:cell ratio 1:5). treg subsets were 
titrated into these cultures at indicated tresp:treg 
subset ratios and percentage of suppression is shown 
(N=3 for each subset). Data were compared using two-
way aNova and no significant differences were found 
between suppression capacities of treg subsets. (B) 
Proliferative capacity of treg subsets without or with 
anti-cD3/cD28 microbeads stimulation in the absence 
or presence of exogenously added Il-2. Proliferation 
was determined by measuring [3H]-thymidine 
incorporation at day 4 (mean plus standard deviation, 
N=3 for each subset). 
Data were compared 
using one-way 
aNova, significant 
differences are 
indicated by asterisks 
(*: p<0.05, **: p<0.01, 
***: p<0.001). (c) 
treg subsets were 
stimulated with PMa 
and ionomycin and 
culture supernatants 
were analyzed for 
the concentration of 
indicated cytokines 
by luminex (N=3 for 
each subset). Data 
were compared using 
one-way aNova, 
significant differences 
are indicated by 
asterisks (*: p<0.05, 
**: p<0.01, ***: 
p<0.001).
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of markers associated with bone marrow (CXCR4: means <10%) and gut homing 
(CCR9: means <10%; ITGα4β7: means <10%) was low. In contrast, Treg in lilN, 
inlN and SPl showed expression of gut homing associated marker CCR9 (means 
25-30%), although there was low expression of gut homing associated receptor 
ITGα4β7 (means <10%), while expression of skin homing receptors was lower on 
Treg in secondary lymphoid organs as compared to PB and BM Treg (means CCR4: 
5-15%; CCR10: means <10%; ITGα4β1: means 15-25%). Although significant portions 
of Treg in secondary lymphoid organs expressed the lymph node homing receptor 
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CCR7 (means 25-40%), 
the percentage of CCR7pos 
Treg was lower than in PB 
and BM Treg, and CD62l 
expression was very low 
on Treg in secondary 
lymphoid organs (means 
<10%). like PB Treg, low 
percentages of Treg in 
secondary lymphoid 
organs expressed a bone 
marrow homing marker 
(CXCR4: means 5-20%).
Besides homing markers 
that are associated with 
specific anatomical sites, 
as described above, 
there are also trafficking 
receptors that are 
associated with specific 
immune functions, such 
as CXCR3, CCR4 and 
CCR6. Treg expression 
of these markers would 
allow them to home to 
the same sites as their 
effector counterparts 
(Th1, Th2 and Th17, 
respectively). Analysis of 
CXCR3, CCR4 and CCR6, 
revealed that PB and BM 
Treg showed expression of CCR4 (means 30-40%) and CCR6 (means 25%), and lower 
expression of CXCR3 (means 15-20%), while lymph node derived Treg preferentially 
expressed CXCR3 (means 35-50%) in combination with lower percentages of CCR4 
(means 5-15%) and CCR6 (means <10%). SPl Treg showed low expression of all 
three markers, except for a few samples with significant CCR6 expression (CXCR3: 
mean <10%; CCR4: mean <10%; CCR6: mean 20%).
In order to assess whether the differences in homing receptor expression patterns 
on Treg in peripheral blood and bone marrow versus those on Treg in secondary 
lymphoid organs have functional implications, we analyzed PB Treg, SPl CD69neg 
Treg and SPl CD69pos Treg subsets with regard to their expression of selected 
chemokine receptors and their migration to corresponding chemokines in vitro 
(Figure 8). SPl CD69pos and CD69neg Treg were similar with regards to the expression 
of chemokine receptors CCR4, CCR6, CCR9 and CXCR3. The migratory capacity 
towards CCl20/MIP-3α corresponded to the expression of its receptor CCR6, with 
high migration of PB Treg, and lower migration of both CD69neg and CD69pos sPL 
Treg. The opposite pattern was observed for CXCl-10/IP-10, corresponding to the 
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FIguRe 5. sIMIlaR tcR-vβ exPRessIoN PatteRN oF RestINg 
aND actIvateD treg IN HuMaN sPleeN aND lyMPH NoDes.
Flowcytometry of tcR-vβ expression of cD69neg and cD69pos treg 
obtained in human liver-draining lymph nodes (lilN), inguinal 
lymph nodes (inlN) and spleen (sPl) samples. Representative 
examples are shown (N=2-6 for each tissue). 
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expression of CXCR3. The 
CCR4 ligand CCl22/MDC 
attracted significantly more 
CD69neg PB Treg than sPL 
Treg, matching the expression 
pattern of CCR4 on these 
cells. Neither PB Treg nor 
SPl Treg showed significant 
migration towards CCl25/
TECK, although its receptor 
CCR9 was expressed on sPL 
Treg. 
Taken together, these 
data suggest that Treg in 
peripheral blood and bone 
marrow express receptors 
enabling them for migration 
to lymph nodes and skin, 
while Treg in secondary 
lymphoid organs express 
markers that enable intra-
lymphoid organ migration 
(CCR7), and have partial 
expression of receptors for 
migration to gut (CCR9 only). 
The migration patterns found 
corroborate the profiles 
found by cell surface homing 
receptor expression.
FIguRe 7. exPRessIoN oF 
HoMINg MaRKeRs oN treg 
IN PeRIPHeRal BlooD aND 
BoNe MaRRow DIFFeRs FRoM 
tHose oF treg IN secoNDaRy 
lyMPHoID oRgaNs.
Flowcytometry of homing marker 
expression on cD4poscD25pos treg in 
human peripheral blood (PB), bone 
marrow (BM), liver-draining lymph 
nodes (lilN), inguinal lymph nodes 
(inlN) and spleen (sPl) samples. 
Percentages of cD4poscD25pos treg 
positive for indicated markers are 
shown (N=4-8 for each tissue). Data 
were analyzed using a random 
effect logistic regression model, and 
significant differences are indicated 
by asterisks (*: p<0.05, **: p<0.01, 
***: p<0.001).
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DIsCUssION              
Treg immunotherapy is a promising approach for many immunologically based 
pathologies. However, many questions about Treg biology remain unanswered. In 
recent years, it has become evident that Treg exert their function both in secondary 
lymphoid tissues as well as in the periphery. Here, we characterized Treg in several 
healthy human tissues (peripheral blood, bone marrow, spleen and lymph nodes) 
in order to find novel clues about Treg localization and behavior under steady state 
conditions. 
Remarkably, the majority of Treg in lymph nodes and spleen appeared to be 
activated and expressing CD69, while Treg in peripheral blood were in a resting, 
CD69neg, state. Previously, activated Treg were also found to be present in human 
tonsils [22]. In mice it was shown that expression of CD69 prevents egress from 
lymph nodes by blocking S1P
1
-signaling [39]. The expression of CD69 might thus 
(temporarily) retain Treg in the lymphoid organs and facilitate proper function. 
Interestingly, we found that the activated Treg population in the secondary 
lymphoid organs exhibited a broad TCR-Vβ pattern, implying that activation takes 
place in a polyclonal fashion. As the repertoire of human naturally occurring Treg is 
shaped towards the recognition of autoantigens [40], the lymph nodes may serve 
as a place where Treg interact with their cognate antigen. Support for this notion 
may come from a mouse study where a portion of naive CD4pos T-cells circulating 
through lymphoid organs was found to interact with endogenous antigens, causing 
a temporary expression of CD69 on these cells [41]. Such CD69pos T-cells remained 
in the lymphoid organs, while CD69neg T-cells migrated elsewhere. Airepos stromal 
cells express numerous autoantigens and are involved in thymal T-cell selection 
processes [42]. More recently, Airepos cells have been found in various human 
extra-thymic sites, including lymph nodes and spleen [43;44]. These Airepos cells 
were already shown to activate and delete autoreactive CD8pos T-cells in mouse 
lymph nodes [45;46]. It can be speculated that these cells are in some way involved 
in the activation of autoantigen-specific Treg in secondary lymphoid organs [47]. 
Preliminary immunohistochemistry stainings on healthy human donor spleen and 
lymph node tissue confirmed the presence of Airepos cells in human secondary 
lymphoid organs (Peters et al., unpublished), however double staining of Aire and 
FoxP3 showed that the Treg were not in the proximity of the Airepos cells. In fact, 
activated Treg showed close proximity to CD4pos T-cells, CD8pos T-cells, and CD19pos 
B-cells. Double staining of FoxP3 and CD11c revealed that Treg were also not in the 
proximity of professional antigen presenting cells. The question thus remains which 
are the cells that activate these Treg. Our data does not exclude other (Aireneg) 
subsets of stromal cells as Treg activators. A candidate marker for a Treg activating 
stromal cell subset might be Deaf1, as this protein which was recently identified 
as an inducer of tissue-specific-antigen expression in pancreatic lymph nodes in a 
mouse model [48]. Whether human Deaf1 has the same function in human lymph 
nodes remains to be established.
Analysis of chemokine receptor expression and migratory capacity of Treg showed 
that Treg can indeed express homing markers associated with migration to 
peripheral tissues. Secondary lymphoid organ derived Treg differed from those in 
peripheral blood and bone marrow by their homing receptor expression pattern. 
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The majority of Treg found in peripheral blood and bone marrow expressed 
homing receptors for migration towards secondary lymphoid organs. Part of the 
Treg found in secondary lymphoid organs expressed CCR7, which likely enables 
them to migrate within these organs [49]. Here we describe that subsets of blood 
and bone marrow Treg express functional receptors associated with skin homing 
and functional receptors associated with Th2 and Th17 regulated responses, 
corresponding with previous reports for peripheral blood Treg [21-23]. On the 
other hand, Treg in lymph nodes and spleen expressed markers more associated 
with Th1 regulated responses. Treg in these sites also showed partial expression of 
gut associated homing markers (only CCR9, no integrin α4β7), although we could 
not show migration towards the CCR9 
ligand CCl25. These data concur 
with a previous report showing that 
memory human tonsil Treg express 
many functionally active homing 
markers specific for peripheral tissue 
homing [22]. In a previous study, 
where chronically inflamed human 
tonsils were studied, activated Treg 
expressed different chemokine 
receptors as compared to resting 
Treg, with associated differences in 
migration patterns [13]. In our study, 
where we were looking at a non-
diseased, steady state situation, we 
found no differences between resting 
and activated Treg in this respect, 
possibly because there was no specific 
requirement for a location towards 
figure 8. treg IN DIFFeReNt tIssues oF 
HealtHy HuMaN DoNoRs MIgRate to 
DIFFeReNt cHeMoKINes.
Flowcytometry of homing marker 
expression and migratory capacity of 
cD4poscD25poscD127negcD69pos treg and 
cD4poscD25poscD127negcD69neg in human spleen 
(sPl) and peripheral blood (PB) samples. (a) 
Percentages of treg positive for indicated 
markers are shown (N=3 for each tissue). Data 
were analyzed using a random effect logistic 
regression model, significant differences are 
indicated by asterisks (*: p<0.05, **: p<0.01, 
***: p<0.001). (B) Migration assays were 
performed using a transwell system, with the 
indicated recombinant human chemokines 
present in the lower compartment. the 
migratory capacity of the treg subsets is shown 
(mean plus standard deviation, N=3 for each 
tissue). Data were compared using one-way 
aNova, significant differences are indicated by 
asterisks (*: p<0.05, **: p<0.01, ***: p<0.001).
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which the activated cells should be guided at that time. 
Treg sorted from spleen, both activated as well as resting, showed clear suppressive 
capacity. This is in concert with the finding that Treg isolated from human inflamed 
tonsils also showed strong suppressive capacity [50]. Remarkably, in contrast to 
peripheral blood derived Treg, Treg isolated from spleen were not anergic, which 
may be explained by the fact that these cells were capable of autologous production 
of Il-2. Next to Il-2, spleen Treg also produced Il-10 and IFNγ. CD69 expression on 
lymphocytes has previously been shown to regulate cytokine production [51]. 
Indeed, Il-10 production was higher by spleen CD69pos Treg as compared to spleen 
CD69neg Treg. However, as both CD69pos and CD69neg Treg in these tissues produced 
Il-2 and IFNγ, CD69 expression does not seem to be involved in this process.
In the current study, both fresh and cryopreserved samples were used for 
phenotypic characterization of Treg. As there is conflicting data about whether 
or not cryopreservation reduces the percentage of Treg in samples [52-54], 
we analyzed spleen samples both freshly after isolation as well as after at least 
one month of cryopreservation in liquid nitrogen. We found no difference in 
the percentage of Treg, their activation status, or their chemokine expression 
pattern (Supplementary Figure 1). For the suppression, proliferation, cytokine 
production and migration assays only freshly isolated cells were used, to prevent 
cryopreservation induced artifacts, as previously described for migratory capacity 
of swine cells [55]. Another potential matter of concern is that the liver-draining 
lymph nodes and spleen samples in this study were derived from deceased donors, 
whereby tissue ischemia may have caused non-specific leukocyte (Treg) activation. 
However, this seems unlikely since the inguinal lymph nodes, derived from living 
kidney transplant recipients showed a similar Treg activation pattern.
In summary, we here demonstrate that in healthy steady state conditions, Treg 
in human lymphoid organs are activated in a polyclonal way. These cells, at least 
temporarily, lose their anergic state and thereby obtain the capacity of self-
renewal by autocrine production of the T-cell growth factor Il-2 and the potential 
to proliferate while maintaining their suppressive potential. Also, these lymphoid 
tissue derived Treg expressed functional homing markers enabling them to migrate 
to peripheral sites. These findings not only add to our understanding of Treg biology 
in human lymphoid organs, but even more so may provide us with further clues 
how to optimize Treg based clinical protocols. For example infused Treg selected 
for an CCR7posCD62lpos phenotype, and thus having the capacity to migrate to 
secondary lymphoid organs, may there, as supported by our observations, further 
expand and obtain peripheral homing characteristics in vivo. 
REfERENCEs              
1.  Brunstein,C.G., Miller,J.S., Cao,Q., McKenna,D.H., Hippen,K.l., Curtsinger,J., DeFor,T., levine,B.l., 
June,C.H., Rubinstein,P., McGlave,P.B., Blazar,B.R., and Wagner,J.E., Infusion of ex vivo expanded 
T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection 
kinetics. Blood. 2011. 117: 1061-1070.
2.  Di,I.M., Falzetti,F., Carotti,A., Terenzi,A., Castellino,F., Bonifacio,E., Del,P.B., Zei,T., Ostini,R.I., 
Cecchini,D., Aloisi,T., Perruccio,K., Ruggeri,l., Balucani,C., Pierini,A., Sportoletti,P., Aristei,C., 
falini,B., Reisner,y., Velardi,A., Aversa,f., and Martelli,M.f., Tregs prevent GVHD and promote 
78
CHAPTER 3
immune reconstitution in HlA-haploidentical transplantation. Blood. 2011. 117: 3921-3928.
3.  Trzonkowski,P., Bieniaszewska,M., Juscinska,J., Dobyszuk,A., Krzystyniak,A., Marek,N., 
Mysliwska,J., and Hellmann,A., First-in-man clinical results of the treatment of patients with graft 
versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. clin.
immunol. 2009. 133: 22-26.
4.  Mottet,C., Uhlig,H.H., and Powrie,F., Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. 
J.Immunol. 2003. 170: 3939-3943.
5.  Nguyen,V.H., Zeiser,R., Dasilva,D.l., Chang,D.S., Beilhack,A., Contag,C.H., and Negrin,R.S., In vivo 
dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-
versus-host disease following allogeneic transplantation. Blood. 2007. 109: 2649-2656.
6.  Menning,A., Hopken,U.E., Siegmund,K., lipp,M., Hamann,A., and Huehn,J., Distinctive role 
of CCR7 in migration and functional activity of naive- and effector/memory-like Treg subsets. 
eur.J.Immunol. 2007. 37: 1575-1583.
7.  Szanya,V., Ermann,J., Taylor,C., Holness,C., and Fathman,C.G., The subpopulation of CD4+CD25+ 
splenocytes that delays adoptive transfer of diabetes expresses l-selectin and high levels of CCR7. 
J.Immunol. 2002. 169: 2461-2465.
8.  Ermann,J., Hoffmann,P., Edinger,M., Dutt,S., Blankenberg,F.G., Higgins,J.P., Negrin,R.S., 
Fathman,C.G., and Strober,S., Only the CD62l+ subpopulation of CD4+CD25+ regulatory T cells 
protects from lethal acute GVHD. Blood. 2005. 105: 2220-2226.
9.  Taylor,P.A., Panoskaltsis-Mortari,A., swedin,J.M., Lucas,P.J., Gress,R.E., Levine,B.L., June,C.H., 
Serody,J.S., and Blazar,B.R., l-Selectin(hi) but not the l-selectin(lo) CD4+25+ T-regulatory cells are 
potent inhibitors of GVHD and BM graft rejection. Blood. 2004. 104: 3804-3812.
10.  lee,M.K., Moore,D.J., Jarrett,B.P., lian,M.M., Deng,S., Huang,X., Markmann,J.W., Chiaccio,M., 
Barker,C.F., Caton,A.J., and Markmann,J.F., Promotion of allograft survival by CD4+CD25+ 
regulatory T cells: evidence for in vivo inhibition of effector cell proliferation. J.Immunol. 2004. 
172: 6539-6544.
11.  Davidson,T.S. and Shevach,E.M., Polyclonal Treg cells modulate T effector cell trafficking. 
eur.J.Immunol. 2011. 41: 2862-2870.
12.  Velasquez-lopera,M.M., Correa,l.A., and Garcia,l.F., Human spleen contains different subsets of 
dendritic cells and regulatory T lymphocytes. clin.exp.Immunol. 2008. 154: 107-114.
13.  lim,H.W., Hillsamer,P., and Kim,C.H., Regulatory T cells can migrate to follicles upon T cell 
activation and suppress GC-Th cells and GC-Th cell-driven B cell responses. J.clin.Invest. 2004. 114: 
1640-1649.
14.  Chung,y., Tanaka,S., Chu,F., Nurieva,R.I., Martinez,G.J., Rawal,S., Wang,y.H., lim,H., Reynolds,J.M., 
Zhou,X.H., Fan,H.M., liu,Z.M., Neelapu,S.S., and Dong,C., Follicular regulatory T cells expressing 
Foxp3 and Bcl-6 suppress germinal center reactions. nat.med. 2011. 17: 983-988.
15.  Wollenberg,I., gua-Doce,A., Hernandez,A., Almeida,C., Oliveira,V.G., Faro,J., and Graca,l., 
Regulation of the germinal center reaction by Foxp3+ follicular regulatory T cells. J.Immunol. 2011. 
187: 4553-4560.
16.  linterman,M.A., Pierson,W., lee,S.K., Kallies,A., Kawamoto,S., Rayner,T.F., Srivastava,M., 
Divekar,D.P., Beaton,l., Hogan,J.J., Fagarasan,S., liston,A., Smith,K.G., and Vinuesa,C.G., Foxp3+ 
follicular regulatory T cells control the germinal center response. nat.med. 2011. 17: 975-982.
17.  lim,H.W., Hillsamer,P., Banham,A.H., and Kim,C.H., Cutting edge: direct suppression of B cells by 
CD4+ CD25+ regulatory T cells. J.Immunol. 2005. 175: 4180-4183.
18.  Giroux,M., yurchenko,E., St-Pierre,J., Piccirillo,C.A., and Perreault,C., T regulatory cells control 
numbers of NK cells and CD8alpha+ immature dendritic cells in the lymph node paracortex. 
J.Immunol. 2007. 179: 4492-4502.
19.  Siewert,C., Menning,A., Dudda,J., Siegmund,K., lauer,U., Floess,S., Campbell,D.J., Hamann,A., and 
Huehn,J., Induction of organ-selective CD4+ regulatory T cell homing. eur.J.Immunol. 2007. 37: 
978-989.
20.  lee,J.H., Kang,S.G., and Kim,C.H., FoxP3+ T cells undergo conventional first switch to lymphoid 
tissue homing receptors in thymus but accelerated second switch to nonlymphoid tissue homing 
receptors in secondary lymphoid tissues. J.Immunol. 2007. 178: 301-311.
21.  Hirahara,K., liu,l., Clark,R.A., yamanaka,K., Fuhlbrigge,R.C., and Kupper,T.S., The majority of 
human peripheral blood CD4+CD25highFoxp3+ regulatory T cells bear functional skin-homing 
79
activated regulatory t-cells  in human lymphoid organs
3
receptors. J.Immunol. 2006. 177: 4488-4494.
22.  lim,H.W., Broxmeyer,H.E., and Kim,C.H., Regulation of trafficking receptor expression in human 
forkhead box p3+ regulatory T cells. J.Immunol. 2006. 177: 840-851.
23.  Iellem,A., Colantonio,l., and D’Ambrosio,D., Skin-versus gut-skewed homing receptor expression 
and intrinsic CCR4 expression on human peripheral blood CD4+CD25+ suppressor T cells. 
eur.J.Immunol. 2003. 33: 1488-1496.
24.  Clark,R.A. and Kupper,T.S., Il-15 and dermal fibroblasts induce proliferation of natural regulatory T 
cells isolated from human skin. Blood. 2007. 109: 194-202.
25.  Ishimaru,N., Nitta,T., Arakaki,R., yamada,A., lipp,M., Takahama,y., and Hayashi,y., In situ patrolling 
of regulatory T cells is essential for protecting autoimmune exocrinopathy. Plos one. 2010. 5: 
e8588.
26.  Vukmanovic-Stejic,M., Agius,E., Booth,N., Dunne,P.J., lacy,K.E., Reed,J.R., Sobande,T.O., Kissane,S., 
Salmon,M., Rustin,M.H., and Akbar,A.N., The kinetics of CD4+Foxp3+ T cell accumulation during a 
human cutaneous antigen-specific memory response in vivo. J.clin.Invest. 2008. 118: 3639-3650.
27.  Eksteen,B., Miles,A., Curbishley,S.M., Tselepis,C., Grant,A.J., Walker,l.S., and Adams,D.H., 
Epithelial inflammation is associated with CCl28 production and the recruitment of regulatory T 
cells expressing CCR10. J.Immunol. 2006. 177: 593-603.
28.  Huehn,J., Siegmund,K., lehmann,J.C., Siewert,C., Haubold,U., Feuerer,M., Debes,G.F., lauber,J., 
Frey,O., Przybylski,G.K., Niesner,U., de la,R.M., Schmidt,C.A., Brauer,R., Buer,J., Scheffold,A., and 
Hamann,A., Developmental stage, phenotype, and migration distinguish naive- and effector/
memory-like CD4+ regulatory T cells. J.exp.Med. 2004. 199: 303-313.
29.  Zhao,D., Zhang,C., yi,T., lin,C.l., Todorov,I., Kandeel,F., Forman,S., and Zeng,D., In vivo-activated 
CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. Blood. 2008. 
112: 2129-2138.
30.  Koch,M.A., Tucker-Heard,G., Perdue,N.R., Killebrew,J.R., Urdahl,K.B., and Campbell,D.J., The 
transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 
inflammation. nat.immunol. 2009. 10: 595-602.
31.  Zheng,y., Chaudhry,A., Kas,A., deRoos,P., Kim,J.M., Chu,T.T., Corcoran,l., Treuting,P., Klein,U., and 
Rudensky,A.y., Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control 
T(H)2 responses. nature. 2009. 458: 351-356.
32.  Chaudhry,A., Rudra,D., Treuting,P., Samstein,R.M., liang,y., Kas,A., and Rudensky,A.y., CD4+ 
regulatory T cells control TH17 responses in a Stat3-dependent manner. science. 2009. 326: 986-
991.
33.  Duhen,T., Duhen,R., lanzavecchia,A., Sallusto,F., and Campbell,D.J., Functionally distinct subsets 
of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood. 2012. 119: 4430-
4440.
34.  Probst-Kepper,M., Geffers,R., Kroger,A., Viegas,N., Erck,C., Hecht,H.J., lunsdorf,H., Roubin,R., 
Moharregh-Khiabani,D., Wagner,K., Ocklenburg,F., Jeron,A., Garritsen,H., Arstila,T.P., 
Kekalainen,E., Balling,R., Hauser,H., Buer,J., and Weiss,S., GARP: a key receptor controlling FOXP3 
in human regulatory T cells. J.cell Mol.Med. 2009. 13: 3343-3357.
35.  Stockis,J., Colau,D., Coulie,P.G., and lucas,S., Membrane protein GARP is a receptor for latent TGF-
beta on the surface of activated human Treg. eur.J.Immunol. 2009. 39: 3315-3322.
36.  Tran,D.Q., Andersson,J., Wang,R., Ramsey,H., Unutmaz,D., and Shevach,E.M., GARP (lRRC32) 
is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ 
regulatory T cells. Proc.Natl.acad.sci.u.s.a. 2009. 106: 13445-13450.
37.  Wang,R., Wan,Q., Kozhaya,l., Fujii,H., and Unutmaz,D., Identification of a regulatory T cell specific 
cell surface molecule that mediates suppressive signals and induces Foxp3 expression. Plos oNe. 
2008. 3: e2705.
38.  Wang,R., Kozhaya,l., Mercer,F., Khaitan,A., Fujii,H., and Unutmaz,D., Expression of GARP 
selectively identifies activated human FOXP3+ regulatory T cells. Proc.Natl.acad.sci.u.s.a. 2009. 
106: 13439-13444.
39.  Shiow,l.R., Rosen,D.B., Brdickova,N., Xu,y., An,J., lanier,l.l., Cyster,J.G., and Matloubian,M., CD69 
acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid 
organs. nature. 2006. 440: 540-544.
40.  Simons,D.M., Picca,C.C., Oh,S., Perng,O.A., Aitken,M., Erikson,J., and Caton,A.J., How specificity 
80
CHAPTER 3
for self-peptides shapes the development and function of regulatory T cells. J.leukoc.Biol. 2010. 
88: 1099-1107.
41.  Tomura,M., Itoh,K., and Kanagawa,O., Naive CD4+ T lymphocytes circulate through lymphoid 
organs to interact with endogenous antigens and upregulate their function. J.Immunol. 2010. 184: 
4646-4653.
42.  Anderson,M.S. and Su,M.A., Aire and T cell development. curr.opin.Immunol. 2011. 23: 198-206.
43.  Heino,M., Peterson,P., Kudoh,J., Nagamine,K., lagerstedt,A., Ovod,V., Ranki,A., Rantala,I., 
Nieminen,M., Tuukkanen,J., Scott,H.S., Antonarakis,S.E., Shimizu,N., and Krohn,K., Autoimmune 
regulator is expressed in the cells regulating immune tolerance in thymus medulla. Biochem.
Biophys.Res.commun. 1999. 257: 821-825.
44.  Poliani,P.l., Kisand,K., Marrella,V., Ravanini,M., Notarangelo,l.D., Villa,A., Peterson,P., and 
Facchetti,F., Human peripheral lymphoid tissues contain autoimmune regulator-expressing 
dendritic cells. am.J.Pathol. 2010. 176: 1104-1112.
45.  Gardner JM, Devoss JJ, Friedman RS et al. Deletional tolerance mediated by extrathymic Aire-
expressing cells. Science 2008;321:843-847.
46.  lee JW, Epardaud M, Sun J et al. Peripheral antigen display by lymph node stroma promotes T cell 
tolerance to intestinal self. Nat.Immunol. 2007;8:181-190.
47. Roozendaal R, Mebius RE. Stromal cell-immune cell interactions. Annu.Rev.Immunol. 2011;29:23-
43.
48.  yip l, Su l, Sheng D et al. Deaf1 isoforms control the expression of genes encoding peripheral 
tissue antigens in the pancreatic lymph nodes during type 1 diabetes. Nat.Immunol. 2009;10:1026-
1033.
49.  Ueha,S., yoneyama,H., Hontsu,S., Kurachi,M., Kitabatake,M., Abe,J., yoshie,O., Shibayama,S., 
Sugiyama,T., and Matsushima,K., CCR7 mediates the migration of Foxp3+ regulatory T cells to 
the paracortical areas of peripheral lymph nodes through high endothelial venules. J.leukoc.Biol. 
2007. 82: 1230-1238.
50.  Simark-Mattsson,C., Dahlgren,U., and Roos,K., CD4+CD25+ T lymphocytes in human tonsils 
suppress the proliferation of CD4+. scand.J.Immunol. 2002. 55: 606-611.
51.  Sancho,D., Gomez,M., and Sanchez-Madrid,F., CD69 is an immunoregulatory molecule induced 
following activation. trends immunol. 2005. 26: 136-140.
52.  Elkord,E., Frequency of human T regulatory cells in peripheral blood is significantly reduced by 
cryopreservation. J.Immunol.Methods. 2009. 347: 87-90.
53.  Sattui,S., de la,F.C., Sanchez,C., lewis,D., lopez,G., Rizo-Patron,E., White,A.C., Jr., and Montes,M., 
Cryopreservation modulates the detection of regulatory T cell markers. cytometry B.clin.cytom. 
2012. 82: 54-58.
54.  van Hemelen,D., Oude Elberink,J.N., Heimweg,J., van Oosterhout,A.J., and Nawijn,M.C., 
Cryopreservation does not alter the frequency of regulatory T cells in peripheral blood 
mononuclear cells. J.Immunol.Methods. 2010. 353: 138-140.
55.  Abda,R., Chevaleyre,C., and Salmon,H., Effect of cryopreservation on chemotaxis of lymphocytes. 
cryobiology. 1998. 36: 184-193.
81
activated regulatory t-cells  in human lymphoid organs
3
suPPleMeNtaRy FIguRe 1. cRyo-
PReseRvatIoN Does Not aFFect 
tHe exPRessIoN oF actIvatIoN aND 
HoMINg MaRKeRs oF treg.
Mononuclear cells were obtained from 
spleen samples of healthy human donors. 
the percentages of cD4poscD25poscD127neg 
treg positive for indicated markers were 
determined by flowcytometry directly after 
isolation (Fresh, F) and after cryopreservation 
in liquid nitrogen (cryo, c). each line 
represents one sample (N=3). Data were 
compared using t-tests and no significant 
differences were found.
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KERATINOCYTE / T-CELL INTERACTIONS
4
ABsTRAC T           
Both keratinocytes and T-cells are crucial players in cutaneous immune responses. 
We hypothesized that direct interactions between keratinocytes and T-cell subsets 
could shape the nature or strength of the local immune response. 
We investigated direct interactions between keratinocytes and T-cell subsets, 
focused on keratinocyte chemokine production and T-cell phenotype and cytokine 
production. A newly developed in vitro serum-free co-culture model using 
primary keratinocytes and T-cells subsets from healthy human donors was used. 
Keratinocyte chemokine production was analyzed with luminex, T-cell phenotype 
and cytokine production were analyzed with flow cytometry.
Our data show that upon co-culture with CD4pos or CD8pos T-cells primary human 
keratinocytes increased production of functionally active chemokines CCl2, 
CCl20 and CXCl10 and that regulatory T-cells did not regulate keratinocyte 
chemokine production. Next to that, we found that keratinocytes skewed CD4pos 
and CD8pos T-cell populations towards an Il-17pos CCR6pos RORγtpos phenotype in 
a cell-cell contact independent manner, and that Treg were able to decrease the 
absolute number of Il-17 producing T-cells in keratinocyte/T-cell co-cultures. 
Correspondingly, freshly isolated skin-derived T-cell populations contained 
relatively high percentages of Il-17pos cells. 
We provide evidence that keratinocyte/T-cell communication may regulate 
leukocyte influx in the skin, and that keratinocytes enrich T-cell populations for 
Th17/Tc17 cells. Accumulation of Th17/Tc17 cells, but not chemokine production, 
appears under the control of regulatory T-cells. Dysregulation of these processes 
may well contribute to the pathophysiology of inflammatory skin diseases.
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INTRODUC TION              
Recent views suggest that tissues play an important role in local immunity, 
regulating and guiding the immune system towards a response that keeps the 
tissues clear of danger, while optimally protecting host tissue cells from damage 
caused by inflammatory responses [1;2]. In the skin, keratinocytes (KC) are 
recognized as crucial cells in immune responses [3]. In healthy as well as in inflamed 
skin, KC produce bactericidal products, chemokines, cytokines, and many other 
immunologically active molecules. In doing so, they attract and activate leukocytes, 
thereby regulating the strength and nature of the local immune reaction. 
CD4pos and CD8pos T-cells are crucial players in the adaptive immune response. 
For CD4pos Thelper cells, several different lineages have been described [4], each 
producing distinct cytokines, with distinct effector functions. While Th1, Th2 and 
Th17 cells are involved in the clearance of intra- and extracellular pathogens, 
regulatory T-cells (Treg) dampen responses, which is crucial for the maintenance 
of (self-)tolerance and homeostasis. In analogy to the CD4pos Thelper lineages, 
the heterogeneous populations of CD8pos effector T-cells can be divided into Tc1, 
Tc2 and Tc17 cells [5]. In healthy human skin, CD4pos and CD8pos T-cells are present 
in close range of KC, with high numbers of dermal T-cells and lower numbers of 
epidermal T-cells [6]. Dermal as well as epidermal T-cell numbers increase during 
inflammation, and these cells are generally regarded as important contributors to 
inflammatory skin damage.
Treg can also express skin homing markers and are found in healthy human skin [7], 
supporting the notion of an active role for these cells in the periphery. In mouse 
models, Treg homing into the skin has been found crucial for the maintenance of 
skin homeostasis [8].
In the skin, immune regulation is an active and ongoing process, with notable 
contributions of both KC and T-cells. Although previous studies have focused on 
the interaction between KC and T-cells, the outcomes have been contradictory [9-
13]. This ambiguity may be explained by the use of immortalized KC or KC from 
immune privileged hair follicles in some of these studies, which clearly differ from 
primary KC [14;15]. Others studied the influence of T-cell derived cytokines on 
KC, without co-culturing these two cell types [16-25]. In most KC culture systems 
described, serum was added to the culture medium. However, serum has been 
shown to hinder T-cell proliferation in KC/T-cell co-cultures [26]. 
In this study, we examined direct interactions between KC and T-cells in vitro, 
using a newly developed serum-free co-culture system with primary KC from 
healthy human skin and purified T-cell subsets from healthy human donors. We 
used this KC/T-cell co-culture system to demonstrate that KC possess the capacity 
to regulate leukocyte influx in the skin by producing chemokines, and we reveal 
that this process in turn is influenced by T-cells. In the same system, we provide 
evidence that KC enrich T-cell populations for Th17/Tc17 cells, and that Treg restrain 
absolute numbers of Il-17 producing T-cells. 
87
KERATINOCYTE / T-CELL INTERACTIONS
4
MATERIAL s AND METHODs            
sOURCEs Of HUMAN CELLs
All human cells were obtained from healthy human donors upon written informed 
consent with regard to scientific use, according to the Dutch Medical Research 
Involving Human Subjects Act (WMO). Peripheral blood cells were isolated from 
buffy coats (Sanquin Bloodbank, Nijmegen, The Netherlands). KC, fibroblasts and 
skin resident T-cells were obtained from human skin derived from abdominal wall 
correction surgeries. 
T-CEllS
Peripheral blood cells were isolated by density gradient centrifugation 
(lymphoprep, Nycomed Pharma, Roskilde, Denmark). Skin T-cells were isolated 
from biopsies by incubation in PBS with collagenase type I-A (3%; Sigma-Aldrich, 
St louis, MO) and dispase II (1.2 mg/ml; Roche Applied Science, Indianapolis, IN), 
combined with mechanical disaggregation. After addition of human pooled serum 
and DNAse (0.25 mg/ml; Roche Applied Science), cells were forced through a 
cell strainer (70 μm; BD Biosciences, San Jose, CA). For experiments comparing 
skin T-cells with peripheral blood T-cells, both populations underwent skin T-cell 
isolation procedures. Exposure of peripheral blood cells to the enzymes used in 
skin T-cell isolation did not alter cytokine production (data not shown).
Where indicated, CD3pos, CD4pos or CD8pos T-cells were selected by MACS-sorting, 
using 15 μl anti-CD3, anti-CD4 or anti-CD8 magnetic microbeads/107 PBMC 
(Miltenyi Biotec, Bergisch Gladbach, Germany), respectively. Isolations routinely 
resulted in a >95% pure target T-cell fraction. Treg were isolated by first depleting 
non CD4pos T-cells, using mAbs directed against CD8 (RPA-T8), CD14 (M5E2), CD16 
(3G8), CD19 (4G7), CD33 (P67.6), CD235a (GA-R2(HIR2) (BD Biosciences), and CD56 
(MOC-1) (Dako, Glostrup, Denmark) combined with sheep-anti-mouse-IgG coated 
magnetic beads (Dynal Biotech, Oslo, Norway), followed by CD25pos selection by 
MACS-sorting, using 10 μl anti-CD25 magnetic microbeads/107 CD4pos cells (Miltenyi 
Biotec), resulting in a >80% pure CD4posCD25pos population. Where indicated, T-cells 
were labeled with 1 μM CFDA-SE (Invitrogen, Carlsbad, CA) per 5-10x106 cells.
KERATINOCyTEs
KC were prepared as previously described [27]. Briefly, KC were isolated from 
human skin biopsies by trypsin treatment and added (5x104 KC/cm2) to precultured 
irradiated (3295 cGy for 4.10 minutes) cells from the mouse fibroblast 3T3 cell 
line in Green’s medium. KC were cultured until wells were almost confluent, and 
cryopreserved until further use. After thawing, KC were seeded in 96-well flat 
bottom plates (104/well) or in 24-well flat bottom plates (2x104/well), and cultured 
until wells were almost confluent. KC were then provided with differentiation 
medium, consisting of keratinocyte basal medium (lonza, Verviers, Belgium) 
supplemented with penicillin/streptomycin (50 IU/ml; life Technologies, Grand 
Island, Ny), phosphoethanolamine (0.1 mM; Sigma-Aldrich) and ethanolamine 
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(0.1 mM; Sigma-Aldrich) for 3 hours, as longer incubation times led to KC death in 
subsequent KC/T-cell co-cultures (data not shown). Where indicated, recombinant 
human Il-1α (30 ng/ml; PeproTech, Rocky Hill, NJ) and TNFα (30 ng/ml; PeproTech) 
were added to the differentiation medium to stimulate KC.
fIBROBLAsTs
The epidermis was stripped from skin biopsies, the dermal layer was mashed and 
incubated for 1-2 hours in PBS with collagenase A (0.25%) and dispase (0.25%). 
Fibroblasts were forced through a cell strainer (70 μm) and cryopreserved until 
further use. After thawing, fibroblasts were seeded in 96-well flat bottom plates 
(5x103 cells per well), and cultured in DMEM (life Technologies) supplemented with 
glucose (4.5 g/l; Invitrogen), l-glutamine (4 mmol/l; life Technologies), penicillin/
streptomycin (50 IU/ml) and 10% defined bovine calf serum (Hyclone). Medium 
was refreshed every 2-3 days until the wells were almost confluent. 
KC/T-CEll AND FIBROBlAST/T-CEll CO-CUlTURES
Co-cultures were set up in XVivo15 medium (lonza), supplemented with l-glutamine 
(2 mM), penicillin (50 U/ml; Invitrogen), streptomycin (50 μg/ml; Invitrogen). This 
medium was found to be superior to RPMI, DMEM and KGM with regard to survival 
of KC combined with survival and proliferation of T-cells (data not shown). KC and 
fibroblast cultures were extensively washed with PBS before setting up co-cultures 
in order to minimize carryover of growth factors. 5x104 T-cells were stimulated 
with 104 anti-CD3/anti-CD28 mAb coated microbeads (Dynal Biotech). Stimulation 
with anti-CD3 (2 µg/ml UCHT1; BD Biosciences) or anti-CD28 (2 µg/ml CD28.2; BD 
Biosciences) alone did not induce T-cell proliferation (Supplementary Figure 1). In 
indicated experiments, exogenous Il-1ra (125 ng/ml; R&D Systems, Minneapolis, 
MN) was added to cultures; this concentration was previously found to efficiently 
block Il-1 signaling effects in T-cells [28]. For transwell experiments, T-cells were 
cultured in 0.4 µM transwell inserts for 24-well plates (Greiner Bio-one, Monroe, 
NC). Medium was refreshed at day 3 of co-culture. 
ANTIBODIEs AND fLOWCyTOMETRy
The phenotype of cells was analyzed by five-color flowcytometry (FC500, Beckman 
Coulter, Fullerton, CA). For cell surface staining, the following conjugated mAbs 
were used: CD183/CXCR3(1C6)-PC5, CD194/CCR4(1G1)-PC7, CD196/CCR6(11A9)-
PE, CD4(SFCI12T4D11)-ECD or -PC7, CD8(SFCI21Thy2D3)-ECD, CD45(J33)-ECD and 
CD3(UCHT1)-PC7 or -ECD (Beckman Coulter). For intracellular staining, fix/perm 
buffers (eBioscience, San Diego, CA) were used according to manufacturer’s 
instructions, in combination with the following conjugated mAbs: RORγt(AFKJS-9)-
APC, GATA3(TWAJ)-AlexaFluor647, Il-17(eBio17B7)-AlexaFluor647, IFNγ(4S.B3)-PC7 
(eBioscience), T-bet(4B10)-PE (Santa Cruz Biotechnology, Santa Cruz, CA), Il-4(8D4-
8)-PE (BD Biosciences), Il-17(197301)-FITC, and CCl20(67310)-APC (R&D Systems). In 
suppression assays, cells were counted using Flow-Count fluorospheres (Beckman 
Coulter). Isotype controls were used for gate settings. Data were analyzed using 
CXP software (Beckman Coulter).
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CyTOKINE AND CHEMOKINE PRODUCTION
For determination of T-cell cytokine or chemokine production by flowcytometry, 
non-adherent T-cells from co-cultures or freshly isolated peripheral blood or skin 
T-cells were transferred into 96 wells U-bottom plates. PMA (12.5 ng/ml; Sigma-
Adrich), ionomycin (0.5 μg/ml; Sigma-Adrich) and Brefeldin A (5 μg/ml; Sigma-
Aldrich; added after 1 hour of culture when fresh cells were used) were added. 
After 4 hours of culture with Brefeldin A, cells were harvested and cytokine 
production was analyzed. 
For determination of cytokine or chemokine concentration by luminex, culture 
supernatants were taken at indicated time points and the concentrations of Il-1α, 
Il-1β, CCl2, CXCl10 (Invitrogen) or CCl22 (Millipore, Billerica, MA, USA) (Invitrogen) 
were determined, according to manufacturers’ instructions.
MIGRATION AssAy
The migration capacity of T-cell populations freshly isolated from peripheral 
blood was determined in a transwell assay. Culture wells were supplied with KC-
T-cell culture supernatants, with XVivo15 serum-free medium (negative control) 
or with XVivo15 medium plus CXCl12 (0.5 μg/ml; positive control) (R&D systems). 
CD3pos T-cells were isolated from peripheral blood and labeled with the following 
conjugated mAbs: CD8(DK25)-FITC (Dako), CD25(M-A251)-PE (BD biosciences), 
CD3(UCHT1)-ECD, CD4(13B8.2)-PC5 (Beckman Coulter) and CD127(eBioRDR5)-
PC7. 0.5-1x106 T-cells were added into 3 μm membrane inserts (Millipore). Tests 
were set up in duplicate (supernatant or chemokine filled wells) or quadruplicate 
(medium control). After 2 hours incubation, cells were harvested from the bottom 
compartment. 104 flowcount microspheres were added and samples were analyzed 
using flowcytometry. Chemotaxis indices of cells or cell subsets were calculated as 
the index of migrating cells in the presence of chemokine or culture supernatant to 
that in medium controls. 
sTATIsTICAL ANALysIs
Data were analyzed using paired T-tests, one-way ANOVA, or two-way ANOVA, as 
indicated in figure legends. P-values less than 0.05 were considered statistically 
significant, indicated by asterisks. Data sets were tested using D’Agostino & Pearson 
omnibus normality tests and the overall majority of data sets were not significantly 
different from normal distributions, indicating that parametric statistical tests may 
be used. 
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REsULTs               
CD4POs AND CD8POs T-CEllS STIMUlATE KERATINOCyTES TO PRODUCE 
fUNCTIONALLy ACTIVE CHEMOKINEs
Here, using a newly developed in vitro KC/T-cell serum-free co-culture system with 
primary human KC and T-cells, we investigated the effect of interactions between 
these two cell types. We focused on production of CCl2, CCl20 and CXCl10, 
chemoattractants for subsets of CD4pos and CD8pos T-cells. These three chemokines 
are produced in vivo by human KC, and play an important role in inflammatory 
skin diseases. first, we established that, corresponding with other reports, in our 
culture system primary human KC alone produced CCl2 and CXCl10, but not CCl20 
[17;20;23;25], and revealed increased production of CCl2, CXCl10 as well as CCl20 
after pre-stimulation with Il-1α and TNFα, proinflammatory cytokines that are 
released in vivo upon skin damage [29] (data not shown). 
Next, we added increasing numbers of freshly isolated human CD4pos or CD8pos 
T-cells to cultures of cytokine pre-stimulated KC. Upon addition of T-cells which were 
activated by anti-CD3/anti-CD28 antibody coated microbeads, the concentrations 
of CCl2, CCl20 and CXCl10, measured in culture supernatant at day four of the KC/
T-cell co-cultures, increased significantly in a dose-dependent fashion (Figure 1A). 
Chemokine concentrations were comparable in KC/T-cell co-cultures with either 
CD4pos cells or CD8pos T-cells. Similar data were obtained when non-stimulated KC 
were used (data not shown). In cultures of T-cells alone, concentrations of CCl2, 
CCl20 and CXCl10 were very low (Figure 1A), implying that the interaction between 
KC and T-cells drove the chemokine increase. Addition of non-activated T-cells did 
not lead to enhanced chemokine production (Figure 1B). Although we found only 
trace amounts of chemokines in our cultures with activated T-cells alone (Figure 
1B), in literature, subsets of T-cells have been described to produce CCl20 [30]. 
In order to determine the source of CCl20 in our KC/T-cell co-culture system, we 
used a single cell FACS-based intracellular CCl20 analysis on the T-cell population 
after co-culture with KC (Figure 1C). Even though low percentages of CD4pos and 
CD8pos T-cells were indeed capable of CCl20 production, there were no significant 
FIguRe 1 (Next Page). Kc PRoDuctIoN oF FuNctIoNal cHeMoKINes Is gReatly INcReaseD 
uPoN co-cultuRe wItH t-cells. 
(a) Indicated numbers of anti-cD3/anti-cD28 microbead activated cD4pos or cD8pos t-cells (bead:cell 
1:5) were cultured alone or with Il-1α/tNFα pre-stimulated Kc. chemokine concentrations in 
supernatant collected at day four were determined by luminex. (B) cD4pos or cD8pos t-cells were 
co-cultured with Il-1α/tNFα pre-stimulated Kc in the presence or absence of anti-cD3/anti-cD28 
microbeads. chemokine concentrations in supernatant collected at day four were determined by 
luminex. (c) anti-cD3/anti-cD28 microbead activated cD4pos or cD8pos t-cells were cultured alone 
or with Il-1α/tNFα pre-stimulated Kc. at day four, intracellular ccl20 in t-cells was determined by 
flowcytometry, after additional PMa/ionomycin stimulation. (D) Migration assays were set up with 
culture supernatants of Il-1α/tNFα pre-stimulated Kc cultured alone or with anti-cD3/anti-cD28 
microbead activated cD4pos or cD8pos t-cells (bead:cell 1:5) for four days. Migration assays were 
performed using a transwell system, with indicated supernatants in the lower compartment and 
fresh cD3pos t-cells in the upper compartment. Numbers of migrated t-cell subsets were analyzed 
using flowcytometry and indexed to the number of migrating cells in medium control. Figure shows 
mean + sD. (aBcD) Data summarize two to four independent experiments. Data were compared using 
two-way aNova (a), t-tests (B, c) or aNova (D), significant differences are indicated by asterisks (*: 
p<0.05, **: p<0.01, ***: p<0.001).
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differences between T-cell populations cultured alone or with KC. Therefore, T-cells 
are unlikely to be the source of the markedly higher concentrations of CCl20 in 
KC/T-cell co-cultures. To our knowledge, CCl2 and CXCl10 are not produced by 
T-cells. These data thus suggest that KC are the main producers of chemokines in 
KC/T-cell co-cultures.
Next, we wondered whether the chemokines produced by KC were functionally 
active. Therefore, we set up a flowcytometry based in vitro transwell migration 
assay, to study the migration of freshly isolated CD4pos or CD8pos T-cells towards KC/
T-cell co-culture supernatants (Figure 1D). Supernatants of KC cultured alone did 
not attract significant numbers of T-cells. On the other hand, the supernatants of 
KC which had been co-cultured with T-cells were able to attract CD4pos and CD8pos 
T-cells. Interestingly, the migration capacity of freshly isolated Treg towards KC-T-
cell culture supernatants was similar to that seen for CD4pos and CD8pos T-cells. 
These data suggest that CD4pos and CD8pos T-cells induce chemokine production by 
KC, in sufficient concentrations to attract fresh CD4pos, CD8pos T-cells and Treg, as 
part of the inflammatory process.
REGUlATORy T-CEllS DO NOT INHIBIT CHEMOKINE PRODUCTION 
IN KERATINOCyTE/T-CEll CO-CUlTURES
Treg are known for their inhibitory actions on conventional CD4pos and CD8pos 
T-cells. We wondered whether Treg would influence the T-cell induced chemokine 
production by KC. Therefore, freshly isolated CD4posCD25pos Treg were titrated 
into KC/T-cell co-cultures. Using a CFSE-based co-culture suppression assay, 
we established that also in a KC/T-cell co-culture, Treg reduced CD4pos as well as 
CD8pos T-cell proliferation, thereby confirming Treg function in this system (Figure 
2A). Notably, addition of Treg had no effect on chemokine production in KC/T-cell 
co-cultures with either CD4pos or CD8pos T-cells (Figure 2B), nor did they affect the 
percentage of CCl20 producing T-cells in co-cultures (Figure 2C). Correspondingly, 
the migration of fresh T-cells to culture supernatants of KC/T-cell/Treg co-cultures 
was similar to migration to KC/T-cell co-cultures without Treg (Figure 2D). These 
data suggest that with regard to chemokine production, the interaction between 
KC and T-cells is beyond the regulatory capacity of Treg.
KERATINOCyTES ENRICH FOR AN Il-17 PRODUCING PHENOTyPE 
IN HUMAN CD4POs AND CD8POs T-CEll POPUlATIONS
Having determined that T-cells influence KC to produce more chemokines in co-
cultures, attracting more T-cells, we then wondered how T-cells would respond 
to KC. We employed our KC/T-cell serum-free co-culture system to study 
effects of primary KC on anti-CD3/anti-CD28 mAb coated bead activated T-cells. 
Using flowcytometry the expression of selected Th1, Th2 and Th17 associated 
cytokines, transcription factors and chemokine receptors was analyzed (Figure 
3). Interestingly, co-culture with KC led to an increase in the percentage of Il-17 
producing CD4pos T-cells (Figure 3A). This increase was paralleled by an increase in 
the expression of the Th17 related transcription factor RORyt (Figure 3B) and the 
Th17 associated surface marker CCR6 (Figure 3C). In the CD4pos T-cell population, 
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figure 2. treg Do Not 
INFlueNce cD4Pos or 
cD8Pos t-cell INDuceD 
Kc cHeMoKINe PRo-
DuctIoN. 
(a) cFse labeled anti-cD3/
anti-cD28 micro-bead 
activated cD4pos or cD8pos 
t-cells (bead:cell 1:5) were 
co-cultured with Il-1α/
tNFα-stimulated Kc in 
the presence or absence 
of treg. the percentages 
of divided (cFselow, 
excluding cFseneg treg) 
t-cells were determined 
by flowcytometry at day 
five and percentages of 
divided cells in cultures 
with treg were indexed to 
those in cultures without 
treg. (B) co-cultures were 
set up with Il-1α/tNFα pre-
stimulated Kc and anti-
cD3/anti-cD28 microbead 
activated cD4pos or cD8pos 
t-cells plus indicated 
numbers of additional 
treg. supernatant was 
collected at day four and 
chemokine concentrations 
were determined by 
luminex. (c) co-cultures 
were set up with Il-1α/
tNFα pre-stimulated Kc 
and cFse labeled anti-
cD3/anti-cD28 microbead 
activated cD4pos or cD8pos 
t-cells with or without 
additional treg. at day 
four, intracellular ccl20 in 
t-cells (excluding cFseneg 
treg) was determined 
by flowcytometry, after 
additional PMa/ionomycin 
stimulation. (D) Migration 
assays were set up with 
culture supernatants of 
Il-1α/tNFα-stimulated Kc 
and anti-cD3/anti-cD28 
microbead activated cD4pos 
or cD8pos t-cells with or 
without additional treg for 
four days. Migration assays were performed using a transwell system, with indicated supernatants 
in the lower compartment and fresh cD3pos t-cells in the upper compartment. numbers of migrated 
t-cell subsets were analyzed using flowcytometry and indexed to the number of migrating cells 
in medium control. Figure shows mean + sD. (aBcD) Data summarize two to four independent 
experiments. Data were compared using t-tests (a, c), two-way aNova (B), or aNova (D), significant 
differences are indicated by asterisks (*: p<0.05, **: p<0.01, ***: p<0.001).
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expression of Th1 and Th2 related cytokines (IFNγ and Il-4, respectively) and 
transcription factors (T-bet and GATA3, respectively) was not significantly altered. 
The expression of the Th1 associated surface maker CXCR3 was decreased, while 
the expression of the Th2 associated marker CCR4 did not change significantly. In 
CD8pos T-cells, co-culture with KC also led to increased expression of Il-17, RORγt 
and CCR6 (Figure 3). The expression of IFNγ and CXCR3 was reduced in CD8pos 
T-cells, while no significant changes in Il-4, T-bet, GATA3 and CCR4 were observed. 
Co-culture of T-cells with either non-stimulated or cytokine pre-stimulated KC 
yielded similar results (Supplementary Figure 2). 
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FIguRe 3. Kc eNRIcH FoR Il-17PosrorγtPos 
t-cells IN Kc/t-cell co-cultuRes. 
cFse labeled anti-cD3/anti-cD28 microbead 
activated cD4pos or cD8pos t-cells (bead:cell 
1:5) were cultured alone or with Kc, and the 
percentages of t-cells expressing cytokines 
(a), transcription factors (B) and homing 
markers (c) within divided (cFselow) cells were 
determined by flowcytometry at day five. 
(aBc) Data summarize twelve to eighteen 
independent experiments. Data were 
compared using t-tests (*: p<0.05, **: p<0.01, 
***: p<0.001). 
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Taken together, these results indicate that KC enrich for a Th17/Tc17-like phenotype 
in both CD4pos and CD8pos T-cells. 
KERATINOCyTES ENRICH FOR AN Il-17 PRODUCING PHENOTyPE 
IN T-CEll POPUlATIONS THROUGH SOlUBlE FACTORS 
In order to understand how KC enrich for Il-17 producing CD4pos and CD8pos T-cells 
in co-cultures, we investigated contact-dependency in transwell experiments. 
As co-culture of T-cells with either non-stimulated or cytokine pre-stimulated KC 
yielded similar results we used non-stimulated KC, excluding possible effects of 
exogenously added cytokines. The data revealed that preventing direct KC/T-cell 
contact did not reduce the increase of Il-17 producing T-cells in CD4pos or CD8pos 
T-cell populations (Figure 4A), implying that KC skew phenotype distribution in 
T-cell populations through soluble factors, in a cell-cell contact independent 
mechanism. Il-1β is a major driving force in Il-17 production [5;31]. KC have 
been described to produce pro-Il-1β and pro-Il-1α [3;32]. The biological activity 
of Il-1α and Il-1β partly overlap, making it plausible that both Il-1 subtypes can 
affect Il-17 production. We wondered if Il-1α and/or Il-1β were produced in our 
culture system, and if these cytokines could be responsible for the increase in IL-
17 producing CD4pos and CD8pos T-cells. First, Il-1α and Il-1β production in KC/T-
cell co-cultures was measured in culture supernatants (Figure 4B). Il-1α could not 
be detected in cultures of KC alone. However, the Il-1α concentration increased 
when KC were co-cultured with CD4pos or CD8pos T-cells. Il-1β could not be detected 
in culture supernatants, irrespective of the presence of T-cells. To examine if Il-
1α was responsible for the increase in Il-17pos T-cells, exogenous recombinant Il-1 
receptor antagonist (Il-1ra) was added to co-cultures. Il-1ra did not prevent the 
increase in Il-17 producing T-cells in KC/T-cell co-cultures (Figure 4C), indicating 
that in our system, Il-1 is not a crucial factor for the increased percentage of Il-17 
producing T-cells. 
REGUlATORy T-CEllS PREVENT ACCUMUlATION OF HIGH 
NUMBERS OF Il-17POs CD4POs AND CD8POs T-CEllS
Next, we wondered whether Treg could interfere in the KC induced Il-17 
enrichment in T-cell populations. Using a CfsE-based co-culture suppression assay, 
we found that Treg suppressed CD4pos and CD8pos T-cell proliferation irrespective of 
the presence of KC (Figure 5A), implying that the presence of KC did not affect the 
suppressive capacity of Treg. 
Interestingly, although the number of dividing cells was far lower in the presence 
of Treg, the dividing cell population revealed similar percentages of cells expressing 
specific cytokines, transcription factors, and homing markers as compared to 
cultures without Treg (Figure 5BCD). Therefore, as addition of Treg suppressed T-cell 
proliferation without affecting relative distribution of phenotypes, the absolute 
number of Il-17 producing cells in KC/T-cell co-cultures was decreased (Figure 5E). 
These results imply that Treg inhibit the accumulation of high numbers of T-cells by 
suppression of proliferation, and that T-cells that have bypassed Treg suppression 
are still sensitive to the effects of KC, which enrich for an Il-17pos phenotype.
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FIguRe 4. Kc INFlueNce oN Il-17Pos t-cell 
eNRIcHMeNt Is MeDIateD By a soluBle FactoR, 
otHeR tHaN Il-1.
(a) Direct Kc/t-cell contact was prevented by transwell 
inserts (tw) in cultures of cFse labeled anti-cD3/anti-
cD28 microbead activated cD4pos or cD8pos t-cells 
(bead:cell 1:5) cultured alone or with Kc and the 
percentages of t-cells producing Il-17 within divided 
(cFselow) cells were determined by flowcytometry at 
day five. (B) culture supernatants of Kc and/or anti-
cD3/anti-cD28 microbead activated cD4pos or cD8pos 
t-cells were collected at indicated days and cytokine 
concentrations were determined by luminex. (c) 
exogenous Il-1ra was added to cFse labeled anti-cD3/
anti-cD28 microbead activated cD4pos or cD8pos t-cells 
cultured alone or with     Kc. the percentage of t-cells 
producing Il-17 within divided (cFselow) cells were 
determined by flowcytometry at day five. (aBc) Data 
summarize four independent experiments. Data were 
compared using aNova (a, c) or two-way aNova (B) (*: 
p<0.05, **: p<0.01, ***: p<0.001). 
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SKIN-DERIVED FIBROBlASTS AlSO ENRICH FOR Il-17POsRORγTPOs 
CEllS IN CD4POs T-CEll POPUlATIONS
To determine whether the skewing of T-cell populations in co-cultures was limited 
to KC, the phenotypical and functional characteristics of T-cells co-cultured with 
skin-derived fibroblasts were determined. As shown in Figure 6, fibroblast/T-
cell co-culture also led to an increase in the proportion of Il-17 producing CD4pos 
T-cells, as well as increased expression of RORγt. In CD8pos T-cell populations, no 
significantly altered Il-17 production or expression of RORγt was observed upon 
co-culture with fibroblasts. 
FRESHly ISOlATED SKIN-DERIVED T-CEll POPUlATIONS 
CONTAIN MORE Il-17POs CEllS THAN PERIPHERAl BlOOD T-CEll 
POPULATIONs           
To determine whether the enrichment of Il-17pos T-cells by KC as found in our co-
culture system also takes place in healthy human skin, we isolated T-cells from 
skin and for comparison from peripheral blood of healthy human donors. We 
determined the production of Il-17 by T-cells either directly ex vivo, or after 4 hours 
of activation with PMA/ionomycin (Figure 7). Upon activation with PMA/ionomycin, 
peripheral blood contained approximately 2% Il-17 producing CD4pos, and 1% Il-17 
producing CD8pos T-cells. Remarkably, already 8% of non-stimulated freshly isolated 
skin derived CD45posCD3posCD4pos T-cells and 18% of CD45posCD3posCD8pos T-cells 
produced Il-17 directly ex vivo, and these percentages increased to as high as 11% 
for CD4pos T-cells and even 21% for CD8pos T-cells upon short-term activation with 
PMA/ionomycin. Skin derived T-cells were not enriched for IFNγ or Il-4 producing 
cells, as compared to blood T-cells (data not shown).
DIsCUssION                      
Evidence accumulates that tissue derived cells and immune cells co-operate in the 
regulation of local adaptive immune responses [1;2]. In the skin, both KC and T-cells 
have been described to be crucial in this process. CD4pos, CD8pos T-cells as well as 
Treg are present in close range of KC, in the dermis and the epidermis of healthy 
human skin [6;7]. 
Here, we found that upon in vitro co-culture with CD4pos or CD8pos T-cells, KC 
increased production of CCl2, CCl20 and CXCl10. In these co-cultures, Treg did 
not regulate KC chemokine production. Also, we showed that upon co-culture, KC 
skewed CD4pos and CD8pos T-cell populations towards an Il-17posCCR6posRORγtpos 
phenotype, which was corroborated by the finding of an Il-17 positive subset of 
skin derived T-cells directly ex vivo. 
Il-17 plays a crucial role in immune homeostasis in the human skin. It has been 
implicated in the defense against many extracellular bacterial and fungal 
pathogens that are frequently found on human skin, but rarely cause harmful 
infections [33;34]. The finding that KC under normal circumstances may stimulate 
Il-17 responses in T-cells, albeit to a limited extent, fuels the notion that tissues 
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figure 5. treg ReDuce tHe aBsolute NuMBeR 
oF Il-17Pos t-cells IN Kc/t-cell co-cultuRes.
(a) cFse labeled anti-cD3/anti-cD28 microbead 
activated cD4pos or cD8pos t-cells (bead:cell 1:5) 
were co-cultured with treg in the presence or 
absence of Kc. the percentages of divided (cFselow, 
excluding cFseneg treg) t-cells were determined 
by flowcytometry at day five and percentages of 
divided cells in cultures with Kc were indexed to 
those in cultures without Kc. (BcD) cFse labeled 
anti-cD3/anti-cD28 microbead activated cD4pos 
or cD8pos t-cells were cultured Kc in the presence 
or absence of treg, and the percentages of t-cells 
expressing cytokines (B), transcription factors (c) 
and homing markers (D) within divided (cFselow, 
excluding cFseneg treg) cells were determined 
by flowcytometry at day five. (e) the absolute 
numbers of divided (cFselow, excluding cFseneg 
treg) Il-17 producing t-cells were determined by 
flowcytometry at day five. (aBcDe) Data summarize 
four to six independent experiments. Data were 
compared using t-tests (*: p<0.05, **: p<0.01, ***: 
p<0.001). 
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provide dedicated environmental cues to steer the class of response needed to 
maintain homeostasis. The finding that skin-derived fibroblasts also led to skewing 
towards an Il-17pos phenotype of CD4pos T-cell, suggests that skewing towards an IL-
17pos phenotype could be inherent to the skin environment, although KC are clearly 
more apt for this task, as fibroblasts had no effect on CD8pos T-cells. Additionally 
we show here that human skin indeed contains a relatively high percentage of Il-
17 producing T-cells. Indeed in animals and humans, resident Th17 T-cells can be 
found in normal skin as well as in gut tissue [35-39]. In a recent study, it was shown 
that Il-17 producing T-cells can be cloned from human dermis and epidermis [40]. 
In addition, others showed that co-culture of human KC with pre-existing Th17 cells 
led to increased Il-17 production [12]. 
Even though the presence of active Th17/Tc17 cells in the skin can help in the 
clearance of infections, these cells can also have deleterious effects. Th17 and 
Tc17 cells have been implicated in inflammatory skin diseases such as psoriasis 
and atopic dermatitis [38;39;41]. Maintenance of 
a healthy skin phenotype or development of an 
inflammatory phenotype depends on a delicate 
balance between proinflammatory and suppressive 
factors. An overshoot of KC in their attempt to 
skew towards an Il-17 enriched environment, or 
hyperreactive T-cells that respond to normal KC 
signals too strongly, could well contribute to the 
pathology of chronic inflammatory skin diseases 
[22;42]. The dysregulated immune response 
might also be due to a lack of regulation by Treg. 
Indeed, in patients with psoriasis, the suppressive 
function of Treg was shown to be impaired [43;44]. 
Our data suggests that bona fide Treg prevent 
excessive immunity by inhibiting the accumulation 
of too high numbers of aggressive T-cells, hereby 
decreasing the absolute number of Il-17 producing 
cells. 
Tissue cells such as KC can fine tune local immunity 
by producing T-cell subtype specific chemokines. 
Corresponding with other reports on KC 
production of CCl2 [25], CXCl10 [17], and CCl20 
[20;23], in our culture system non-stimulated 
KC produced some CCl2 and CXCl10, and KC 
increased production of these chemokines and 
CCl20 upon pre-stimulation with Il-1α and TNFα, 
proinflammatory cytokines that are released upon 
skin damage. To our knowledge, our data show for 
the first time that the presence of CD4pos or CD8pos 
T-cells stimulates KC to increase the production 
of CCl2, CXCl10 and CCl20. Treg do not seem to 
have an influence on T-cell induced chemokine 
production by KC. Previous studies have shown the 
FIguRe 6. FIBRoBlasts eNRIcH 
FoR Il-17PosrorγtPos cells IN 
cD4Pos t-cell PoPulatIoNs, 
But Not cD8Pos t-cell 
PoPulatIoNs.
cFse labeled anti-cD3/anti-cD28 
microbead activated cD4pos or 
cD8pos t-cells (bead:cell 1:5) were 
cultured alone or co-cultured with 
skin-derived fibroblasts, and the 
percentages of t-cells expressing 
Il-17 and RoRγt within divided 
(cFselow) cells were determined by 
flowcytometry at day five. Data 
summarize four independent 
experiments. Data were compared 
using t-tests (*: p<0.05, **: 
p<0.01, ***: p<0.001). 
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effects of T-cell culture supernatants or recombinant chemokines on KC chemokine 
production. It has been shown that KC stimulated in vitro with supernatant from 
Th1 cells increase production of chemokines which were chemotactic for Th1, but 
not for Th2 cells [16]. Vice versa, stimulation with Th2 cells promoted chemokine 
production that primarily attracted Th2 cells [16]. Interestingly, it has been shown 
that KC increase production of CCl20, a ligand for the Th17-associated receptor 
CCR6, upon stimulation with Th17 associated cytokines such as Il-17 and Il-
22 [18;19;24]. These data prompt the hypothesis that when T-cells from a given 
lineage arrive on scene, they may stimulate KC to produce increased chemokine 
levels in order to attract more T-cells from that same lineage. In this manner, KC, 
chemokines and T-cells may form a positive feedback loop, increasing immune 
responses on site. Poor control of this feedback loop could potentially play a 
role in the pathogenesis of inflammatory skin diseases. Indeed, CCl2, CCl20 and 
CXCl10 have all been implicated in psoriasis. KC in lesional skin from psoriasis 
patients express significantly higher levels of CCl2 as compared to KC in healthy 
skin [45]. Also, higher numbers of cells expressing CCR2, the receptor for CCl2 
(mainly macrophages), have been reported in lesional skin and peripheral blood of 
psoriatic patients as compared to the healthy controls [46], although this was not 
the case in all studies [47]. Many CCR6 expressing Th17 and Tc17 cells are present 
in psoriatic skin, and high expression of CCl20 by KC from psoriatic lesions has 
repeatedly been demonstrated [19;21]. There are also many Th1 cells in psoriatic 
skin [19;21]. Th1 cells preferentially express CXCR3, and KC in psoriatic lesions have 
been shown to express its ligand CXCl10 [45;47;48], and serum concentrations of 
CXCl10 are higher in psoriatic patients as compared to healthy donors [49]. 
In conclusion, we show that KC possess the capacity to regulate leukocyte influx 
in the skin by producing chemo-kines, and that this process in turn is influenced 
by T-cells. In addition, we provide evidence that KC enrich T-cell populations for 
Th17/Tc17 cells, and that Treg restrain absolute numbers of Il-17 producing T-cells. 
Therefore, KC, effector T-cells and regulatory T-cells will have to co-operate closely 
to maintain the balance between beneficial and pathological skin immunity, 
clearing pathogens without creating harmful infections. More work is needed to 
clarify the interactions between KC and T-cell subtypes in both healthy as well as 
FIguRe 7. Il-17Pos t-cells 
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pathological states. To this end, the serum-free KC/T-cell co-culture system we 
describe could be a valuable tool.
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suPPleMeNtaRy FIguRe 1. exogeNous t-cell RecePtoR stIMulatIoN aND 
costIMulatIoN sIgNals aRe RequIReD FoR t-cell PRolIFeRatIoN IN KeRatINocyte/t-
cell co-cultuRes.
cFse labeled cD4pos or cD8pos t-cells were co-cultured with Kc in the presence or absence of exogenous 
anti-cD3, anti-cD28 monoclonal antibodies or anti-cD3/anti-cD28 microbeads (bead:cell 1:5). the 
percentages of divided (cFselow) t-cells were determined by flowcytometry at day five. Representative 
data from one out of three independent experiments are shown.
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4suPPleMeNtaRy FIguRe 2. cytoKINe PRe-stIMulatIoN oF Kc Does Not alteR Il-17Pos 
t-cell eNRIcHMeNt IN Kc/t-cell co-cultuRes.
to study the influence of cytokine pre-stimulation of Kc on t-cell phenotype in Kc/t-cell co-culture, 
cFse labeled anti-cD3/anti-cD28 microbead activated cD4pos or cD8pos t-cells (bead:cell 1:5) were 
cultured with Kc that were or were not pre-stimulated with Il-1α and tNFα for three hours, and the 
percentages of t-cells expressing cytokines (a), transcription factors (B) and homing markers (c) 
within divided (cFselow) cells were determined by flowcytometry at day five. (aBc) Data summarize 
four to nine independent experiments. Data were compared using t-tests (*: p<0.05, **: p<0.01, ***: 
p<0.001). 
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ABsTRAC T           
Regulatory T-cell (Treg) based immunotherapy is a potential treatment for several 
immune disorders. By now, this approach proved successful in preclinical animal 
transplantation and autoimmunity models. In these models the success of Treg 
based immunotherapy crucially depends on the antigen-specificity of the infused 
Treg population. For the human setting, information is lacking on how to generate 
Treg with direct antigen-specificity ex vivo to be used for immunotherapy. 
Here, we demonstrate that in as little as two stimulation cycles with HlA 
mismatched allogeneic stimulator cells and T-cell growth factors a very high 
degree of alloantigen-specificity was reached in magnetic bead isolated human 
CD4posCD25high Treg. Efficient increases in cell numbers were obtained. Primary 
allogeneic stimulation appeared a prerequisite in the generation of alloantigen-
specific Treg, while secondary allogeneic or polyclonal stimulation with anti-CD3 
plus anti-CD28 monoclonal antibodies enriched alloantigen-specificity and cell 
yield to a similar extent. 
The ex vivo expansion protocol that we describe will very likely increase the 
success of clinical Treg-based immunotherapy, and will help to induce tolerance to 
selected antigens, while minimizing general immune suppression. This approach is 
of particular interest for recipients of HlA mismatched transplants. 
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INTRODUC TION               
Regulatory T-cells (Treg) play a critical role in various immunological processes. 
These cells dampen immune responses, which is important in maintenance of 
(self-) tolerance and homeostasis. Immunotherapy based on Treg (either in vivo 
facilitation of Treg or infusion of ex vivo isolated/manipulated Treg) is therefore 
a potential treatment for many immune disorders. Such an approach has been 
proven successful in animal models of stem cell transplantation [1-7], solid 
organ transplantation [8;9], auto-immunity [10-14] and even in infertility [15]. 
Treg therapy in human patients will require high cell numbers, which might be 
obtained by ex vivo expansion. It has been shown that human naturally occurring 
CD4posCD25high Treg can be expanded polyclonally, by using anti-CD3 and anti-CD28 
antibody stimulation in combination with Il-2 and/or Il-15 [16-21]. These polyclonal 
expansion protocols greatly increase Treg numbers, while preserving suppressive 
capacity. However, there are some drawbacks regarding clinical application of 
polyclonally expanded Treg. First, since this type of activation encompasses Treg 
with a broad range of specificities, the infused polyclonal Treg may suppress 
immune responses other than the target response, thereby increasing the risk for 
opportunistic infections and tumor-growth. Second, due to the low percentage of 
Treg within a polyclonal cell pool that is specific for a given target antigen, large 
numbers of Treg need to be infused. These difficulties could be overcome by using 
antigen-specific Treg. In animal models, antigen-specific Treg have been shown 
to be far more efficient than polyclonal Treg [4;6;7;12-14]. Even as few as 5x103 
antigen-specific Treg were sufficient to prevent the onset of diabetes in a mouse 
model [14]. 
For the human setting, information is scarce on how to generate sufficient numbers 
of antigen-specific Treg ex-vivo from naturally occurring Treg [22]. The aim of this 
study was to design a successful strategy to obtain high numbers of Treg with 
direct alloantigen-specificity for use in transplantation settings. Based on previous 
findings, we hypothesized that it would be beneficial to combine polyclonal 
stimulation, to boost expansion, with alloantigen stimulation, to increase antigen-
specificity. To test this hypothesis, we alternated these two stimulation methods 
in primary and secondary Treg expansion cycles and assessed cell numbers, 
phenotype, function and antigen-specificity before and after expansion. We 
succeeded in defining a protocol that yields high numbers of strictly alloantigen-
specific human Treg.
MATERIAL s AND METHODs            
Treg EXPANSION STRATEGIES
To determine the optimal expansion strategy for obtaining high numbers of 
functionally active human alloantigen-specific Treg from CD4posCD25high Treg, we 
devised four different strategies, consisting of two subsequent cycles of expansion 
with alternated polyclonal and alloantigen-specific stimulation (Figure 1). 
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CELL PREPARATION AND IsOLATION
Buffy coats were purchased from Sanquin bloodbank (Nijmegen, The Netherlands). 
These buffy coats were obtained from healthy human donors upon written 
informed consent with regard to scientific use. 
The current study did not require approval from an ethical committee according 
to the Dutch Medical Research Involving Human subjects Act. PBMC were isolated 
by density gradient centrifugation (lymphoprep, Nycomed Pharma, Roskilde, 
Denmark). CD4pos T-cells were negatively selected using mAbs directed against CD8 
(RPA-T8), CD14 (M5E2), CD16 (3G8), CD19 (4G7), CD33 (P67.6), CD235a (GA-R2(HIR2) 
(BD Biosciences, San Jose, 
CA), and CD56 (MOC-1) 
(Dako, Glostrup, Denmark) 
combined with sheep-anti-
mouse-IgG coated magnetic 
beads (Dynal Biotech, Oslo, 
Norway), routinely resulting 
in a >90% pure CD4pos T-cell 
fraction. CD25high Treg and 
CD25neg conventional T-cells 
were separated by MACs-
sorting, using 10 µl anti-
CD25 magnetic microbeads 
/ 107 CD4pos cells (Miltenyi 
Biotec, Bergisch Gladbach, 
Germany). HlA typing was 
performed by serological 
and DNA based techniques 
according to international 
(ASHI/EFI) standards [23].
CD4POsCD25HIGH Treg EXPANSION
Cell cultures were performed in 96-well round bottom plates with culture 
medium consisting of RPMI-1640 supplemented with pyruvate (0.02 mM; 
Invitrogen, Carlsbad, CA), penicillin (100 U/ml; Invitrogen), streptomycin (100 µg/
ml; Invitrogen), and 10% human pooled serum, in a 37oC, 95% humidity, 5% CO
2
 
incubator. 
To optimize Treg expansion conditions, the mode and strength of stimulation, 
exogenous cytokine concentration, and expansion cycle length were varied in early 
experiments, as reported in the Results section. For assessment of cell division 
using CFSE, 1-5x106 cells were labeled with 0.5 µM CFDA-SE (Invitrogen) prior to 
stimulation. The final expansion protocols are described below. 
For primary and secondary cycle alloantigen-specific expansion, 2.5x104 T-cells 
were cultured with 105 γ-irradiated (30 Gy) HlA mismatched allogeneic PBMC 
(target alloantigen, ratio alloPBMC:Treg = 4:1). 
figure 1. scHeMatIc oveRvIew oF treg exPaNsIoN 
stRategIes. 
treg were expanded in two cycles, in which alloantigen and 
polyclonal stimulation were alternated, resulting in four 
distinct strategies: two subsequent cycles with alloantigen 
stimulation; primary cycle with alloantigen stimulus and 
secondary cycle with polyclonal stimulus; primary cycle with 
polyclonal stimulus and secondary cycle with alloantigen 
stimulus; and two subsequent cycles with polyclonal 
stimulation.
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For first cycle polyclonal expansion, 2.5x104 T-cells were cultured with 1.25x104 
anti-CD3/anti-CD28 coated microbeads (Dynal Biotech). For secondary cycle 
polyclonal expansion, 2.5x104 Treg were cultured with 5 µg/ml platebound anti-
CD3 (UCHT1, BD Biosciences, 4 hours in PBS in incubator) plus 1 µg/ml soluble anti-
CD28 (CD28.2, BD Biosciences). 
Exogenous Il-2 (25 U/ml, Chiron, Amsterdam, the Netherlands) and Il-15 (10 ng/ml 
BioSource International, Camarillo, CA) were added to all expansion cultures. Wells 
were split and fresh medium containing cytokines was added every 3 days. After 
10 days, the cells were harvested, washed and rested for 2 days in 5% HPS culture 
medium with 5 ng/ml Il-15 before analysis or further expansion. In all experiments, 
Tconv were included as control.
fLOWCyTOMETRy
The phenotype of cells was analyzed by five-color flowcytrometry (FC500, 
Beckman Coulter, Fullerton, CA). For cell surface staining, the following conjugated 
mAbs were used: CD25(M-A251)-PE, CD70(Ki-24)-PE, CD127(hIl-7R-M21)-
AlexaFluor647 (BD Biosciences), CD27(M-T271)-FITC (Dako), CD4-(SFCI12T4D11)-
PCy7 and CD62l(DREG56)-ECD (Beckman Coulter, Fullerton, CA). To stain apoptotic 
cells, 7-amino-actinomycin-D (7AAD, Sigma-Aldrich, Zwijndrecht, the Netherlands) 
was added to cells prior to acquisition. For intracellular staining, Fix and Fix/Perm 
buffer (eBioscience, San Diego, CA) were used according to the manufacturer’s 
instructions in combination with FoxP3(259D/C7)-AlexaFluor647 or Bcl-2(100)-
PE (BD Biosciences). Isotype controls were used for gate settings. In some 
experiments, cells were counted by flowcytometry using Flowcount fluorospheres 
(Beckman Coulter).
STIMUlATION ASSAy TO ANAlyZE T-CEll ANERGy 
T-cell anergy was examined in (re-)stimulation assays. 2.5x104 cells were stimulated 
with 105 γ-irradiated allogeneic stimulator PBMC in the presence or absence of Il-2 
(12.5 U/ml). Classically, T-cell anergy is defined as a low proliferative capacity upon 
stimulation with antigen only, which can be reversed by addition of exogenous Il-
2. Proliferation was measured at indicated time-points by determination of [3H]-
thymidine incorporation as described above. Tests were set up in triplicate; results 
were expressed as mean + SD counts per 5 minutes.
CO-CUlTURE SUPPRESSION ASSAy
Suppressive capacity of Treg was studied in mixed lymphocyte reaction (MlR) co-
culture suppression assays. Proliferation was determined by either [3H]-thymidine 
incorporation or CFSE dilution assays.
for assessment of cell division using [3H]-thymidine, 5x104 naïve autologous 
CD4posCD25neg responder T-cells (Tresp) were stimulated with 105 γ-irradiated 
allogeneic stimulator PBMC (either target PBMC or HlA mismatched third party 
PBMC). Treg or Tconv were titrated into the cultures. Proliferation was measured 
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at day 5. To this end, 0.5 μCi [3H]-thymidine (Amersham Biosciences, Piscataway, 
NJ) was added to each well. After 8 hours, [3H] incorporation was measured using 
a beta-plate counter (Packard, Canberra, Australia). Tests were set up in triplicate; 
[3H] incorporation was expressed as mean + SD counts per 5 minutes.
FIguRe 2. PHeNotyPIcal aND 
FuNctIoNal cHaRacteRIstIcs oF 
FResHly Macs-IsolateD treg. 
cD4pos t-cells were negatively isolated 
from PBMc and separated into cD25pos 
(treg) and cD25neg (tconv) t-cell fractions 
by magnetic cell sorting. Data from a 
typical isolation is shown. (a) cell surface 
expression of cD25, cD127, cD27, cD70 
and cD62l, and intracellular expression 
of FoxP3 were analyzed on treg (black 
filled histograms) or tconv (grey line 
histogram). (B) Proliferative capacity of 
treg or tconv upon stimulation with Hla 
mismatched irradiated allogeneic PBMc 
was determined in the absence (black 
bar) or presence (grey bar) of exogenous 
Il-2. Proliferation was determined by 
measuring [3H]-thymidine incorporation 
at day 5. (c) suppressive capacity of treg 
in alloantigen responses was determined 
in a MlR co-culture using [3H]-thymidine 
incorporation. autologous naïve 
cD4poscD25neg tresp cells were stimulated 
with Hla mismatched irradiated 
allogeneic PBMc. treg (black lines) or 
tconv (grey lines) were added into these 
cultures at indicated tresp:treg/tconv 
ratios. Proliferation was determined by 
measuring [3H]-thymidine incorporation 
at day 5. Results are expressed as 
percentage of [3H] incorporation + sD, 
indexed to [3H] incorporation of naïve 
tresp and antigen only. (D) suppressive 
capacity of treg in alloantigen responses 
was determined in a MlR co-culture using 
cFse dilution. cFse labeled autologous 
naïve cD4poscD25neg tresp cells were 
stimulated with PKH26 labeled Hla 
mismatched irradiated allogeneic PBMc. 
treg (black lines) or tconv (grey lines) were 
added into these cultures at indicated 
tresp:treg/tconv ratios. Proliferation was 
determined by measuring cFse dilution of 
tresp at day 5. Results are expressed as 
percentage of proliferating cells, indexed 
to percentages of proliferating cells in 
cultures of naïve tresp and antigen only. (e) example cFse of suppression assay as described in Figure 
2D. tresp only (grey filled histogram), tresp+treg (1:1, black line) and tresp+tconv (1:1, grey line) are 
shown, numbers indicate percentage of proliferating cells, indexed to percentages of proliferating 
cells in cultures of naïve tresp and antigen only.
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For assessment of cell division using CFSE dilution, naïve autologous 5-10x106 
CD4posCD25neg Tresp were labeled with 1 µM CFDA-SE prior to stimulation, and 
allogeneic stimulator PBMC were labeled with 2 µM PKH26 (Sigma-Aldrich). 2.5x104 
CfsEpos Tresp were stimulated with 105 PKH26pos irradiated allogeneic stimulator 
PBMC (either target PBMC or HlA mismatched third party PBMC). Unlabeled 
Treg or Tconv were titrated into the cultures. At day 5, 7-amino-actinomycin-D 
(7AAD, Sigma-Aldrich) was added to the samples. Tresp division was analyzed 
by flowcytrometry (FC500, Beckman Coulter), excluding 7AADpos cells, PKH26pos 
stimulator cells and CFSEneg Treg or Tconv and expressed as percentage dividing 
cells. 
REsULTs                
OPTIMAL CONDITIONs fOR PRIMARy AND sECONDARy Treg 
EXPANSION CyClES
With the objective to obtain the highest numbers of functionally active Treg 
with optimal direct alloantigen-specificity, we devised four expansion strategies, 
employing polyclonal and alloantigen-specific stimulation in two subsequent cycles 
of Treg expansion (Figure 1). The cells that were obtained with these expansion 
strategies were compared in terms of absolute cell numbers, phenotype, 
suppressive capacity, antigen-specificity and anergy. Prior to analysis of the four 
selected Treg expansion strategies, individual expansion cycles were optimized, 
with regard to strength and mode of stimulation. 
FIguRe 3. DeteRMINatIoN oF oPtIMal stReNgtH oF alloaNtIgeN treg stIMulatIoN. 
(a) treg were stimulated with indicated ratios of irradiated allogeneic PBMc in the presence of Il-2 
and Il-15. Proliferation was determined by measurement of [3H]-thymidine incorporation at day 5. 
Data are representative of three independent experiments. (B) treg primed with alloantigen were 
restimulated with indicated ratios of irradiated allogeneic PBMc in the presence of Il-2 and Il-15. 
Proliferation was determined by measurement of [3H]-thymidine incorporation at day 3. Data are 
representative of three independent experiments. (c) efficiency of primary alloantigen stimulated 
expansion is related to the number of Hla-DRB1 mismatches. Freshly isolated treg were expanded in 
one cycle in the presence of Il-2 and Il-15 and stimulation by gamma irradiated allogeneic PBMc with 
one (N=10) or two (N=6) mismatches on Hla class II DRB1 genes. expansion values were calculated 
by relating the number of cells set up in the initial culture to the number of cells after expansion 
(after two days rest). expansion was higher with alloantigen mismatched on two Hla-DRB1 genes as 
compared to alloantigen with one mismatch. this difference was found to be statistically significant 
in a Mann whitney test (P=0.025).
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Cell sorting based on multiple surface markers such as CD25, CD127, CD62l and 
CD27 yields a high purity of FoxP3pos Treg. However, these tools are not available 
for clinical grade purposes. Therefore, we specifically chose to use magnetic 
bead isolation for purification of Treg, as this most closely fits with the currently 
available GMP isolation tools. Cells isolated by this procedure expressed CD25 and 
FoxP3, but not CD127 (Figure 2A), thus displaying a typical Treg phenotype [24-
27]. In contrast, CD4posCD25neg conventional T-cells (Tconv) did not express FoxP3 
or CD25, and were positive for CD127. The majority of the isolated Treg as well as 
FIguRe 4. DeteRMINatIoN oF 
oPtIMal MoDe aND stReNgtH 
oF PRIMaRy PolycloNal treg 
stIMulatIoN. 
(a) treg were stimulated with 
indicated ratios of anti-cD3 + anti-
cD28 microbeads or with indicated 
concentrations of platebound anti-
cD3 plus soluble anti-cD28 (1 μg/
ml) in the presence of Il-2 and Il-
15. Proliferation was determined 
by measurement of [3H]-thymidine 
incorporation at day 4. (B) Indexed 
cell yield after primary polyclonal 
treg culture using optimal strength of 
anti-cD3/anti-cD28 microbeads (set 
to 100%) or platebound anti-cD3 plus 
soluble anti-cD28 stimulation. (c) cell 
division pattern and survival/death 
signals of treg after different primary 
polyclonal stimulations. treg were 
stained with cFse and stimulated with 
optimal strength of anti-cD3/anti-cD28 
microbeads or platebound anti-cD3 plus 
soluble anti-cD28. cFse dilution pattern, 
7aaD staining and Bcl-2 expression of 
treg population were assessed at day 
4. In the lowest row, Bcl-2 expression 
is depicted gated on dividing treg 
only. Data are representative of four 
independent experiments.
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Tconv expressed the differentiation marker CD27, not its ligand CD70, and were 
positive for CD62l.
The freshly isolated Treg were hyporesponsive upon restimulation (Figure 2B) and 
able to suppress proliferation of autologous CD4posCD25neg T-cells upon stimulation 
with alloantigen (Figure 2C, D and E), >50% suppression was seen with Tresp:Treg 
ratios of 4:1 or lower (Figure 2C). Tconv were not anergic, nor suppressive.
For alloantigen driven expansion, the optimal strength of alloantigen stimulation 
was determined by titrating irradiated HlA mismatched allogeneic PBMC into 
Treg cultures, in the presence of exogenous Il-2 and Il-15. In a primary MlR, 
proliferation was maximal with stimulator:responder ratios of 4:1 (Figure 3A). 
Secondary stimulation with alloantigen showed similar results (Figure 3B). The data 
shown in Figure 3B were obtained with Treg primed with alloantigen, but similar 
results were observed when polyclonally primed Treg were used (data not shown). 
Consequently, for expansion experiments, a stimulator:responder ratio of 4:1 was 
FIguRe 5. DeteRMINatIoN oF 
oPtIMal MoDe aND stReNgtH 
oF secoNDaRy PolycloNal treg 
stIMulatIoN. 
(a) treg were primed with anti-
cD3/anti-cD28 microbeads and 
restimulated with indicated ratios 
of anti-cD3/anti-cD28 microbeads 
or with indicated concentrations of 
platebound anti-cD3 plus soluble 
anti-cD28 in the presence of Il-2 and 
Il-15. Proliferation was determined 
by measurement of [3H]-thymidine 
incorporation at day 3. (B) Indexed 
cell yield after secondary polyclonal 
treg culture using optimal strength 
of anti-cD3/anti-cD28 microbeads 
(set to 100%) or platebound anti-cD3 
plus soluble anti-cD28 stimulation. 
(c) cell division pattern and survival/
death signals of treg after different 
secondary polyclonal stimulations. 
treg were stained with cFse and 
stimulated with optimal strength of 
anti-cD3/anti-cD28 microbeads or 
platebound anti-cD3 plus soluble 
anti-cD28. cFse dilution pattern, 
7aaD staining and Bcl-2 expression 
of treg population were assessed at 
day 4. Data are representative of four 
independent experiments.
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used. Interestingly, a higher number of HlA-DRB1 mismatches between stimulator 
and responder resulted in higher expansion rates (P<0.05) (Figure 3C). Mismatches 
at other HlA genes did not significantly correlate with expansion efficiency (data 
not shown). 
For polyclonal stimulation we used CD3 and CD28 triggering, and we compared 
anti-CD3/anti-CD28 mAb coated microbeads with platebound anti-CD3 plus soluble 
anti-CD28 mAb stimulation. For primary expansion of Treg, higher proliferation 
rates were achieved with anti-CD3/anti-CD28 beads as compared to platebound 
anti-CD3 plus soluble anti-CD28 mAb (Figure 4A). Cell yield after expansion of Treg 
with either stimulation mode, using optimal dosage, was higher for anti-CD3/anti-
CD28 bead stimulation as compared to platebound anti-CD3 plus soluble anti-CD28 
stimulation (Figure 4B). To explain these differences, we assessed cell division 
and survival in Treg cultures for both stimuli (Figure 4C). Upon stimulation with 
anti-CD3/anti-CD28 mAb coated beads, the majority of cells were triggered to 
proliferate as determined by CFSE dilution. Expression of 7AAD, a marker for late 
apoptotic cells, was low. Bcl-2, an anti-apoptotic protein, was expressed by 70-85% 
of the cells. Further gating revealed that the dividing cell population specifically 
expressed Bcl-2. Upon stimulation with platebound anti-CD3 plus soluble anti-
CD28 mAb, and independent of the concentration used, a large portion of cells 
was not triggered to proliferate. Again 7AAD staining was low. The percentage of 
cells that expressed Bcl-2 was lower as compared to cells stimulated with anti-CD3/
anti-CD28 beads, this correlated with the percentage of dividing cells. The results 
indicate that the lower cell yield after stimulation of Treg with platebound anti-
CD3 plus soluble anti-CD28 mAb is merely caused by less efficient triggering of Treg 
FIguRe 6. DeteRMINatIoN oF oPtIMal leNgtH oF PRIMaRy aND secoNDaRy treg 
exPaNsIoN cycles. 
(a) optimal length of primary treg expansion cycles. treg were stimulated with cFse labeled 
alloantigen (solid line, solid circle) or polyclonal (dotted line, open circle) stimulus in the presence 
of Il-2 and Il-15. at indicated time points, treg numbers were counted by Facs (excluding cFsepos 
allogeneic stimulator cells) and related to treg numbers at initial set up. (B) optimal length of 
secondary treg expansion cycles. treg were primed with alloantigen (solid lines) or polyclonal 
(dotted lines) stimulation as indicated in the presence of Il-2 and Il-15 and rested for 2 days prior 
to restimulation. cells were restimulated with cFse labeled alloantigen (solid circles) or polyclonal 
stimulus (open circles) in the presence of Il-2 and Il-15. at indicated time points, treg numbers were 
counted by Facs (excluding cFsepos allogeneic stimulator cells) and related to treg numbers at initial 
set up. Data are representative of three independent experiments.
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proliferation, and is not the result of enhanced cell death.
These experiments were also conducted for secondary polyclonal stimulation. In 
this situation, platebound anti-CD3 plus soluble anti-CD28 stimulation was superior 
as a secondary stimulus as compared to anti-CD3/anti-CD28 microbead stimulation 
(Figure 5A). Expansion cultures stimulated with platebound anti-CD3 plus soluble 
anti-CD28 yielded more Treg as compared to cultures stimulated with anti-CD3/
anti-CD28 beads (Figure 5B). Attempting to explain these findings, we again 
assessed cell division and survival in Treg cultures using both stimuli (Figure 5C). 
In contrast to the results after primary stimulation, both polyclonal stimuli now 
induced massive proliferation as assessed by CFSE dilution. Also, both 7AAD staining 
and Bcl-2 expression were comparable between Treg cultures stimulated with 
either anti-CD3/anti-CD28 beads or platebound anti-CD3 plus soluble anti-CD28 
mAb. The data shown in Figure 5 were obtained with Treg primed with anti-CD3/
anti-CD28 beads, similar results were observed when alloantigen primed Treg were 
used (data not shown). Overall, these data prompted us to use platebound CD3 
plus soluble CD28 mAb for polyclonal Treg restimulation in further experiments.
Several reports have described the use of high dose Il-2 in Treg expansion protocols 
[16;17]. Our laboratory and others have shown that combination of Il-2 and Il-15 
increases Treg proliferation 
[21;28]. We thus added 
titrated concentrations of Il-2 
(range 12.5 U/ml to 200 U/ml) 
with a fixed concentration 
of Il-15 (10 ng/ml) to Treg 
cultures to determine the 
optimal Il-2 dose in our 
system. Concentrations of 25 
U/ml or higher gave similar 
results in terms of Treg 
yield (data not shown). We 
therefore chose to use 25 U/
ml Il-2 in combination with 
10 ng/ml Il-15 for expansion 
experiments.
To determine the optimal 
cycle length, cell numbers 
were counted at several time 
points during primary and 
secondary expansion cycles. 
Expansion values were 
calculated and are depicted 
in Figure 6. In primary Treg 
expansion cycles with either 
alloantigen or polyclonal 
stimulation, cultures reached 
maximal cell numbers after 
10-12 days. In secondary 
fIguRe 7. treg exPaNsIoN aFteR PRIMaRy aND 
secoNDaRy cycles wItH alteRNateD alloaNtIgeN 
oR PolycloNal stIMulatIoN. 
treg and tconv were expanded according the schedule 
in Figure 1 and rested for two days. treg numbers were 
determined and related to treg numbers at initial set-up. 
Data represent average expansion + sD of seven independent 
experiments.
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expansion cycles with alloantigen stimulation, peak cell numbers were found 
at day 10. In secondary expansion cycles with polyclonal stimulation, peak cell 
numbers were found at day 10 if cells had been primed with alloantigen. However, 
when Treg had been primed with polyclonal stimulation, a plateau in cell numbers 
in a secondary polyclonal stimulation cycle was reached around day 7. Since our 
prime interest was to obtain alloantigen-specific Treg, the strategy comprising 
two subsequent cycles with polyclonal stimulation actually served as a control. 
Consequently, we standardized the expansion cycle length at 10 days for all 
strategies.
FIguRe 8. PHeNotyPIcal 
cHaRacteRIzatIoN oF 
exPaNDeD treg. 
treg and tconv were 
expanded according 
the schedule in figure 1 
and rested for two days. 
cell surface expression 
of cD25, cD127, cD27, 
cD70 and cD62l, and 
intracellular expression 
of FoxP3 was analyzed 
on treg (black filled 
histograms) or tconv (grey 
line histogram). Data are 
representative of four 
to seven independent 
experiments. 
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CELL yIELD AfTER Treg EXPANSION WITH COMBINED AllOANTIGEN AND 
POLyCLONAL sTIMULATION sTRATEGIEs
Having optimized the conditions for the primary and secondary expansion cycles, 
we now isolated Treg and Tconv and subsequently applied multiple expansion 
cycles according to the strategies depicted in Figure 1. Average Treg expansion 
values are shown in Figure 7. Contrary to our expectation that stimulation cycles 
with alloantigen would provide lower cell yields as compared to cycles of polyclonal 
expansion, Treg numbers obtained after each of the four expansion strategies were 
similar (average fold expansion 780, SD 300, p=0.71, N=4). 
PHENOTyPIC CHARACTERIZATION OF EXPANDED Treg
A potential risk of Treg expansion is the outgrowth of contaminating cell types 
such as CD8pos T-cells or NK-cells. In our experiments, we did not find major 
contaminations, since typically >90% of the expanded cells were CD4pos T-cells. 
The majority of Treg expanded with either strategy was CD25high, and CD127neg 
(Figure 8). The majority of Treg retained expression of FoxP3pos after two cycles of 
expansion. Expanded Tconv cells were largely FoxP3neg. Previously, we and others 
have shown that Treg constitutively expressing CD27 are stronger suppressors 
[17;28]. Typically, after expansion, a portion of Treg retained a CD27pos phenotype, 
while the remaining Treg shifted towards a CD27neg phenotype. Treg expanded with 
two cycles of polyclonal stimulation repeatedly showed the highest percentage of 
CD27pos cells (50 to 80%), while cells expanded with two subsequent alloantigen 
stimulation cycles had the lowest percentage of CD27pos cells (10 to 40%). The two 
strategies with alternated alloantigen and polyclonal stimulation cycles showed 
intermediate percentages of CD27pos cells. The expression of CD70, the ligand for 
CD27, was reversely correlated with CD27 expression. CD62l is also described as a 
marker for Treg with high suppressive potency [25]. Whereas expression of CD62l 
was lost on expanded Tconv cells, a substantial portion of Treg retained expression 
of this marker.
FUNCTIONAl CHARACTERIZATION OF EXPANDED Treg
Treg RETAIN ANERGIC PROPERTIES AFTER EXPANSION
One of the hallmarks of Treg is their anergic (hyporesponsive) behavior in vitro. Treg 
retained their anergic state after expansion, irrespective of the strategy employed, 
while in contrast Tconv were not anergic. Indeed, Treg did not proliferate upon 
stimulation in absence of exogenous T-cell growth factors, while addition of Il-2 
restored the proliferative capacity (Figure 9).
EXPANDED Treg sHOW ENHANCED sUPPREssIVE CAPACITy AND CAN 
ACQUIRE FUll ANTIGEN-SPECIFICITy WITHIN TWO EXPANSION CyClES
The main characteristic of alloantigen-specific Treg should be their strong 
suppressive capacity when stimulated by target antigen (in transplantation settings 
this would be donor antigen), in parallel with a lack of suppressive activity in the 
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case of stimulation by other antigens such as fully HlA mismatched third party 
alloantigen. To assess suppressive capacity, we used both the classic [3H]-thymidine 
incorporation co-culture suppression assay as well as a CFSE based assay. The latter 
is used because in some instances it is difficult to draw clear conclusions from the 
[3H]-thymidine assay when using multiple cell populations.
Figure 10 shows that highly antigen-specific Treg were obtained in two situations. 
Treg expanded with two cycles of alloantigen stimulation showed very high 
suppressive activity in target antigen driven MlR (>90% suppression in all ratios 
tested, Figure 10A) 
and hardly any 
suppression of 
third party antigen 
driven MLR. The 
cells obtained after 
the strategy starting 
off with a primary 
a l l o s t i m u l a t i o n , 
followed by 
secondary polyclonal 
stimulation, also 
yielded potent 
Treg with high 
antigen-specificity, 
as indicated by 
strong suppression 
of target antigen 
driven responses 
(>50% suppression 
with Tresp:Treg ratios 
of 16:1 or lower, 
Figure 10A) and low 
inhibition of third 
party HlA mismatched allostimulated MlR. Importantly, these data show that 
under these circumstances a very high degree of antigen-specificity can already 
be obtained after two cycles of expansion. This is relevant since we have noticed 
that multiple expansion cycles, irrespective of the mode of stimulation, can lead 
to reduced suppressive capacity, cell exhaustion, and subsequent cell death 
(data not shown). The expansion strategy starting off with a primary polyclonal 
stimulus followed by a secondary alloantigen stimulus yielded very potent 
suppressors, showing >90% suppression of target antigen driven MlC at all ratios 
tested (highest ratio tested 32:1, Figure 10A). However, this cell population was 
still capable of suppression in third party alloantigen driven responses, albeit at 
a much lower efficiency than target antigen driven responses (>50% suppression 
at Tresp:Treg ratios 2:1 or lower, Figure 10A), indicating a strong enrichment Treg 
specific for target antigen, but incomplete exclusion of Treg with other specificities. 
As expected, Treg expanded with two cycles of polyclonal stimulation showed 
suppression of both target antigen as well as 3rd party alloantigen driven MlR to a 
similar, moderate degree (>50% suppression at 8:1 and 4:1 or lower, respectively, 
FIguRe 9. PRolIFeRatIve caPacIty oF exPaNDeD tReg. 
treg and tconv were expanded according the schedule in Figure 1 
and rested for two days. Proliferative capacity of expanded cells upon 
restimulation with target alloantigen (same as used for expansion) 
was determined in the absence (black bars) or presence (grey bars) 
of Il-2. Proliferation was determined by measuring [3H]-thymidine 
incorporation at day 3. Results are expressed as percentage of 
[3H]-thymidine incorporation + sD. Data are representative of four 
independent experiments.
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Figure 10A). Treg displayed similar suppressive activity in CFSE suppression assays, 
while expanded Tconv were not suppressive (Figure 10B). Note that in the [3H]-
thymidine based suppression assays (Figure 10A), the low counts observed after 
titration of high numbers of expanded Tconv are not indicative of suppression per 
se, but rather a result of the very early proliferation of already primed Tconv cells 
in the co-culture. These cells heavily compete for medium components with the 
naïve Tresp cells that respond later in time. Tconv present in substantial numbers 
may indeed lead to distinct culture kinetics with an earlier proliferation peak and a 
net result of lower counts at day 5.
In summary, optimal results were obtained with Treg expansion in two subsequent 
cycles of alloantigen stimulation: efficient increases in cell numbers, yielding 
highly potent and strictly antigen-specific Treg. The success of Treg expansion with 
alternated alloantigen and polyclonal stimulation depends on the order of the 
stimulation cycles. When Treg were expanded by a primary alloantigen stimulus 
followed by a secondary polyclonal stimulus, cells expanded efficiently and showed 
highly potent, strictly antigen-specific suppressive capacity. The reverse strategy 
with a primary polyclonal stimulus and a secondary alloantigen stimulus yielded 
high numbers of cells and enriched for target antigen-specific Treg. However, Treg 
specific for other antigens were still present. As expected, two cycles of polyclonal 
stimulation yielded high numbers of Treg. These cells were suppressive, but no 
enrichment for alloantigen-specific Treg had taken place. 
DIsCUssION              
High numbers of Treg will be needed for effective Treg immunotherapy in humans 
to facilitate tolerance in patients with autoimmunity or after transplantation. 
ex vivo Treg expansion can provide the solution to obtain these high numbers. 
Therapeutic efficiency can be improved by selecting for target antigen reactive 
Treg, as indicated by preclinical mouse models designed to study the prevention 
of autoimmunity [12-14] and graft-versus-host disease [4;6;7]. At the same time, 
exclusion of Treg with specificities for other antigens lowers the risk for unwanted 
FIguRe 10 (Next Page). suPPRessIve caPacIty oF exPaNDeD treg IN [3H]-tHyMIDINe 
INcoRPoRatIoN suPPRessIoN assays.
treg and tconv were expanded according the schedule in Figure 1 and rested for two days. 
(a) suppressive capacity of treg in target alloantigen and third party alloantigen responses as 
determined in a MlR co-culture using [3H]-thymidine incorporation. autologous naïve cD4poscD25neg 
tresp cells were stimulated with target alloantigen (same as used for expansion) or third party Hla 
mismatched irradiated allogeneic PBMc. expanded treg (black lines) or tconv (grey lines) were added 
into these cultures at indicated tresp:treg/tconv ratios. Proliferation was determined by measuring 
[3H]-thymidine incorporation at day 5. Results are expressed as percentage of [3H] incorporation 
+ sD, indexed to [3H] incorporation of naïve tresp and antigen only. Data are representative of 
seven independent experiments. (B) suppressive capacity of treg in target alloantigen and third 
party alloantigen responses as determined in a MlR co-culture using cFse dilution. cFse labeled 
autologous naïve cD4poscD25neg tresp cells were stimulated with PKH26 labeled irradiated target 
alloantigen (same as used for expansion) or PKH26 labeled third party Hla mismatched irradiated 
allogeneic PBMc. expanded treg (black lines) or tconv (grey lines) were added into these cultures 
at indicated tresp:treg/tconv ratios. Proliferation was determined by measuring cFse dilution of 
tresp at day 5. Results are expressed as percentage of proliferating cells, indexed to percentages 
of proliferating cells in cultures of naïve tresp and antigen only. Data are representative of three 
independent experiments.
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non-specific immune suppression, thus decreasing the risk on opportunistic 
infections and tumor growth. 
Information on strategies for large scale antigen-specific expansion of human Treg 
is scant [22], as previous studies on ex vivo Treg expansion have primarily focused 
on polyclonal stimulation of Treg [16-21]. In the current report, we demonstrate the 
ex vivo generation of Treg with direct alloantigen-specificity from human naturally 
occurring CD4posCD25high Treg in as little as two stimulation cycles, requiring primary 
stimulation with HlA-mismatched allogeneic stimulator cells and Il-2 plus Il-15. 
Experiments were performed with alternating allogeneic and polyclonal (anti-
CD3 and anti-CD28 mAb) stimulation to define the ex vivo conditions resulting in 
optimal enrichment of alloantigen-specific Treg and high cell yield. 
Naturally occurring CD4posCD25high Treg display a polyclonal TCR-Vβ pattern 
[29]. Stimulation of this polyclonal Treg population with allogeneic stimulator 
cells has been shown to specifically activate alloantigen-reactive Treg in mice 
[1;4;6;7;30;31] and humans [28]. Thus, these studies indicate that it is feasible to 
generate alloantigen-specific Treg from the naturally occurring CD4posCD25high 
Treg population. Here, we elaborated on these findings and questioned how 
to generate high numbers of alloantigen-specific Treg starting with polyclonal 
CD4posCD25high Treg populations obtained from peripheral blood. We specifically 
focused on a magnetic bead based method for Treg isolation, so as to fit in with 
currently available clinical grade isolation tools, with the objective to facilitate easy 
translation into clinical practice. Clinical grade (Good Manufacturing Practice, GMP) 
CD4posCD25high Treg isolation by a magnetic bead based method is now feasible 
using the CliniMACS system [32;33], albeit that Treg purity is suboptimal (50-
60%). Our recent data on expansion of CliniMACS isolated Treg confirms that the 
results reported here can indeed be extrapolated to clinical grade purification [See 
Chapter 6 of this thesis]. Clearly, with regard to purity of the starting population 
magnetic bead isolation is inferior to FACS sorting, but this latter method is not 
readily available for GMP purposes. We obtained with high purity fACs sorted Treg 
similar results regarding antigen specificity, but with lower expansion rates and 
higher overall suppressive capacity (unpublished observations). 
To design a successful strategy for obtaining high numbers of alloantigen-specific 
Treg, we hypothesized that it might be beneficial to combine ex vivo expansion 
cycles applying polyclonal stimulation, to boost expansion, and cycles applying 
alloantigen stimulation, to selectively stimulate alloantigen-specific Treg. Our data 
show that a high degree of alloantigen-specificity could be obtained in as little as 
two cycles of expansion. To increase alloantigen-specificity even more, it would be 
an option to repeat alloantigen expansion stimulation for multiple cycles, which 
in theory would progressively enrich for strictly antigen-specific Treg. However, if 
Treg populations were expanded for more than two expansion cycles, we observed 
a loss of suppressive capacity and high cell death (unpublished results). 
Although highest cell yields were expected after expansion with two polyclonal 
stimulation cycles, our data showed similar cell numbers for all strategies. This 
result may in part be due to the fact that we opted for a standardized 10 day 
culture cycle. This choice was made based on the fact that strategies comprising 
one or more alloantigen stimulation cycles showed optimal expansion at day 10. 
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However, expansion of cells in a second subsequent polyclonal stimulation cycle 
reached an optimum at day 7, cell death occurred thereafter. 
Of note, the strategies described in this report generate Treg with direct alloantigen-
specificity. These cells may be especially of benefit for patients receiving an HlA 
mismatched stem cell graft, where this route of alloantigen-reactivity is important 
in graft-versus-host pathology [34]. Although transplantation centers pursue a high 
degree of HlA matching to prevent harmful reactions, HlA-locus mismatched and 
haploidentical transplants are increasingly being performed [35]. In these cases 
current immunosuppressive regimen may benefit from the addition of an antigen-
specific component. In solid organ transplantation, next to direct alloantigen 
recognition, the indirect route of alloantigen presentation clearly contributes to 
graft rejection [36]. With this in mind, it was recently shown, that it is also feasible 
to obtain Treg with indirect alloantigen-specificity by stimulation with autologous 
dendritic cells pulsed with allo-HlA-peptides [37].
Recently, the first clinical trials on Treg immunotherapy have been initiated; in these 
studies, either CliniMACS isolated CD4posCD25high Treg or ex vivo manipulated CD4pos 
T-cell lines containing induced regulatory Tr1 cells are being infused in patients 
receiving stem cell transplantations [22]. So far the first results are promising [see 
Introduction and Discussion of this thesis].
In summary, this study has shown that it is feasible to obtain human functional 
alloantigen-specific Treg in large numbers for immunotherapeutic purposes. This 
may be a valuable aid in the clinical application of Treg, aiming at clinical tolerance 
to selected antigens, while minimizing general immune suppression.
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ABsTRAC T           
Treg based immunotherapy is of great interest to facilitate tolerance in 
autoimmunity and transplantation. For clinical trials, it is essential to have a clinical 
grade Treg isolation protocol in accordance with Good Manufacturing Practice 
(GMP) guidelines. To obtain sufficient Treg for immunotherapy, subsequent ex vivo 
expansion might be needed. 
Treg were isolated from leukapheresis products by CliniMACS based GMP isolation 
strategies, using anti-CD25, anti-CD8 and anti-CD19 coated microbeads. CliniMACS 
isolation procedures led to 40-60% pure CD4posCD25highFoxP3pos Treg populations 
that were anergic and had moderate suppressive activity. Such CliniMACS isolated 
Treg populations could be expanded with maintenance of suppressive function. 
Alloantigen stimulated expansion caused an enrichment of alloantigen-specific 
Treg. Depletion of unwanted CD19pos cells during CliniMACS Treg isolation proved 
necessary to prevent B-cell outgrowth during expansion. 
CD4posCD127pos conventional T-cells were the major contaminating cell type in 
CliniMACS isolated Treg populations. Depletion of CD127pos cells improved the 
purity of CD4posCD25highFoxP3pos Treg in CliniMACS isolated cell populations to 
approximately 90%. Expanded CD127neg CliniMACS isolated Treg populations 
showed very potent suppressive capacity and high FoxP3 expression.
furthermore, our data show that cryopreservation of CliniMACS isolated Treg is 
feasible, but that activation after thawing is necessary to restore suppressive 
potential.
The feasibility of Treg based therapy is widely accepted, provided that tailor made 
clinical grade procedures for isolation and ex vivo cell handling are available. 
We here provide further support for this approach by showing that a high Treg 
purity can be reached, and that isolated cells can be cryopreserved and expanded 
successfully. 
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INTRODUC TION              
Regulatory T-cells (Treg) play a critical role in various immunological processes, 
particularly in maintaining homeostasis and (self-)tolerance. Immunotherapy based 
on Treg infusion is therefore a potential treatment for many immune disorders. This 
approach has been proven successful in animal models of stem cell transplantation 
[1-7], solid organ transplantation [8;9] and autoimmunity [6;10-13]. Therapeutic 
application in humans requires large numbers of Treg, that have to be isolated and, 
if necessary, expanded using clinical grade (Good Manufacturing Practice, GMP) 
protocols. The CliniMACS system provides a relatively versatile method for GMP 
cell isolation and is able to manage large quantities of cells, for example from 
leukapheresis material. 
Other authors have recently shown the feasibility of CliniMACS for CD4posCD25high 
Treg enrichment, but failed to achieve Treg purity of more than 40-60% [14;15]. 
For stem cell transplantation recipients, a suboptimal Treg purity is unlikely to 
be harmful. Currently, many stem cell transplantation recipients are treated with 
donor lymphocyte infusions to enhance graft-versus-leukemia/tumor responses. 
The main adverse effect of this treatment is graft-versus-host-disease (GvHD). The 
aim of Treg immunotherapy in this patient group is to reduce these graft-versus-
host responses. Co-infusion of both non-regulatory T-cells to ensure graft-versus-
leukemia/tumor responses and Treg to prevent excessive GvHD is therefore a 
logical approach in this setting. However, in other patient groups, such as solid 
organ graft recipients and patients with autoimmune diseases, high purity of Treg 
for immunotherapy is crucial. Infusion of non-regulatory cells into patients that 
already suffer from unwanted immunological activity should be prevented, as 
these cells can potentially intensify the disease process. The main aggressive cell 
types in immune responses are cytotoxic CD8pos T-cells and CD4pos conventional 
T-cells, and contamination of CliniMACS isolated Treg populations with these cells 
should be avoided for immunotherapy in patients other than stem cell recipients. 
likewise, contamination of the isolate with B-cells could lead to the infusion of 
activated B-cells with potential adverse immunological consequences.
Although clinimacs based Treg isolation from leukapheresis products will yield large 
numbers of Treg, ex vivo expansion of these cells prior to infusion might still be 
necessary to obtain sufficient numbers of Treg for effective immunotherapy. Treg 
can be expanded efficiently using polyclonal stimulation [16-19]. However, antigen-
specific Treg have been shown to be far more efficient than polyclonal Treg in 
animal models [3;5-7;12;13]. In allogeneic transplantation, the target antigens are 
known (mainly foreign HlA) and human alloantigen-specific Treg can be obtained 
by expansion using stimulation with alloantigen [20;21]. 
For practical reasons, it would be convenient or even necessary to perform 
the leukapheresis procedure weeks/months before the transplantation or 
treatment and store the Treg until they are needed. Currently, information on 
cryopreservation of Treg is lacking. 
In the current study, we confirm that GMP Treg isolation using standard CliniMACS 
procedures results in moderately pure Treg populations. Here, we show that purity 
of CliniMACS isolated Treg can be improved by depletion of CD127pos cells. In 
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FIguRe 1. PHeNotyPIc aND FuNctIoNal cHaRacteRIstIcs oF FResHly clINIMacs 
IsolateD treg.
treg were isolated from leukapheresis products in gMP cliniMacs-based or non-gMP MiniMacs-
based isolation procedures. Data from a typical isolation are shown (N=3). (a) cell surface expression 
of cD4 and cD25 and intracellular expression of FoxP3. (B) Proliferative capacity upon stimulation 
with allogeneic PBMc in the absence or presence of exogenous Il-2, measured at day 5 of culture. 
(c) suppressive capacity in co-cultures of autologous naïve cD4poscD25neg tresp stimulated with 
allogeneic PBMc. significant differences are indicated by asterisks. In figure c, open and filled 
asterisks refer to tconv (used as control for the addition of cells) versus MiniMacs or cliniMacs8/25, 
respectively. 
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addition, we show that CliniMACS isolated Treg can be expanded with maintenance 
of suppressive function using polyclonal or alloantigen stimuli in the presence of 
Il-2. Depletion of CD19pos B-cells during CliniMACS Treg isolation appears to be a 
prerequisite to prevent B-cell outgrowth during expansion. furthermore, we show 
that cryopreservation of Treg is feasible, but that the cells require activation to 
restore suppressive potential.
MATERIAL s AND METHODs            
HUMAN CELLs
Healthy donors were scheduled for leukapheresis procedures to obtain leukocytes 
for donor lymphocyte infusions in hematopoietic stem cell transplantation patients 
in the Radboud University Medical Centre (Nijmegen, The Netherlands). Excess 
leukapheresis material was used for the current study upon written informed 
consent with regard to scientific use. Buffy coats from healthy human donors were 
purchased from Sanquin bloodbank (Nijmegen, The Netherlands), upon written 
informed consent with regard to scientific use and used as a source of stimulator 
PBMC. The current study did not require approval from an ethics committee 
according to the Dutch Medical Research Involving Human subjects Act.
Treg IsOLATION
Healthy donor leukapheresis products were used for CliniMACS CD4posCD25high 
Treg isolation. Cells were washed with PBS/EDTA buffer (Miltenyi Biotec, Bergisch-
Gladbach, Germany, supplemented with 0.5% HSA (Sanquin bloodbank). Anti-
CD8 and/or anti-CD19 coated CliniMACS microbeads (kindly provided by Miltenyi 
Biotec) were added, incubated for 30 minutes and washed. CliniMACS program 
2.1 was run to deplete labeled cells (CliniMACS separation columns were kindly 
provided by Miltenyi Biotec). The labeling procedure was repeated with anti-CD25 
CliniMACS microbeads, and CliniMACS program 1.1 was run to enrich for CD25pos 
cells. 
A non-GMP MiniMACS based CD4posCD25high Treg isolation method was performed 
on leukocytes from the same leukapheresis products as used for CliniMACs Treg 
isolation. PBMC were isolated by density gradient centrifugation (lymphoprep, 
Nycomed Pharma, Roskilde, Denmark). CD4pos T-cells were negatively selected 
using mAbs directed against CD8 (RPA-T8), CD14 (M5E2), CD16 (3G8), CD19 (4G7), 
CD33 (P67.6), CD235a (GA-R2(HIR2) (BD Biosciences, San Jose, CA, USA), and CD56 
(MOC-1) (Dako, Glostrup, Denmark) combined with sheep-anti-mouse-IgG coated 
magnetic beads (Dynal Biotech, Oslo, Norway), routinely resulting in a >90% 
pure CD4pos T-cell fraction. CD25high Treg and CD25neg conventional T-cells (Tconv, 
included in all experiments as control cell population) were separated by MACS-
sorting, using 10 µl anti-CD25 magnetic microbeads / 107 CD4pos cells (Miltenyi 
Biotec).
For CD127pos cell depletion, CliniMACS isolated Treg were stained with anti-CD127-
AlexaFluor647 (BD Biosciences) and CD127pos cells were depleted on an Elite fACs 
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machine (Beckman Coulter, Fullerton, CA, USA). 
Stimulator PBMC were isolated from healthy donor buffy coat by density gradient 
centrifugation (lymphoprep, Nycomed Pharma). 
HLA typing was performed by serological and DNA based techniques according to 
international (ASHI/EFI) standards [28].
TREG CRyOPREsERVATION        
Treg cells were suspended in RPMI-1640 supplemented with pyruvate (0.02 mM; 
Invitrogen, Carlsbad, CA), penicillin (100 U/ml; Invitrogen), streptomycin (100 µg/
ml; Invitrogen), 20% human pooled serum (HPS) and 15% dimethylsulfoxide, were 
kept in -80oC for one week, and were subsequently transferred to liquid nitrogen 
for up to one year. Cells were quickly thawed in a 37oC water bath and washed 
twice before use. 
Treg EXPANSION 
Cell cultures were performed in culture medium consisting of RPMI 1640 
supplemented with pyruvate (0.02 mM), penicillin (100 U/ml), streptomycin (100 
mg/ml), 10% HPS and Il-2 (25 U/ml, Chiron, Amsterdam, the Netherlands) with 
5x104 cells per well in 96-well round bottom plates, in a 37oC, 95% humidity, 5% 
CO
2
 incubator. Stimulation was provided by either 105 γirradiated (30 Gy) fully HlA 
mismatched allogeneic PBMC per well (alloantigen expansion) or 1x104 anti-CD3/
anti-CD28 mAb coated microbeads per well (Dynal Biotech, polyclonal expansion). 
Wells were split and provided with fresh medium containing cytokines every 3 
days. After 10 days, the cells were harvested, washed and rested for 2 days in 5% 
HPS culture medium before functional and phenotypic analyses. 
taBle 1. eNRIcHMeNt oF cD4PoscD25high treg By clINIMacs IsolatIoN.
Number of 
WBC x108 
(SD)
Percentage of cells with indicated phenotype (SD)
CD4pos
CD25high
CD4pos
CD25pos
CD4pos
T-cell
CD8pos
T-cell
CD20pos
B-cell
Leukapheresis * 27.2 (1.9) 3 (3) 8 (8) 60 (1) 26 (7) 16 (15)
CliniMACS8/25 1.5 (0.0) 45 (19) 78 (0) 95 (1) 0 (0) 2 (1)
CliniMACS8/19/25 1.3 (0.1) 46 (13) 81 (5) 97 (1) 0 (0) 0 (0)
MiniMACS - 88 (2) 90 (1) 98 (0) 1 (1) 1 (1)
n=3.
* Partial leukapheresis products were used.
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fLOW CyTOMETRy          
The phenotype of cells was analyzed by five-color flow cytometry (FC500, Beckman 
Coulter). For cell surface staining, the following conjugated mAbs were used: anti-
CD4(SFCI12T4D11)-PCy7, anti-CD19(J4.119)-PE (Beckman Coulter), anti-CD25(4E3)-
biotin, anti-biotin(Bio3-18E7)-PE, anti-CD20(lT20)-PE (Miltenyi Biotec), anti-
CD25(M-A251)-PE, and anti-CD127(hIl-7R-M21)-AlexaFluor647 (BD Biosciences). 
For intracellular staining, Fix and Fix/Perm buffer and anti-FoxP3(PCH101)-FITC 
were used according to the manufacturer’s instructions (eBioscience, San Diego, 
CA, USA). Isotype controls were used for gate settings.
STIMUlATION ASSAy TO ANAlyZE T-CEll ANERGy   
T-cell anergy was examined in (re-)stimulation assays. 2.5x104 cells were stimulated 
with 105 γ-irradiated allogeneic stimulator PBMC in the presence or absence of 
Il-2 (12.5 U/ml). Proliferation was measured at day 5 (primary responses) or day 3 
(secondary responses). To this end, 0.5 μCi [3H]-thymidine (Amersham Biosciences, 
Piscataway, NJ) was added to each well. After 8 hours, [3H] incorporation was 
measured using a beta-plate counter (Packard, Canberra, Australia). Tests were set 
up in triplicate; results were expressed as mean + SD counts per 5 minutes. 
CO-CUlTURE SUPPRESSION ASSAyS        
suppressive capacity of Treg was studied in co-culture suppression assays. 
5x104 autologous responder T-cells (CD4posCD25neg, Tresp) were stimulated 
with 105 irradiated allogeneic stimulator PBMC. Treg were titrated into these 
cultures. Proliferation was measured at day 5 by determination of [3H]-thymidine 
incorporation as described above. Tests were set up in triplicate, results were 
expressed as mean + SD counts per 5 minutes. 
sTATIsTICAL ANALysIs        
Proliferative capacities of different cell populations were compared using Student 
T-tests. A P-value <0.05 was considered statistically significant.
FIguRe 2 (Next Page). PHeNotyPIc aND FuNctIoNal cHaRacteRIstIcs oF exPaNDeD 
clINIMacs IsolateD treg.
cell populations were expanded with polyclonal stimulus or alloantigen stimulus in the presence 
of exogenous Il-2. Data from a typical experiment are shown (N=3). (a) cell surface expression of 
cD25 and intracellular expression of FoxP3. (B) Proliferative capacity upon restimulation with 
allogeneic PBMc (same donor as in alloantigen expansion) in the absence or presence of exogenous 
Il-2, measured at day 3 of culture. (c) suppressive capacity in co-cultures of autologous naïve 
cD4poscD25neg tresp stimulated with allogeneic PBMc (same donor as in alloantigen expansion). 
significant differences are indicated by asterisks. In figure c, open and filled asterisks refer to tconv 
(expanded with same stimulus as treg populations) versus MiniMacs or cliniMacs8/25, respectively. 
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REsULTs               
IsOLATION Of Treg USING ClINIMACS yIElDS 40-60% PURE 
CD4POsCD25HIGH Treg POPULATIONs WITH sUPPREssIVE ACTIVITy 
         
Treg immunotherapy will demand very high numbers of highly pure Treg populations 
isolated in a GMP manner. To obtain large numbers of Treg with optimal purity, 
we performed CD4posCD25high T-cell isolation from healthy donor leukapheresis 
products using the GMP CliniMACs system. The most straight-forward strategy 
to enrich for Treg would be a one step positive selection of CD25pos cells out of 
leukapheresis products. However, this strategy would unintentionally result in 
contaminating (activated) cytotoxic CD8pos T-cells in the isolated Treg populations. 
Therefore, our initial CliniMACS isolation strategy consisted of two steps: first a CD8 
depletion step to exclude CD8pos effector T-cells from the isolated cell populations, 
followed by a CD25 enrichment step to enrich for CD4posCD25high Treg (referred to as 
CliniMACs8/25). For comparison, a laboratory scale MiniMACS based Treg isolation 
protocol was also performed (referred to as MiniMACS). 
leukapheresis products contained on average 3% CD4posCD25high regulatory T-cells 
(Figure 1 and Table 1). less than 0.1% CD8pos cells were present in the isolated 
CliniMACs8/25 populations. While 80% of CliniMACS8/25 cells was CD4posCD25pos, 
only 40-60% was CD4posCD25high (Figure 1A and Table 1). MiniMACS based Treg 
isolation from the same leukapheresis product yielded a higher Treg purity with 
90% CD4posCD25high cells. CliniMACs8/25 populations expressed lower levels of FoxP3 
as compared to MiniMACS isolated Treg populations (Figure 1A). 
A hallmark of CD4posCD25high Treg is their anergic phenotype, defined as low 
proliferative capacity upon T-cell receptor stimulation alone as compared to Tconv 
cells, which can be restored by the addition of exogenous Il-2. Both CliniMACS8/25 
and MiniMACS populations were anergic (Figure 1B). 
FIguRe 3. cRyoPReseRvatIoN oF 
clINIMacs treg aFFects suPPRessIve 
caPacIty, wHIcH caN Be RestoReD By 
actIvatIoN.
suppressive capacity of cryopreserved 
cliniMacs treg in co-cultures of autologous 
naïve cD4poscD25neg tresp stimulated with 
allogeneic PBMc. Data from a typical 
experiment are shown (N=2-4). Prior to co-
culture suppression assay, indicated cell 
populations were expanded for 10 days in the 
presence of exogenous iL-2 and allogeneic 
PBMc (same donor as in co-culture suppression 
assay). significant differences are indicated 
by asterisks. open and filled asterisks refer 
to cryopreservation versus cryopreservation 
plus 4 days rest or cryopreservation versus 
cryopreservation plus expansion, respectively. 1:0 8:1 4:1 2:1 1:1
Ratio Tresp:Treg
0
50
100
150
16:1
Cryopreservation
Cryopreservation + 4 days rest
Cryopreservation + expansion
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Suppressive capacity of Treg populations was determined by titration of Treg 
into co-cultures of autologous CD4posCD25neg responder T-cells stimulated with 
allogeneic stimulator PBMC. As shown in Figure 1C, Treg populations isolated with 
the CliniMACs8/25 strategy were moderately suppressive, reaching 50% suppression 
at a 1:1 Tresp:Treg ratio, while MiniMACS isolated Treg populations were more 
potent, with 50% suppression at Tresp:Treg ratios of approximately 4:1. 
EXPANSION OF ClINIMACS Treg WITH EITHER POLyCLONAL OR 
ALLOANTIGEN sTIMULATION INCREAsEs CELL NUMBERs WHILE 
sUPPREssIVE ACTIVITy Is RETAINED     
       
CliniMACS Treg isolation strategies yield high numbers of Treg, but these numbers 
might still be too low for therapeutic purposes. This issue can be overcome by ex 
vivo expansion of Treg. To analyze expansion potential and effects of expansion on 
phenotypic and functional characteristics, CliniMACS8/25 isolated Treg populations 
were activated using either polyclonal stimulation (anti-CD3/anti-CD28 coated 
microbeads) or alloantigen stimulation (irradiated PBMC from an HlA-mismatched 
donor), in the presence of exogenous Il-2. 
Polyclonal and alloantigen stimulated expansion cultures yielded similar cell 
numbers (Table 2). CliniMACS8/25 populations increased about 30-fold in cell 
numbers in ten days. The phenotype of expanded CliniMACs8/25 populations 
is depicted in Figure 2A. CD25 expression was high in both CliniMACS8/25 and 
MiniMACS populations, while the expression of FoxP3 was lower in expanded 
CliniMACs8/25 cells as compared to expanded MiniMACS populations. After 
expansion, all Treg populations remained anergic (Figure 2B). CliniMACS8/25 
and MiniMACS populations suppressed alloantigen driven responder T-cell 
proliferation to a similar extent (Figure 2C). Notably, alloantigen expanded Treg 
populations showed higher suppressive capacity in alloantigen driven responder 
T-cell responses as compared to polyclonally expanded Treg (>75% suppression at 
a Tresp:Treg ratio of 16:1 versus 50% suppression at Tresp:Treg ratios a Tresp:Treg 
ratio of 8:1, respectively, Figure 2C). This indicates that the alloantigen expanded 
cell populations were enriched for alloantigen-specific Treg. As our group has 
shown previously, the low proliferation observed after addition of alloantigen 
expanded Tconv can be explained 
by distinct culture kinetics with an 
earlier proliferation peak and a net 
result of lower counts at day 5 [21]. 
It would be convenient for Treg 
immunotherapy to be able to store 
Treg cells prior to manipulation 
and/or infusion. The suppressive 
capacity of cryopreserved 
CliniMACs Treg was impaired 
(Figure 3), and could not be 
regained by cell resting for up to 
seven days in culture medium. 
taBle 2. INcRease IN clINIMacs treg NuMBeRs 
By exPaNsIoN
Polyclonal Alloantigen
CliniMACS8/25 31 (16) 28 (14)
CliniMACS8/19/25 34 (17) 34 (11)
MiniMACS 4 (0) 9 (3)
Tconv 46 (1) 55 (10)
Fold increase in cell numbers (sD) after 10 days 
expansion with indicated stimulus in the presence of 
exogenous Il-2, N=3.
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However, expansion of cryopreserved CliniMACs cells restored suppressive 
capacity.
DEPlETION OF CD19POs CELLs DURING CLINIMACs Treg 
ISOlATION IS NECESSARy TO PREVENT B-CEll CONTAMINATION
After CliniMACS8/25 isolation procedures, less than 3% B-cells were present in 
isolated populations, these numbers increased after expansion to 5 to 10% (Figure 
4A). In order to remove B-cells from our CliniMACS isolated Treg populations, 
we tested the efficacy of CD19pos B-cell depletion in the CliniMACS isolation 
procedure. In this strategy, first CD8pos and CD19pos cells were depleted, followed by 
enrichment of CD25pos cells (referred to as CliniMACS8/19/25). less than 0.5% B-cells 
were present after these isolations (see Table 1 and Figure 4B) and no substantial 
B-cell contaminations arose after either polyclonal or alloantigen expansion (see 
Table 2 and Figure 4B). CliniMACS8/19/25 populations were similar to CliniMACS8/25 
cells with respect to the phenotype, anergic state and suppressive potential, both 
directly after isolation as well as after expansion (data not shown). Thus, CD19pos 
depletion effectively prevents B-cell contaminations in CliniMACS Treg populations 
after isolation and after expansion.
DEPlETION OF CD127POs CELLs IMPROVEs CLINIMACs Treg 
PURITy           
CD4posCD25neg/lowFoxP3neg/low Tconv cells were the major contaminating cell type 
in CliniMACS isolated Treg (40-60% of the isolated populations, see Figure 1). 
Recently, it has been described that Tconv express the IL-7 receptor alpha-chain 
CD127, while Treg cells do not express CD127 [22;23]. Indeed, CliniMACS isolated 
populations contained both CD127neg and CD127pos cells, reflecting the presence of 
both Treg and Tconv cells (Figure 5A). To improve the purity of Treg isolated with 
CliniMACS, we hypothesized that depletion of CD127pos cells could be employed to 
exclude contaminating T-cells. Because anti-CD127 CliniMACS beads are currently 
not available, we depleted CD127pos cells from CliniMACS isolated cell populations 
by fACs. 
As shown in Figure 5A, this procedure indeed enabled separation of Treg from 
Tconv cells. In contrast to CD127pos cells, the majority of CliniMACS CD127neg 
cells showed a Treg phenotype: CD4posCD25high and FoxP3pos. since we used 
cryopreserved CliniMACS populations for these experiments, we expanded 
the populations prior to functional characterization. After expansion, CD127neg 
populations retained a high Treg purity, as evidenced by high expression of CD25 
and FoxP3 (Figure 5B). In contrast to CD127pos populations, CD127neg populations 
were anergic after expansion (Figure 5C). As expected, CD127 depletion enhanced 
suppressive potential, as shown by the significantly higher suppressive capacity 
of CD127neg populations as compared to CliniMACS populations that were not 
depleted of CD127pos cells (Figure 5D). 
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DIsCUssION              
Immunotherapy using ex vivo activated and/or expanded CD4posCD25high regulatory 
T-cells appears promising, not only in stem cell transplantation and solid organ 
transplantation, but also for a number of autoimmune disorders. To be optimally 
effective, the availability of tailor-made clinical grade procedures is a prerequisite. 
As previously reported [14,15], CliniMACS GMP Treg isolation strategies based on 
CD25pos enrichment typically result in 40-60% pure Treg with moderate suppressive 
activity. 
The degree of purity of Treg that is required may depend on the actual application. 
In stem cell transplantation, the first clinical trials on Treg immunotherapy have 
recently been initiated. In these studies, either CliniMACS isolated CD4posCD25high 
Treg (with 40-60% purity) or ex vivo manipulated CD4pos T-cell lines consisting of 
5-10% induced regulatory Tr1 cells and consequently a substantial amount of non-
Treg were infused in patients receiving stem cell transplantations [24]. So far, to our 
knowledge, no adverse effects have been reported. However, caution is necessary 
when applying Treg for autoimmune disease or solid organ transplant purposes. 
Here an inadvertently present effector pool might cause serious pathology.
As cytotoxic CD8pos T-cells are a potentially aggressive cell type in immune 
responses, it is highly recommendable to exclude these cells from CliniMACs 
isolated Treg populations. Here, we show that the CD8pos CliniMACS cell depletion 
step was effective: less than 0.1% CD8pos cells were present in isolated Treg 
populations, and no outgrowth of CD8pos cells occurred after expansion of 
CliniMACS Treg populations. Treg isolated by CD25pos enrichment following CD8pos 
depletion contained a small contamination of B-cells (1-3%), which could increase 
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to up to 10% after T-cell expansion. The risks of infusion of expanded and activated 
autologous B-cells are unknown, but could in theory include the development of a 
B-cell lymphoproliferative disorder that can occur after transplantation and is often 
lethal [25-27]. We were able to prevent the contamination by B-cells by including a 
CD19pos B-cell depletion step in the isolation strategy. 
Notwithstanding the favorable effects of combined anti-CD25, anti-CD8 and anti-
CD19 microbead isolation (currently available clinical grade tools), the isolated Treg 
population was of suboptimal purity. Most of the contaminating cells appeared to 
be CD4posCD25neg/low Tconv cells that could potentially lead to immunopathology. To 
further improve CliniMACs Treg purity, Wichlan et al. studied titration of anti-CD25 
microbeads in the enrichment phase of CliniMACS Treg isolation. While the use of 
lower amounts of beads indeed led to populations with higher CD25 expression 
levels [15], the suppressive capacity of the isolated populations did not improve 
and cell yields were significantly lower, indicating that titration of CD25 microbeads 
will not provide the solution to achieve higher purity for CliniMACS Treg isolation. 
These authors also reported that adjustment of CliniMACS flow rates did not lead 
to a higher Treg purity. Hoffmann et al. used three consecutive CliniMACS selection 
cycles for CD25pos cells, to preferentially select CD25high Treg and exclude CD25neg/
low Tconv [14]. However, the degree of Treg purity obtained with this approach was 
similar to that achieved with one CD25 enrichment cycle. 
Recently, it has been described that Tconv express the IL-7 receptor alpha chain 
CD127, while Treg do not express this molecule [22;23]. Thus, in the current study, 
we hypothesized that the conventional T-cells contaminating GMP Treg populations 
could be excluded from the CliniMACS isolated populations by depleting CD127pos 
cells. Since anti-CD127-microbeads for use in CliniMACS are currently not available, 
we depleted CD127pos cells from CliniMACS isolated Treg populations by FACS. This 
procedure indeed increased Treg purity, as shown by uniformly high expression of 
FoxP3 in CD127neg populations. After expansion of CliniMACS CD127neg populations, 
high expression of FoxP3pos was maintained, and the cell populations showed 
potent suppressive capacity. Notably, suppressive capacity of CliniMACS CD127neg 
populations was significantly higher than that of non-depleted CliniMACS 
populations, indicating that CD127 depletion clearly enriched for functional Treg.
The outcome of a particular T-cell based immune response is likely to be determined 
by the balance between the effector and regulatory T-cell pools. Consequently, 
the efficacy of Treg therapy may be determined by the actual number of antigen 
reactive Treg within the infused cell population. Indeed, antigen-specific Treg were 
FIguRe 5 (Next Page). clINIMacs treg IsolatIoN caN Be IMPRoveD By DePletINg cD127Pos 
tconv cells.
cliniMacs populations were stained with anti-cD127 and sorted into cD127neg and cD127pos subsets. 
cliniMacs cells were cryopreserved prior to cell sorting. Data from one of two similar experiments 
are shown. (a) cell surface expression of cD127, cD4 and cD25 and intracellular expression of FoxP3. 
(BcD) cliniMacs populations were expanded with alloantigen stimulation and exogenous Il-2. (B) 
cell surface expression of cD25 and intracellular expression of FoxP3. (c) Proliferative capacity 
upon restimulation with irradiated allogeneic PBMc (same donor as in alloantigen expansion) in 
the absence or presence of exogenous Il-2. (D) suppressive capacity in co-cultures of autologous 
naïve cD4poscD25neg tresp stimulated with irradiated allogeneic PBMc (same donor as in alloantigen 
expansion). significant differences are indicated by asterisks. In figure D, open and filled asterisks 
refer to cliniMacs versus cliniMacs cD127pos or cliniMacs cD127, respectively.
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proven to be more efficient than polyclonal Treg in preclinical mouse models of 
autoimmunity [6;12;13] and graft-versus-host disease [3;5;7]. Previously, we and 
others have shown that human Treg isolated by non-clinical grade strategies can 
be expanded using both polyclonal and alloantigen stimulation methods [16-21]. 
Importantly, we show in this report that this also holds true for clinical grade 
isolated Treg. Due to the moderate purity of CliniMACS isolated Treg populations, 
outgrowth of contaminating cells could be a risk upon expansion. Indeed, 
expanded CliniMACs8/19/25 Treg populations contained a significant percentage of 
FoxP3neg cells, however, this could be prevented by depletion of CD127pos cells from 
the CliniMACS isolated Treg populations.
Clinical implementation of Treg based therapy will be highly facilitated if Treg can 
be stored prior to infusion, as this will allow a more flexible timing of Treg therapy 
and/or therapeutic schemes with multiple Treg treatments over time. We studied 
the feasibility of CliniMACS Treg cryopreservation in liquid nitrogen. Results indicate 
that Treg can survive cryopreservation, as thawed populations showed 70-80% cell 
viability. We noted decreased suppressive activity of thawed Treg populations, 
which could be restored by Treg expansion. An alternative approach would be 
to expand Treg prior to cryopreservation. This resulted in unaltered suppressive 
capacity upon thawing, at least in MiniMACS isolated Treg (Supplemental data, 
Figure S1). 
In summary, we here provide further support for clinical implementation of Treg 
immunotherapy by showing that a high Treg purity can be reached, and that 
isolated cells can be cryopreserved and expanded successfully. 
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Transplantation of solid organs or hematopoietic stem cells is a successful treatment 
for a number of life-threatening diseases. Transplant recipients currently receive 
lifelong treatment with potent immunosuppressive drugs, and this approach has 
resulted in quite acceptable patient and graft survival rates. However, these drugs 
do not offer complete protection from alloantigen-driven immune responses and 
they increase the incidence of infections and malignancies [1;2]. 
The ultimate goal in transplantation medicine is the achievement of alloantigen-
specific tolerance. Alloantigen-specific tolerance is defined as the absence of an 
immune response against alloantigen without immunosuppressive drug treatment, 
while immune responses against other antigens remain intact. To achieve this goal, 
regulatory T-cell (Treg) based therapy is a promising therapeutic modality which 
has already been proven successful in animal models of stem cell transplantation 
[3-8] and solid organ transplantation [9-20]. Treg immunotherapy is also an 
attractive therapeutic option for autoimmune diseases, with favorable results in 
animal models [21-25]. The first small scale Treg based clinical trials in stem cell 
transplantation recipients are promising [26-28], and other trials in stem cell 
transplantation, solid organ transplantation and autoimmunity are ongoing [29-
36]. However, before clinical application of Treg therapy in human patients can 
be incorporated in standard clinical practice, a number of fundamental questions 
need to be answered. 
In this thesis, a number of these issues are addressed. In chapter 2, the current 
status of Treg immunotherapy is reviewed. In order to gain a better understanding 
of Treg biology in the healthy human situation, we have performed two studies 
on basal Treg biology using cells from healthy human donors. In chapter 3, we 
analyzed phenotypic and functional characteristics of Treg isolated from blood, 
bone marrow, liver-draining and inguinal lymph nodes, and spleen of healthy 
human donors. Next, in chapter 4, we describe an in vitro model for immune 
responses in the skin to improve our understanding of immune responses in the 
periphery. We analyzed several aspects of the interplay between keratinocytes 
(KC), effector T-cells and Treg. In chapter 5 and chapter 6, we describe preclinical 
studies focused on practical issues regarding Treg immunotherapy in human 
patients. large numbers of Treg are needed for immunotherapy, preferably with 
high alloantigen-specificity. In chapter 5, we describe a protocol to efficiently 
expand alloantigen-specific Treg. For human therapy, all protocols need to be 
developed according to Good Manufacturing Practice (GMP) guidelines. In chapter 
6 we describe a GMP protocol for isolation of large numbers of Treg. 
ANATOMICAL LOCATION Of Treg AC TIVIT y       
successful Treg immunotherapy requires that the infused Treg home to the correct 
locations. Current evidence suggests that Treg can exert suppressive functions in 
secondary lymphoid organs and at the site of inflammation. 
Treg WITHIN sECONDARy LyMPHOID ORGANs
In chapter 3, we analyzed phenotypic and functional characteristics of Treg isolated 
from several tissues of healthy human donors. We showed that the majority of 
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Treg isolated from blood and bone marrow of healthy human donors express 
markers associated with lymph node homing. Indeed, Treg were present in spleen 
and lymph nodes derived from healthy human donors. Additionally, we showed 
that Treg isolated from secondary lymphoid organs have an activated phenotype 
and have the capacity to inhibit conventional T-cells (Tconv) proliferation in vitro. 
The activation of Treg in secondary lymphoid organs seems to be polyclonal, as 
the activated Treg population displayed a diverse TCR-Vβ repertoire. Human Treg 
antigen-specificities are enriched for autoantigens [37]. Therefore, Treg are likely to 
upregulate activation markers after interactions with endogenous antigens, similar 
to the process described for Tconv in an animal model [38]. During the absence 
of infections, this polyclonal-like activation pattern with many CD69pos Treg in 
lymphoid organs probably reflects a homeostatic state. 
In animal models of transplantation and autoimmunity, it was shown that in 
inflammatory conditions Treg accumulate in the draining lymph nodes [22;39]. 
Moreover, in experimental transplantation models it was demonstrated that 
trafficking of Treg to lymph nodes is necessary for immune regulation, especially 
in the induction phase of transplantation tolerance [40-43]. There are a number 
of Treg suppressor functions that are likely to take place within the secondary 
lymphoid organs, as described in the introduction of this thesis. Most Treg 
mechanisms described limit the number of effector cells available for immune 
responses in the periphery by inhibition of activation, proliferation or maturation 
of these cells. Adoptive transfer of Treg with lymph node homing capacity seem to 
be particularly efficient in the induction phase of immune responses [41-45]. 
Our findings, combined with literature data, suggest that the capacity to home 
to secondary lymphoid organs could be an important characteristic of Treg in 
order to be successfully used for immunotherapy. It is imaginable that infusion 
of lymph node homing Treg would be most effective in the initial phase of an 
immune response, before inflammatory reactions have been established in the 
periphery. For clinical use in transplantation, lymphoid organ homing Treg could be 
administered around the time of transplantation, thereby taking full advantage of 
the capacity of the infused Treg to prevent the formation of alloantigen responses. 
For autoimmunity, pre-emptive Treg therapy is not possible. The immune responses 
are already ongoing before Treg therapy can be considered. Nonetheless, adoptive 
transfer of Treg with a secondary lymphoid organ homing capacity might be very 
useful in the remission phase of relapsing-remitting diseases, to prevent relapses. 
Treg IN THE PERIPHERy            
In animal models, the presence of Treg in the periphery appeared to be essential 
for maintaining immune homeostasis [46;47]. In chapter 3, we first analyzed 
the expression of homing markers on Treg within human secondary lymphoid 
organs to determine where Treg are headed. We also analyzed peripheral homing 
receptor expression on Treg in peripheral blood, as these cells are possibly in the 
process of migrating to their target tissue. As described above, many circulating 
Treg expressed lymphoid organ associated homing markers and were apparently 
headed for secondary lymphoid organs, but there were alo Treg with peripheral 
homing phenotypes. Interestingly, a large subset of the circulating Treg expressed 
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functional homing markers associated with skin homing. The high percentage of 
skin homing Treg found in human peripheral blood is concurring with previous 
reports [48-50] and indeed, Treg have been identified in healthy human skin 
samples [48;51]. We also showed that many Treg in secondary lymphoid organs 
express markers that are associated with homing to the gut. It is evident that Treg 
have a function in maintaining homeostasis in the gut, as the gut is continually 
challenged with invading microorganisms, similar to the skin. In fact, it has 
been shown that commensal bacteria are crucial for the induction of Treg in the 
homeostatic gut microenvironment [52;53].
Besides a function in maintaining healthy immune homeostasis, Treg have also 
been shown to migrate to inflammatory sites in animals [22;39;54;55], as well as 
in humans [56;57], which is crucial for peripheral immune control by Treg [58-60]. 
Adoptive transfer of peripheral homing Treg (isolated using cell surface marker 
expression) showed that these Treg subsets likely have a local regulating function 
during the maintenance phase of tolerance [54;61]. Some Treg subsets even have 
the capacity to dampen established immune responses [22;54;62-64]. These 
data strongly suggest that subsets of Treg can regulate immune responses in the 
periphery. Several mechanisms of immune regulation by Treg at peripheral sites 
have been suggested, as described in the introduction of this thesis. In chapter 4 
we used a newly developed in vitro co-culture system with KC and effector T-cells, 
and determined the influences of Treg in this system, as a model for Treg function 
in skin immunology. We showed that Treg suppressive function is not affected 
by KC and that Treg limit effector T-cell proliferation in KC/T-cell co-cultures, 
thereby indirectly limiting the accumulation of (Il-17pos) T-cells induced by KC. By 
keeping effector T-cell numbers low, Treg may also indirectly inhibit T-cell induced 
chemokine production by KC, although we could not verify this effect in our short 
term co-cultures. In animal models, Treg have also been found to limit Tconv 
proliferation in the periphery [39] and to delay influx of Tconv on site [65].
Our data combined with those of previously published studies suggest that during 
the maintenance phase of immune responses, when inflammatory reactions have 
already been established in the periphery, infusion of Treg with the capacity to 
home to specific sites in the periphery could be useful. In the setting of solid organ 
transplantation, this would mean that the ‘homing code’ for the transplanted 
organ has to be elucidated to enable selection of Treg expressing the required set 
of homing markers. Another approach could be to couple the graft to biomaterials 
which release specific Treg-attracting chemokines [66]. This approach would be 
independent of the type of organ and might also be used to increase Treg migration 
to sites for which the original ‘homing code’ has not yet been elucidated. for stem 
cell transplantation, infusion of Treg with a phenotype associated with homing to 
gut, skin and/or liver could be helpful to protect patients from graft-versus-host 
disease or treat patients with graft-versus-host disease at these clinically most 
relevant sites.
Besides homing markers that are associated with specific anatomical sites, as 
described above, there are also trafficking receptors that are associated with 
specific immune functions, such as receptors that are preferentially expressed by 
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specific Thelper subtypes. Fox example, Th1 cells preferentially express CXCR3, most 
Th2 cells express CCR4 and Th17 cell differentiation is associated with expression of 
CCR6. Expression of these markers by Treg would allow them to home to the same 
sites as the corresponding Tconv. Indeed, in chapter 3, we analyzed the expression 
of these three homing markers on Treg, and showed that many CCR4pos (~40%) and 
CCR6pos (~30%) Treg can be found in peripheral blood, while a high percentage of 
CXCR3pos (~40%) Treg is found in lymph nodes. Others have also described that 
subsets of Treg found in peripheral blood can express Thelper associated homing 
markers [49;67]. Interestingly, Treg that copy expression of chemokine receptors or 
transcription factors associated with specific Thelper lineages have been shown to 
suppress the responses of their effector counterparts [68-72]. These data suggest 
that if a particular Thelper lineage is causing unwanted responses in transplantation 
or in autoimmunity, an appropriate subpopulation of Treg might be selected on the 
basis of homing marker expression. Our data show that different compartments 
of the body are enriched for Treg with specific homing receptors, which implies 
that different sources of Treg (peripheral blood or lymph nodes) should be used to 
isolate high numbers of Treg with the homing marker of choice. 
sTABILIT y Of Treg           
Previously, it was thought that thymus-derived Treg are a stable, lineage committed 
T-cell subset. Much effort has been spent to find markers to distinguish naturally 
occurring, thymus-derived Treg from other, less stable cell types that share many 
phenotypic characteristics with Treg, such as induced Treg (Treg derived from the 
conversion of Tconv in the periphery) and activated Tconv. The (de)methylation 
status of the foXp3 locus was described as a reliable marker to distinguish 
thymus-derived Treg from other cell types [73]. There is a specific region within 
the foXp3 locus that is demethylated in stable, thymus-derived Treg, referred to 
as Treg-specific demethylated region (TSDR). This particular DNA region remains 
methylated in FoxP3pos induced Treg subsets or activated Tconv [73;74]. NP-1 has 
also been described as a specific marker to distinguish naturally occurring Treg 
from induced Treg in animal models [35;36], but seems to be a less useful tool for 
human cells [75]. In recent years, the stability of all T-cell subsets, including thymus-
derived Treg, has been questioned. Indeed, the foXp3 locus of thymus-derived 
Treg shows partial methylation upon repeated stimulation, correlating with loss 
of FoxP3 expression and production of proinflammatory cytokines [76]. In mouse 
models, it has been shown in vivo that Treg can convert to Tconv and vice versa 
[77-79], again challenging the concept of a stable Treg lineage. Truly stable Treg 
subsets might be identified using additional markers and procedures. For example, 
Treg that remain CD27pos after in vitro activation have been shown to retain high 
suppressive capacity [80], while Treg that lose CD27 expression can differentiate 
into Il-17 producing cells [81]. In humans, it has been shown that subsets of Treg 
have the potential to differentiate into Il-17 producing cells [81;82]. Obviously, this 
knowledge raises the concern that adoptively transferred Treg might convert into 
Tconv upon administration. If this happens, therapy aimed at induction of tolerance 
could potentially result in a destructive immune response instead. If there are 
indeed no stable Treg subsets, or if no marker can be found to identify stable Treg 
subsets, it would be necessary to take safety measures. One option is to transfect 
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Treg with a suicide gene before adoptive transfer into patients, similar to the 
strategy adopted in donor lymphocyte infusion studies [83;84]. It has been shown 
that Treg can be transfected with a suicide gene that makes them susceptible to 
apoptosis upon treatment with a certain antibiotic [85]. This way, infused Treg can 
be killed quickly if the cells go renegade and cause damage.
IsOL ATION Of Treg          
Currently, clinical grade large-scale isolation systems allow the separation of 
cell subsets according to GMP standards. These isolation systems make use of 
monoclonal antibodies that are directed against cell surface markers and are 
coupled to magnetic beads. In chapter 6, we described large scale isolation of Treg 
with GMP protocols using the CliniMACS system with negative selection of CD8pos 
and CD19pos cells, followed by positive selection of CD25pos cells. We showed that 
the results obtained with clinical grade large-scale magnetic bead based isolation 
differed considerably from those obtained with laboratory scale magnetic bead 
based isolation (yielding 90% pure Treg populations, based on their CD4posCD25high 
phenotype). CD4posCD25high Treg isolation using a GMP magnetic bead based 
method is feasible, but Treg purity was not optimal (50 - 60% CD4posCD25high cells), 
which is in line with other reports using this system [86-88]. The required purity 
of Treg is dependent on the clinical application. For stem cell transplantation, 
contamination with non-regulatory cells does not have to be a problem. In fact, 
transferred “contaminating” effector cells in the isolated Treg population can 
induce clinical benefit in this setting, as these cells can provide graft-versus-
leukemia responses. In the first clinical trials on Treg immunotherapy in stem cell 
transplantation Treg populations with limited purity were transferred, and no 
adverse effects of the contaminating cells were reported [26-28]. However, for solid 
organ transplantation and autoimmunity a higher Treg purity is desired for Treg 
immunotherapy, as transfer of contaminating effector cells can have a detrimental 
effect in these patients. Irrespective of the clinical goal, the suboptimal purity of 
the current clinical grade isolated Treg is of concern when expansion is needed. 
We showed in chapter 6 that CD8pos T-cells and CD19pos B-cells should be excluded 
from the isolated Treg populations before expansion, to prevent substantial 
outgrowth of these contaminating cells. Contaminating CD4posCD25neg/low Tconv are 
more difficult to exclude, and these cells will also proliferate in expansion protocols 
(potentially even more vigorously than Treg). In fact, Tconv can also be rendered 
antigen-specific using our expansion protocol described in chapter 5. It would be 
very dangerous to infuse a mixture of antigen-specific Treg and antigen-specific 
Tconv, since the mixed population might even enhance instead of reduce the 
alloresponse. To improve Treg purity, we suggested in chapter 6 to add a negative 
CD127 selection step to the isolation process, which greatly increased purity 
in a laboratory setting. However, while products for laboratory grade selection 
for CD127 expression are on the market, currently no appropriate clinical grade 
products are available. Recently, a new isolation method using reversible staining 
methods has been described, which allows for serial positive and negative selection 
steps [45]. Serial isolation of CD4, CD25 and CD45RA positive cells resulted in 90 - 
95% pure triple positive Treg. Although this method can potentially be adapted to 
adhere to GMP rules, up to now only laboratory scale isolation of Treg with this 
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method has been described. Another method to increase Treg purity while also 
increasing Treg numbers is to include rapamycin in expansion cultures. Rapamycin 
is an immunosuppressive drug that allows Treg expansion while inhibiting the 
outgrowth of Tconv, thereby ensuring an expanded cell population with high Treg 
purity and high stability [89-91]. For future therapeutic Treg application using 
certain subsets of Treg, for example Treg which express a specific trafficking 
receptor as discussed above, additional isolation protocols need to be developed 
for clinical use.
NUMBERs Of Treg NEEDED fOR IMMUNOTHERAPy    
In chapter 5, we described efficient in vitro Treg expansion protocols using 
alloantigen-specific or polyclonal proliferation stimuli. Our Treg expansion 
protocols yielded an approximately 800-times increase of Treg numbers. The 
alloantigen-specific stimulated expansion protocol yielded Treg that efficiently 
suppressed target alloantigen-driven responses, but not other responses, while 
the polyclonally expanded Treg populations moderately suppressed responses 
driven by all stimuli tested.
It is currently not known how many Treg will be needed for effective dampening 
of immune responses in humans. In animal studies, 1 - 5 x 106 polyclonal Treg are 
needed to prevent or treat alloresponses and autoimmune responses, depending 
on the model characteristics [17;19;21;22;92;93]. In animal models of stem cell 
transplantation, as few as 0.5 - 1 x 106 Treg can be sufficient to prevent graft-versus-
host disease induction [3]. Most studies use immunodeficient mice (average weight 
20 grams), and Treg are transferred on the day of disease induction (transfer of 
effector cells or induction of inflammation). Roughly extrapolating these numbers 
to the human clinical setting reveals that for a 70 kg weighing person, 1.75 - 17.5 
x 109 polyclonal Treg would be needed. In the first human clinical trials on Treg 
immunotherapy as low as 0.1 - 4 x 106 polyclonal Treg / kg bodyweight (for 70 
kg: 7- 280 x 106 Treg) were administered to stem cell transplantation recipients, 
and the results are promising [26-28]. In our experiments in chapter 6, we used 
split aphaeresis products to isolate Treg and obtained 60 - 90 x 106 Treg with a 
CD4posCD25pos phenotype (accompanied with a similar amount of contaminating 
cells, mostly Tconv) . A full aphaeresis product would thus yield approximately 
120 - 180 x 106 Treg (plus similar numbers of contaminating cells). So even though 
very high Treg numbers can be obtained, expansion will likely still be necessary 
to increase cell numbers. Using the polyclonal expansion protocols described in 
chapter 5 would increase the number of cells to 96 - 144 x 109 Treg, and would thus 
yield sufficient numbers of Treg. 
Antigen-specific Treg immunotherapy has several advantages over polyclonal Treg 
therapy. If Treg specific for other targets present in the polyclonal Treg population 
dampen immune reactions that should not be suppressed, their infusion would 
increase the risk for opportunistic infections and tumor-growth. So using antigen-
specific Treg would reduce the risk of non-specific immune suppression. Also, due 
to the low percentage of Treg within a polyclonal cell pool that is specific for a 
given antigen, large numbers of Treg need to be infused to efficiently suppress 
alloantigen reactivity. Using antigen-specific Treg reduces the number of Treg 
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needed for effective immunotherapy. In animal studies using antigen specific Treg, 
only 0.03 - 2 x 106 Treg are needed for successful immunotherapy [6;7;20;24;25;94]. 
Extrapolation of these numbers to the human clinical setting indicates that 0.1 - 
7 x 109 antigen-specific Treg would be needed. The efficient alloantigen-specific 
expansion protocol described in chapter 5 will help to provide sufficient numbers 
of Treg with direct alloantigen-specificity for transplantation settings. Other 
protocols yielding Treg with direct alloantigen-specificity [80;95], and protocols 
yielding Treg with indirect alloantigen-specificity [96;97] have been described. For 
autoimmunity, no expansion protocols for human autoantigen-specific Treg have 
been described to date. In an animal study, it has been shown that endogenous 
Treg from diabetic-prone mice can be expanded ex vivo using recombinant peptide 
stimulation [24]. A similar strategy can possibly be developed to obtain sufficient 
numbers of autoantigen-specific Treg for human patients.
Selection of Treg subsets according to additional criteria might further improve 
the efficacy of Treg immunotherapy. For example selection of Treg on the basis of 
trafficking receptor expression (as discussed above) might make Treg therapy more 
efficient and/or more specific. However, due to lack of experimental experience 
with this approach, no estimation of numbers of Treg needed in patients can be 
given.
TIMING Of Treg INfUsION          
Treg immunotherapy might be effective for the induction of tolerance in 
transplantation, but also for dampening other unwanted immune responses, 
such as in autoimmune diseases. Transplantation is probably the best setting to 
gain the first experience with this type of therapy, as the time of initiation of the 
undesirable immune response is exactly known. In most animal models, Treg are 
administered before or around the time of transplantation. This approach seems 
to be effective, as it leads to prevention of alloantigen responses and promotes 
long-term tolerance [39]. When alloantigen-specific Treg are to be used, adoptive 
transfer around the time of transplantation requires foregoing knowledge of donor 
HlA-type and culture-time to select for alloantigen-specific Treg. This should be 
possible for planned transplantations such as stem cell transplantations and living 
donor solid organ transplantation. However, when solid organs derived from 
deceased donors are transplanted, there is obviously no prior knowledge of the 
donor characteristics and no time to select for alloantigen-specific Treg before to 
the transplantation. It is currently not known what would be more effective in this 
situation: polyclonal Treg around the time of transplantation, or alloantigen-specific 
Treg at a later point in time. In most animal models, Treg are given as a single 
infusion. It is not known whether a single infusion will be sufficient and optimal 
in clinical settings. Multiple infusions, with additional Treg administration at later 
stages after transplantation might be more effective to control ongoing responses. 
Also, a combination of specific subsets of Treg administered at different time points 
could hypothetically be very effective. For example, it could be beneficial to infuse 
Treg with direct antigen specificity at the time of transplantation to prevent acute 
rejection, followed by Treg with indirect antigen specificity at a later time point 
to prevent chronic rejection. Alternatively, it might be beneficial to infuse Treg 
with a lymphoid organ homing phenotype at the time of transplantation to limit 
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the induction of allograft rejection, followed by Treg with a target organ homing 
phenotype at a later time point to dampen local immune responses.
Clinical implementation of Treg based therapy will be highly facilitated if Treg 
can be stored prior to infusion, as this will allow a more flexible timing of Treg 
therapy. In chapter 6, we have shown that Treg survive cryopreservation, although 
suppressive capacity was decreased. fortunately, our experiments also show that 
Treg that are expanded in vitro either before or after cryopreservation retain 
normal suppressive capacity. 
CONCLUDING REMARKs         
Treg immunotherapy is a very promising approach to specifically dampen 
unwanted immune responses, such as alloantigen responses in transplantation 
and autoantigen responses in autoimmunity. Even though animal studies and 
small scale clinical trials have shown great potential, many important aspects of 
Treg biology and Treg immunotherapy have not been clarified yet. In this thesis, 
we described a number of studies addressing these issues, like Treg phenotype 
and function in secondary lymphoid organs and in a skin model, Treg expansion 
and selection of alloantigen-specific Treg, and Treg isolation in a clinical grade 
manner. slowly but surely, progress is made towards unravelling Treg behaviour 
in healthy states, as well as in inflammation in animal models and in humans. 
Tolerance biomarkers to monitor the success of Treg immunotherapy and to guide 
safe tapering of immunosuppressive drug treatment in patients with alloantigen or 
autoantigen tolerance have been described and should be validated in prospective 
trials [98]. In the future, all this knowledge can be used to optimize Treg 
immunotherapy and reduce immunosuppressive drug treatment in transplantation 
and autoimmunity. Although the isolation and selection of Treg for each patient 
will be costly and time-consuming, reaching the goal of inducing antigen-specific 
tolerance has the potential to greatly reduce patient morbidity and mortality by 
preventing transplant loss, graft-versus-host disease and autoimmune symptoms, 
without the increased incidence of infections and tumours associated with current 
immunosuppressive treatments. 
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Het immuunsysteem is essentieel voor  het uitschakelen van ziekmakende micro-
organismen en kankercellen. Uit de hand gelopen immuunreacties kunnen 
echter ook leiden tot grote schade aan gezonde weefselcellen. Daarom is het 
immuunsysteem voorzien van regulatiemechanismen. Verschillende soorten 
cellen zijn gespecialiseerd in het onderdrukken van immuunresponsen. Van deze 
cellen zijn regulatoire T-cellen (Treg) het meest bekend en het best bestudeerd. 
Deze cellen verminderen weefselschade door escalerende immuunreacties (onder 
andere door effector T-cellen) af te remmen en ze voorkómen ongewenste reacties 
tegen onschadelijke stoffen of zelf-antigenen. 
Immunotherapie op basis van Treg transfusie kan mogelijk effectief zijn bij 
de behandeling van verschillende aandoeningen die veroorzaakt worden 
door ongewenste immunologische reacties, zoals afstotingsreacties bij 
transplantaties of reacties tegen lichaamseigen cellen bij auto-immuunziekten. 
De ideale therapeutische interventie na transplantatie van solide organen of 
van stamcellen leidt tot specifieke tolerantie, gedefinieerd als de afwezigheid 
van een immuunrespons tegen donorcellen zonder algemene immuunsysteem-
onderdrukkende behandeling met geneesmiddelen, terwijl immuunresponsen 
tegen andere doelwitten, zoals tumorcellen en schadelijke micro-organismen, intact 
blijven. Op een vergelijkbare manier zou bij auto-immuniteit de immuunreactie 
tegen lichaamseigen doelwitten moeten worden onderdrukt zonder algemene 
immuunsysteem-onderdrukkende behandeling met geneesmiddelen en met 
behoud van normale immuniteit tegen andere doelwitten. Veel dierstudies tonen 
de potentie van Treg immunotherapie aan voor het induceren van tolerantie bij 
transplantatie en auto-immuniteit. Er zijn in de laatste jaren meerdere klinische 
onderzoeken met Treg immunotherapie gestart en de eerste rapportages zijn 
veelbelovend. Echter,  het is belangrijk om een aantal kwesties met betrekking tot 
Treg biologie in gezonde of zieke mensen en met betrekking tot de therapeutische 
toepassing van Treg op te helderen voordat Treg therapie veilig kan worden 
gebruikt in de standaard klinische praktijk. Enkele belangrijke vragen zijn: Op welke 
locatie(s) oefenen verschillende Treg subsets hun regulerende functie uit? Welke 
Treg subset(s) is (zijn) het meest effectief? Hoe zit het met de isolatie van Treg 
voor klinische toediening? Hoeveel Treg zijn er nodig, en hoe kan het benodigde 
aantal Treg verkregen worden? Wat is de optimale timing van Treg transfusies? 
Zullen getransfundeerde Treg in de patiënt een stabiel Treg fenotype behouden, 
of is er een risico dat ze veranderen in agressieve T-cellen? In dit proefschrift 
richten we ons op een aantal van deze fundamentele aspecten in Treg biologie 
en Treg immunotherapie. We onderzochten de rol van Treg in het menselijk 
immuunsysteem, en de mogelijke toepassingen voor immunotherapie, vooral bij 
transplantatie.
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Hoofdstuk 1 geeft een korte inleiding op het immuunsysteem met een focus 
op Treg en op Treg gebaseerde immunotherapie voor transplantatie en auto-
immuniteit. In hoofdstuk 2 wordt wat dieper ingegaan op Treg gebaseerde therapie 
in transplantaties. 
In hoofdstuk 3 zijn Treg uit verschillende weefsels van gezonde humane donoren 
bestudeerd. We analyseerden verschillende kenmerken van Treg uit bloed, 
beenmerg, milt en lymfeklieren, allemaal onderdelen van het immuunsysteem. 
Het doel van deze studie was om beter te begrijpen waar en hoe Treg hun normale 
regulerende functies uitoefenen. We vonden dat Treg die in bloed en beenmerg 
voorkomen niet geactiveerd zijn. Treg uit bloed vertoonden (de voor Treg 
kenmerkende) immuun-onderdrukkende eigenschappen, en ze lieten in celkweken 
alleen delingsactiviteit zien wanneer zowel celdelingsstimulatie als groeifactor Il-2 
aan de kweken toegevoegd werd. Interessant is dat de meerderheid van de Treg in 
secundaire lymfoïde organen (lymfeklieren en milt) kenmerken van activatie lieten 
zien. Treg uit de milt vertoonden net als de Treg uit bloed immuunregulerende 
capaciteit, maar in tegenstelling tot de Treg uit bloed lieten Treg uit miltweefsel in 
celkweken uitgebreide celdeling zien na toevoeging van celdelingsstimulatie, ook 
zonder Il-2. Mogelijk kan dit verschil verklaard worden doordat Treg uit de milt 
zelf Il-2 produceerden, terwijl Treg uit bloed dit niet deden. Om in het lichaam te 
kunnen navigeren, worden cellen voorzien van receptoren voor adres-eiwitten, 
die ervoor zorgen dat ze specifieke plaatsen in het lichaam kunnen herkennen 
en hierheen kunnen migreren. Uit analyse van deze receptoren op het oppervlak 
van de Treg en uit analyse van de migratie bleek dat subpopulaties van humane 
Treg de potentie hebben naar perifere weefsels te migreren, en dat de doelwitten 
van migratie anders zijn voor Treg uit verschillende weefsels. Treg uit bloed en 
beenmerg hebben receptoren die geassocieerd zijn met migratie naar lymfeknopen 
en huid, terwijl de receptoren op Treg uit lymfeklieren en milt meer geassocieerd 
zijn met migratie naar de darmen. De gegevens uit deze studie suggereren dat 
secundaire lymfoïde organen een belangrijke plaats innemen in de normale Treg 
biologie. Tevens impliceren deze gegevens dat bepaalde subklassen van Treg een 
functie hebben buiten de secundaire lymfoïde organen. 
Voor toepassing van Treg immunotherapie in de kliniek is het belangrijk om de 
rol van Treg in de lokale immuunrespons in weefsels te begrijpen. In hoofdstuk 
4 wordt dit onderzocht, waarbij we kozen voor de huid als modelorgaan omdat 
hier lymfocyten verblijven en hier veel potentieel schadelijke micro-organismen 
binnen kunnen dringen. We bestudeerden de interactie tussen de belangrijkste 
huidcellen, keratinocyten, en effector T-cellen, en we bestudeerden de invloed van 
Treg op deze interactie. Hiervoor hebben we een nieuw kweeksysteem opgezet, 
waarin keratinocyten, effector T-cellen en Treg van gezonde humane donoren 
samen gekweekt kunnen worden. We laten zien dat de keratinocyten en effector 
T-cellen elkaar beïnvloeden, en dat ze samenwerken om een  effectieve lokale 
immuunrespons te vormen.  Effector T-cellen die geactiveerd zijn zorgen ervoor 
dat keratinocyten adres-eiwitten aanmaken die nieuwe effector T-cellen en andere 
immuuncellen aantrekken (CCl2, CCl20 en CXCl10), waardoor de immuunreactie 
ter plaatse versterkt wordt. De keratinocyten zorgen er op hun beurt voor dat 
de populatie effector T-cellen waarmee ze in contact komen verrijkt wordt voor 
een subpopulatie met bepaalde celkenmerken (Il-17posCCR6posRORγtpos).  Deze 
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subpopulatie is belangrijk bij de normale afweer van de huid tegen bacteriën en 
schimmels. Echter, een overmaat van deze Il-17pos effector T-cellen is geassocieerd 
met huidziekten zoals psoriasis en atopisch eczeem. Toevoeging van Treg aan de 
celkweken had geen invloed op de productie van cel-aantrekkende eiwitten door 
keratinocyten, wel remden Treg de celdeling van de effector T-cellen, waardoor 
de aantallen Il-17pos effector T-cellen beperkt bleven. De gegevens uit deze studie 
impliceren dat weefselcellen zoals keratinocyten en effector T-cellen samenwerken 
in het opbouwen en vormgeven van lokale immuunreacties, en dat Treg ook lokaal 
in de weefsels een regulerende rol hebben.
In de volgende hoofdstukken richtten we ons op een aantal praktische aspecten 
van Treg immunotherapie. Voor succesvolle immunotherapie zullen hoge aantallen 
Treg nodig zijn. In diermodellen van Treg immunotherapie bij transplantatie is 
aangetoond dat de therapie veel efficienter is wanneer gebruik wordt gemaakt van 
Treg die specifiek reageren op lichaamsvreemde eiwitten (allo-antigenen) van het 
transplantaat (bij transplantatie van solide organen) of van de ontvanger (bij stamcel 
transplantatie). Deze cellen zijn in de diermodellen specifiek in staat reacties tegen 
deze eiwitten te remmen, terwijl ze andere immuunreacties intact laten. Treg met 
deze kenmerken worden allo-antigeen specifieke Treg genoemd. In hoofdstuk 
5 beschrijven we een zeer efficiënt protocol waarmee grote hoeveelheden 
menselijke allo-antigeen specifieke Treg kunnen worden verkregen. We laten zien 
dat door middel van celkweken in slechts twee celactivatie-cycli met allogene 
stimulator cellen en T-cel groeifactoren een zeer hoge mate van specificiteit van 
Treg voor allo-antigenen  kan worden bereikt. Daarbij wordt ook een efficiënte 
vermeerdering van celaantallen verkregen: ten opzichte van de startaantallen 
zijn er gemiddeld bijna 800 maal zoveel cellen na twee twee celactivatie-cycli. Dit 
protocol biedt uitzicht op succesvolle Treg-gebaseerde immunotherapie, gericht op 
de inductie van tolerantie voor geselecteerde allo-antigenen. 
Vervolgens rapporteren we in hoofdstuk 6 een studie waarin we het isoleren 
van Treg voor klinische toepassing onderzochten. Voor klinische toediening van 
Treg is het essentieel dat er een Treg isolatie-protocol beschikbaar is dat voldoet 
aan Good Manufacturing Practice (GMP) richtlijnen. In deze studie maakten 
we gebruik van leukaferese materiaal. Leukaferese is een procedure waarbij 
het bloed van een donor door een machine wordt geleid die witte bloedcellen 
(immuuncellen) isoleert en achterhoudt, terwijl de rest van het bloed (rode 
bloedcellen, bloedplaatjes, plasma) terug wordt gegeven aan de donor. Op deze 
manier kunnen grote aantallen immuuncellen worden verkregen zonder dat de 
donor daar last van heeft.  Tevens gebruikten we magnetische bolletjes met daarop 
antilichamen tegen verschillende celoppervlaktekenmerken van Treg (anti-CD25) 
en van ongewenste andere cellen (anti-CD8 en anti-CD19). Hiermee isoleerden 
we Treg uit de mix van immuuncellen in het leukaferese materiaal met behulp 
van CliniMACS, een machine gebaseerd op magnetische cel-isolate die voldoet 
aan GMP richtlijnen en die al in de kliniek gebruikt wordt voor bijvoorbeeld het 
isoleren van stamcellen voor stamceltransplantatie. Deze isolatie procedure 
leidde tot 40-60% zuivere Treg populaties (CD4posCD25posCD127negFoxP3pos), die 
een matige immuunrespons-regulerende  capaciteit vertoonden. De geïsoleerde 
celpopulaties konden worden vermeerderd met behulp van kweekprotocollen, 
zoals beschreven in hoofdstuk 5, waarbij ook een verrijking voor allo-antigeen 
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specifieke Treg kon worden bewerkstelligd. Echter, we vonden de suboptimale 
zuiverheid van de geïsoleerde Treg populaties zorgelijk. Conventionele T-cellen 
(CD4posCD25neg/lowCD127posFoxP3neg) waren de belangrijkste vervuilende cellen 
in CliniMACS geïsoleerd Treg populaties. Het weghalen van CD127pos cellen 
verbeterde de zuiverheid van de Treg tot ongeveer 90%. Deze populaties met 
hogere zuiverheidsgraad hadden een zeer krachtige immuunrespons-regulerende 
capaciteit. Tevens toonden we in deze studie aan dat geïsoleerde Treg populaties 
onder bepaalde omstandigheden met behoud van hun functie in vloeibare stikstof 
bewaard kunnen worden, wat klinische toepassing kan vergemakkelijken. 
In hoofdstuk 7 worden de bevindingen samengevat en bediscussieerd vanuit 
een breder oogpunt. langzaam maar zeker wordt vooruitgang geboekt bij het 
ontrafelen van Treg biologie. In de toekomst kan deze kennis worden gebruikt 
om Treg immunotherapie in de kliniek te brengen en te optimaliseren. Hoewel de 
isolatie en selectie van Treg voor elke patiënt kostbaar en tijdrovend is, heeft het 
doel, induceren van specifieke tolerantie, het potentieel om de ziektelast en de 
sterfte door transplantatie en auto-immuunziekten belangrijk te verminderen.
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